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A B B R E V I A T I O N S  
T3--triiodothyronine 
T4----thyroxine 
EFA--essential fatty acids 
FFA--free fatty acids 
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UFA--unsaturated fatty acyls 
MUFA--monounsaturated fatty acyls 
PUFA--polyunsaturated fatty acyls 
HMGR--~-hydroxy-fl -methylglutaryI-CoA rcductase 
CPT---carnitine palmitoyl transferas¢ 
TH, ~TH--pyridine nucleotid¢ transhydrogenase, energy-independent or -dependent 
UI--unsaturation index [Y~(% fatty acyl group x number of unsaturated bonds)] 
[~]----concentration of ~P 
I. THYROID HORMONE MECHANISMS 
The availability of thyroid hormones affects reactions in almost all pathways of lipid 
metabolism, as has been documented in previous reviews. 23'226'231'233'477't'41 Changes in lipid 
metabolism are only a portion of the diverse, pleiotypic effects of altered thyroid states 
on cell metabolism. Attempts have been made to reduce this diversity into one or a few 
common initial events. Such an event should include the specific binding of 
L-triiodothyronine (LT3) or thyroxine (LT4) at a cellular locus that exists only in 
thyroid-sensitive cells. Integrated overviews of thyroid regulation have been based on the 
consequences of receptor occupancy only in nuclei, with subsequent gene expres- 
sion; 125'45~-4~'599 in mitochondria, with subsequent modulation of cell energy metabo- 
lism; 2:6'2aL233 in both nuclei and mitochondria; 577 and in nuclei, mitochondria, plasma 
membranes, and perhaps cytosolfl 2 Evidence is reviewed here that thyroid hormones act 
at nuclear receptors to express genes for a few lipogenic enzymes and perhaps their 
modifiers, and that ensuing changes in membrane lipid compositions mediate processes 
that underlie part of the pleiotypy. Lipids of membranes are considered both as regulating 
membrane-dependency that modulates protein enzyme-, transporter- or receptor-mediated 
activities, and as permitting unmediated cation leakage. Pertinent thyroid hormone 
mechanisms are first examined in general terms, then empirical observations of thyroid 
influence over lipid composition, and mechanisms whereby thyroid deficiency or ad- 
ministration regulates reactions in lipid metabolism. Effects of hormone-dependent 
lipid metabolism on membrane receptors, transporters, and enzymes are described in 
Sections III and IV. 
A. Calorigenic and Anabolic Effects 
Like other hormones, T3 and T4 are necessary intercellular messengers that 
coordinate cellular metabolic adaptations 447 to a constantly changing external and internal 
environment. Three general coordinative roles can be distinguished for thyroid hormones. 
First, thyroid accelerates, and thyroid deficiency slows, catabolic, exergonic oxidative 
reactions in most cells. Thus, an appropriate level of thyroid hormone is necessary for an 
optimal rate of free energy liberation. Energy utilization by the ubiquitous 
Na+K+-ATPase is also thyroid-dependent, and is proposed to determine calorigenic rates 
(see Section III.D). Thyroid up-regulates lipid catabolism. Lipolysis of stored triglycerides 
and oxidation of fatty acids support increased calorigenesis. Second, thyroid hormones 
simultaneously exert major anabolic effects; lipogenesis is stimulated, which seems parad- 
oxical for the calorigenic role of the hormones. In thyrotoxic subjects, the energetically 
wasteful combination of lipid synthesis and oxidation has been thought to act as a futile 
cycle to promote heat production. However, since hypothyroidism slows both synthesis 
and oxidation, normal T3 and T4 concentrations must also stimulate both processes 
constructively. This is seen in the requirement for thyroid hormones for growth and 
development in the mammalian fetus and neonate. I propose that thyroid-stimulated fatty 
acid synthesis and desaturations regulate mitochondrial oxidations via altered membrane 
fatty acyl compositions. Third, thyroid hormones have a permissive function, being 
necessary for and/or synergistic with actions of other hormones, e.g. lipolytic hormones, 
insulin, cortisol (in increasing mRNA synthesis), and testosterone (in inducing liver ct2v- 
globulin). The increase in scope of controls through permissive actions contributes to the 
synchronization of cell metabolism for whole-body adaptations, and is discussed in the 
next two sections. 
Lipids and thyroid hormones 201 
What organismic purpose is served when thyroid hormones stimulate both lipogenesis 
and fatty acid oxidation? Two are discussed in subsequent sections. One is calorigenic, in 
a futile cycle. The other is regulatory, the control of concentrations of specific metabolites 
through differential effects on both synthesis and further degradation. Some of these 
metabolites are effectors and also expand the hormone signal, e.g. cholesterol, cAMP, and 
membrane fatty acyl groups. 
B. Thyroid Hormone Entry into Cells 
Thyroid hormones act by binding to stereospecific, high-affinity, limited-capacity 
protein sites that impart a message when occupied that in turn alters cell metabolism. Sites 
with such properties are 'receptors', although that term is often used for just binding sites. 
Reasons to believe that the lipophilic T3 or T4 molecules themselves do not alter 
mitochondrial membrane permeability are discussed in Section IV. Thyroid hormone 
receptors exist in plasma membranes, 455 cytosol, 26 endoplasmic reticulum, 84'85 mito- 
chondrial inner membranes (Ref. 577, but see Ref. 189), and nuclei. Injected labeled 
hormone reaches all these sites within minutes (see Ref. 116). Receptor occupancy 
promotes gene expression in nuclei (see Section II.D), possibly oxidative phosphorylation 
in mitochondria (see Section IV), T3 and 2-deoxyglucose uptake, and CaE+-ATPase 
activity in selected plasma membranes (see Section III.E.1), and T3 transport in cytosol. 
Several sets of thyroid hormone-binding 'receptors' are described. 'The' nuclear receptor 
in all vertebrates that circulate T3 is a 50.5 kDa protein, and its occupancy initiates thyroid 
action. 454 A second 'receptor' is a common, abundant, LT3-binding protein of molecular 
mass ~55 kDa that is found in membranes of the endoplasmic reticulum and their 
continuations into the nuclear envelope in all lines of cultured cells examined, s4'85 This 
protein is present in all tissues of an adult monkey, even those not thyroid-responsive, 
unlike the nuclear 50.5 kDa receptor. In cultured cells of rat pituitary tumor (GH3), 48-hr 
incubation with T3 decreases the number of 55 kDa protein molecules by specifically 
accelerating their degradation, but without changing their initial rate of synthesis or the 
amount of p55-coding mRNA. 44~ Thus, T3 regulates at a post-translational level. A 
similar mechanism of down-regulation of the 50.5 kDa nuclear receptor operates in GHI 
cells after incubation with T3 for 24 hr, but on briefer exposure T3 inhibits synthesis. TM 
Since T3 does not down-regulate liver T3-receptors in vivo, 52~ the susceptibility of the 
55 kDa protein to T3 control does not necessarily make it a 'receptor'. The sequence of 
the 55 kDa protein is not similar to that of human plasma thyroid-binding prealbumin or 
globulin. 526'628 However, a brief note says that the coding region of the 55 kDa protein has 
an 85% and 98% sequence homology to the endoplasmic reticulum enzymes protein 
disulfide isomerase and the fl-subunit of prolyl 4-hydroxylase, respectively. 85 It is not stated 
that the 55 kDa protein has these enzymatic activities, but the fl-subunit has the same 
disulfide isomerase activity in vitro as the disulfide isomerase itself, and monoclonal 
antibody to this subunit inhibits isomerase activityY 6 The fl-subunit is present in many 
cells in great excess over the active hydroxylase ~tfl-tetramers. 
A third 'receptor' group comprises nuclear proteins, encoded by the c-erb-A gene, that 
are present in small amounts in many adult and embryonic cells. They have the binding 
properties of the nuclear T3-receptor although their functional capacities are not as yet 
described; weights are 46, 52, and 55 kDa; sequences of two cellular c-erb-A proteins are 
dissimilar to that of the nuclear 55 kDa protein. 526'628 A viral counterpart encoded by the 
v-erb-A oncogene does not bind T3 similarly. A high degree of sequence homology 
between c-erb-A protein and human glucocorticoid- and estradiol-receptor proteins 
suggests that all three may have evolved from a primordial receptor gene. 63° All have a 
cysteine-rich region thought to bind DNA; the protein disulfide isomerase that resembles 
the nuclear 55 kDa protein also has a cysteine-rich sequence in the active site. 127 
A fourth set of 'receptor' proteins with high affinity for thyroid hormones is identified 
in nuclei of tissues that do not contain the nuclear 55 kDa protein and do not respond 
to administered hormone by increasing their respiration or lipogenesis. One is in the adult 
JPLR 27/~-D 
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rat brain but not in liver, and is proposed to be one of many receptors that account for 
the diversity of thyroid hormone effects. ~°5 Another is in testis. 29a These binders await 
certification as receptors. Are the criteria for defining a receptor molecule by its binding 
properties to thyroid hormones sufficiently rigorous to exclude other lipophilic proteins 
found in membranes? A similar question applies to the identification of the mitochondrial 
T3-receptor as the ADP/ATP carrier (see Section IV.B.1). 
Thyroid entry into cells is apparently membrane-mediated, being saturable, specific, and 
sensitive to temperature and to protein- and lipid-modifications? 92 Plasma membrane 
receptors may be involved in T3 entry into cells. Triiodothyronine enters the cell across 
the plasma membrane via an energy-dependent transporter system. ~4'3~'49~ Extranuclear 
proteins bind 96% of hepatocyte T3; the minor fraction of T3 in hepatic nuclei plays a 
major role in promoting gene expression of lipogenic enzymes. In a rat pituitary tumor 
line, cytosol proteins compete less and nuclei contain 44% of cell T3.156 Recent evidence 
shows that another energy-dependent, stereospecific system carries LT3 across the hepatic 
cytosol to the nuclear binding sites; ~'45~ it accounts for the in situ nuclear LT3 content 
being 100 times greater than would be predicted from affinity constants of isolated nuclei 
or solubilized receptors. Free LT3 does bind to its nuclear receptor, however, unlike the 
steroids which must complex with a cytoplasmic receptor before they bind and act on 
nuclear components. The absence of reports that incubation of nuclei with T3 in vitro 
stimulates nuclear RNA polymerases therefore remains puzzling--unless it is an 
LT3-protein complex that actually binds to nuclear receptors. A T3-binding protein in rat 
kidney cytosol mediates T3-uptake by kidney mitochondria, perhaps by donating its T3 
to a T3-receptor in the mitochondrial outer membrane, which is transported by other 
T3-carrier proteins in the intermembrane space, to a T3-receptor in the inner membrane? 4 
Transport of LT3 across the cytosol seems to be tissue-specific. The T3-pump in the 
plasma membrane or the cytosol is invoked as the source of a highly selective differential 
effect of a T3-analogue on heart and liver. To measure the contribution of the pump to 
the selectivity, Underwood et al. 6~4 compare binding and displacement of LT3 and 
analogues in vivo and in vitro (to eliminate operation of the pump). As biologic responses 
to nuclear-receptor-binding, they assay mitochondrial glycerol-3-phosphate dehy- 
drogenase and depression of plasma [cholesterol] in hypothyroid rats 48 hr after one dose 
of LT3 or analogue. The Y-pyridazinone-3,5-dibromothyronine (SK&F-94901) is highly 
selective for liver: it has 18 % of the inducing potency of LT3 in liver (0.1% in heart), liver 
binds it in vivo 50% as well as LT3 (heart, 1.3%), and liver nuclei bind it in vitro 0.9% 
as well as LT3 (heart, 2%). LT3 and SK&F-94901 depress plasma [cholesterol] effectively 
and equally (see Section II.H). This selective access to liver nuclei is proposed to reside 
in the hormone-concentrating mechanisms, presumably in the energy-dependent plasma 
membrane and/or cytosol hormone-transporters---where hepatic cytosol may contain 
more SK&F-94901 than heart cytosol either because hepatocytes accumulate it more 
actively or cardiomyocytes exclude it. DT4 has no selective potency, and induces 
glycerol-3-phosphate dehydrogenase in either heart or liver about 10% as effectively as 
LT3, as might be expected from the relative binding of DT4 and LT3 by the nuclear 
receptor. 
II .  L I P I D  M E T A B O L I S M  
A. Cell Lipid Composition 
Thyroid state influences cell and plasma lipid composition, but some reports are 
contradictory, probably because of differences in degree and duration of abnormal thyroid 
levels, and the many other effectors of lipid composition. Lipids in plasma of hyperthyroid 
rats, as compared with normals, show the expected decreases in free and esterified 
cholesterol concentrations, but also increases in [~PL] and in the PC/PL ratio, m 
Erythrocyte membranes do not equilibrate lipid content with plasma, as is shown by their 
greater cholesterol content and normal PC/PL ratio, although PL/protein also increases; 
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the PL contents of i 8: l, 18: 2 and 20: 4 acyls remain unchanged. In livers of rats, either 
hypo= or hyperthyroidism halves total lipid content, while hypothyroidism depresses 
cholesterol/protein by 20%; 396 Ellefson and Mason 13° find TG content low in hypothyroids, 
PL contents high in hyperthyroids; Tata 596'59s'5~ finds diminished PL/protein ratios in livers 
of hyperthyroid rats. 
In hepatic microsomes Faas and Carter t4°:41 report that hypo- or hyperthyroidism leaves 
unaltered the contents of PL, TG and cholesterol, and the distribution of the different PL 
classes. On the other hand, Ruggiero et al. 5~° see that hyperthyroidism decreases 
microsomal PL and cholesterol contents. 
Hyperthyroidism induced with our original enormous doses of LT4, 40 #g/g/day 246 and 
given for 6 days, increases the PL content of rat liver mitochondria but does not change 
the proportions of the PL classes (although no CL fraction was distinguished), whilst 
hypothyroidism does not change either in the studies by Nelson and Cornatzer: 24 In liver 
mitochondria of our hypothyroid rats, we find normal amounts of total lipids, PL and NL 
per g protein and increased CL/PL ratios. 2~ Studies combining measurements of CL and 
cytochrome a contents per g protein in whole cell homogenates and in purified mito- 
chondria, with stereological micrographic analyses of liver cells and mitochondria, have 
compared hypothyroids and normals, and used a prolonged T4-treatment (doses every 
other day for 21 days). 277 Hypothyroidism selectively decreases, and T4 increases, the 
relative area of mitochondrial inner membranes, but the ratios of mitochondrial/liver 
protein and mitochondrial/cell volume do not change. In hypothyroid cells and mito- 
chondria, CL and cytochrome a contents per g protein decrease 20-40% below normal 
levels; T4, 0.1/~g/g, restores normal values. When normal rats receive 1.2/zg/g T4, CL and 
cytochrome a contents increase to 20-40% above normal. 
Mitochondrial membranes also proliferate in thyrotoxic rat hearts. ~ Taken together 
with data showing that cell ~PL contents are 27% lower in hypothyroids than in 
euthyroids, 596 and our data exhibiting high CL/PL ratios in hypothyroids, it would appear 
that hypothyroidism, or this prolonged T4-regimen, alters amounts of i~PL per g protein 
more severely than amounts of CL. Thyroid state affects the CL contents of individual 
liver mitochondria rather than the number of mitochondria per cell. Reasons to think that 
the CL/PL ratio of such an altered mitochondrion regulates its inner membrane properties 
are discussed in Section IV. 
Fatty acyl compositions of PL are more consistently found to be thyroid-dependent, 
although details vary. Some of the effects of thyroid state on PL fatty acyl composition 
result from changes in the fatty acyl proportions in one or more PL classes, others from 
a shift in the proportions of PL classes that have distinctive fatty acyl compositions. 24s For 
example, CL contains much more 18:2 acyls and less other PUFA than PC, PE, or PI) 53 
Liver PL from hypothyroid rats, as compared with euthyroids, have slightly lowered 18:2 
and 20:4 contents, and vigorous LT4 treatment (2/~g/g/day x 14 days) of either hypo- 
thyroid or normal rats increases percentage contents of 20:4 while decreasing percentage 
contents of 18: 2, indicating that T4 activates the 'degradation' of hepatic unsaturated fatty 
acyls. 396'47~ In other studies, ~3° liver phospho!ipids in hypothyroid rats have contents of 
16:0, 18:1 and 18:2 that are 80% above normal levels, and 20:4 contents that are 70°/0 
below normal, and what might be a 20: 3 acyl appears; in thyrotoxic rats, 18: 1 and 18: 2 
contents increase by 90%, and 20:4 decreases 25%. Since the hormone augments adipose 
tissue 16:0 and 18:1 contents, Ellefson and MasonS3° propose that the hormone stimulates 
fatty acid de novo synthesis, fatty acid mobilization from fat-~liver, and desaturations of 
saturated and unsaturated fatty acids. In hypothyroid hamsters, liver lipids are slightly 
depleted in 18: 2; in thyrotoxic hamsters, 18: 2 and 20: 4 decrease more severely while 18 : 1 
content increases. ~ The results of Peifer 47~ on thyroid effects are more difficult to fit into 
the pattern because the rats were fed diets containing 1°/0 18:2oJ6, 1%o 18:3co3, and 8% 
saturated fatty acids, and made hyperthyroid by inclusions of dessicated thyroid powder 
for 2 months. In these hyperthyroids, liver lipids were 40°/0 below untreated 'controls' in 
percentage contents of 18:2 and 22:6, while in heart lipids, 18:2 percentage was halved 
and 22:6 percentage was 2.6-times elevated. This diet would produce EFA-deficiency as 
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well as the ready replacement of cardiac co 6-PUFA by co 3-PUFA noted by Gudbjarnason 
e t  al.; ~96 the hormone was thought to accelerate the desaturative biosynthesis of both 22:6 
and 20:4 from their dietary precursors. 
Since cell PL are almost all in membranes, it is to be expected that organdie and cell 
membranes reflect the PL fatty acyl composition changes. Liver mitochondrial fatty acyl 
profiles in thyrotoxic rats have slightly lower 18:2 and 33% lower 20:4 percentages. 47s 
Heart mitochondria from hypothyroid rats and hamsters show no fatty acyl changes, while 
those in thyrotoxics have slightly lowered 18: 2; 468'575 this is discussed further in Section IV. 
Table 1 compares total lipid contents of fatty acyl groups in liver mitochondria prepared 
from fasted control or hypothyroid rats, or from rats of either group killed after 
injection(s) of LT3.  235'236 In our studies, hypothyroidism elevates mitochondrial contents 
of 18:2, 18:3co6, and 20:3co6 fatty acyls and depletes 20:4 acyls. One LT3-injection into 
hypothyroid rats rapidly substitutes saturated acyls for a part of the unsaturated fatty 
acyls. The hormone depresses mitochondrial 18:2, 20:4 and 22:6 fatty acyl contents to 
as low as 50% of the levels in untreated hypothyroids by 1-2.5 hr. The 35%-increased 
contents of 16:0 and 18:0 acyls replace the polyenes, and the UI diminishes to 71% of 
that in untreated hypothyroids and to 62% of that in the euthyroid controls. Only 
weeks-long EFA-deficiency (see Section IV.E), or a few hours of feeding carbohydrate to 
previously starved euthyroid rats (see Section II.B), depletes liver mitochondrial co 6-PUFA 
to this extent. Three-day LT3-treatment of control rats also raises liver mitochondrial 18: 0 
content but, in addition, depletes 18:2 and 20:4 acyls. 
Changes in oxidative phosphorylation at 25°C accompany the early depressions of 
mitochondrial PUFA contents within 3 hr after hypothyroid rats are injected with LT3 (see 
Section IV.A), as well as during the more chronic depletions of co6-PUFA in EFA- 
deficiency (see Section IV.E), but do not appear to have been examined during carbo- 
hydrate refeeding. Altered thermotropic properties of partial reactions also occur in liver 
and heart mitochondria when thyroid status is changed (see Section IV). These findings 
indicate that the changes in mitochondrial fatty acyl composition are great enough to have 
functional consequences. 
Liver microsomes from hypothyroid rats have abnormal fatty acyl compositions similar 
to those in their mitochondria, but these have no effect on A9-desaturase activity. 243 
TABLE 1. Fatty Acyl Compositions of  Liver Mitochondria of  Hypothyroid and Control Rats, and 
Changes after LT3 Injection(s)* 
Hypothyroids + LT3 
(hours after injection) 
Fatty Controls Hypothyroids Controls 
acyls (6) (9) 0.5 (2) 1.0-2.5 (8) 4.0 (3) + LT3 (4) 
16:0 12.6 16.0 b 16.2 21.2 E 21.1 16.7 
18:0 17.3 17.2 18.5 23.4 D 16.5 24.6 E 
18:1 17.9 18.2 14.3 19.6 21.7 15.1 
18:2 18.7 24.1 b 22.9 17.6 E 18.8 12.5 A 
18 : 3 0.3 1.3 c 1.2 1.5 1.8 2.5 
20:3 1.0 2.0 d 2.9 1.4 1.8 0.7 
20:4 23.5 16.7 b 16.5 9.4 c 9.6 16.9 E 
22:6 4.6 3.2 2.6 1.5 a 3.1 4.7 
Unsat. 
Index 189 167 166 I 18 B 136 162 
"co6 131 122 126 81 ° 84 E 105 
"093 29 26 21 17 ° 22 36 
*Fatty acyl percentage contents are shown as means; for 55 values, the coefficient of  variation is 
16.6% _+ 1.9% SE. The number of  experiments, each on one rat, is in parentheses. The unsaturation 
index (U.I. = Y~[%fatty acyl group u number of  unsaturated bonds]) is shown for all unsaturated 
fatty acyl groups and separately for to6- and co3-acyls. Some hypothyroid rats were injected with 
LT3 ( +  LT3) intraperitoneally, 1 #g/g, and killed at the times indicated; some control rats were 
similarly injected with LT3, 1 #g/g/day for 3 days, and killed on the 4th day (controls +LT3).  
Student's t test was used for group comparisons', p < ~).001; ha0.005; ~:0.01; riD0.025; or'0.05; lower 
case symbols denote p values for comparisons of  Hypothyroids vs. Controls, upper case symbols 
for comparisons of  Hypothyroids + LT3 vs. Hypothyroids and Controls + LT3 vs. Controls. 
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LT3-injection changes microsomal composition slightly later and less extensively than in 
mitochondria. The proportion of 20:4 acyls falls at 2.5hr and reaches 75% of the 
hypothyroid level (49% of the control level) at 4.0 hr. With the accompanying decrease 
in 22:6 acyl percentage, the unsaturation index falls to 89% of the hypothyroid value at 
4 hr. Three daily injections of LT3 into control rats have little effect on microsomal fatty 
acyl composition, other than to increase 18:0 content and decrease the ~06-unsaturation 
index. 
In liver mitochondria of hypothyroid rats, it is the phosphatidylcholines and phos- 
phatidylethanolamines that contain excess 18 : 2 fatty acyls and are depleted in 20: 4 acyls, 
while the CLs have normal contents of 18:2 but the ratio CL/PL is increased. 248 Hepatic 
nuclea~ 9 phospholipids prepared from hypothyroid rats show the same abnormal fatty 
acid composition as mitochondria (Table 1) and microsomes, suggesting a general defect 
in unsaturated fatty acid metabolism. Because laboratory diets for rats contain no 
arachidonic acid, the desaturative biosynthesis of 20: 4 fatty acyls from dietary 18: 2 seems 
at fault. Although fatty acyl-CoA A6-desaturase activity is cited as 'rate-limiting' in this 
conversion, 56 the appearance of 20:3096 acyls suggests a more limiting defect in the 
A5-desaturase in hypothyroidism. Thyroid regulation of desaturase activities is discussed 
below (see Section II.I). 
B. Fatty Acid Synthesis 
Thyroid status is one of the regulators of de novo fatty acid synthesis. In general, rapid 
(0-24 hr), reversible modifications of existing enzymes regulate fatty acid synthesis by 
several mechanisms. 621 Allosteric effectors signal intracellular conditions, and cyclic 
nucleotide- or Ca2+-mediated phosphorylation/dephosphorylation regulates under hor- 
monal control for whole-organism needs. The acetyl-CoA carboxylase, 445 which is said to 
be 'rate-limiting' under most circumstances, is rapidly activated by citrate and inactivated 
by long-chain fatty acyl-CoA, but no certain thyroid influence via these effectors is 
established. Phosphorylation inactivates, and dephosphorylation reactivates, the acetyl- 
CoA carboxylase and fatty acid synthetase enzymes. An appropriate stimulus starts 
synthesis of some lipogenic enzymes even more quickly than the actions of rapid effectors 
or covalent modifiers. Synthesis rather than degradation is stated to regulate the activity 
of the fatty acid synthetase, 5 the malic enzyme,177 the glucose-6-phosphate dehydrogenase, 
and the 6-phosphogluconate dehydrogenase, through the selective expression of genes and 
the nuclear synthesis or supression of mRNAs (see Section II.B.2). 
Hypothyroidism in developing or adult rats depresses hepatic fatty acid synthetase 
activity by 50%, and diminishes but does not abolish carbohydrate-induced activation of 
fatty acid synthetase. 336'62° Cultures of hepatocytes obtained from hypothyroid rats 
synthesize fatty acids from acetate half as fast as nonnals. 173 Incubation of these 
hepatocytes with ~ 1 nM LT3 stimulates synthesis in 2 hr and triples the rate by 4 hr 
independently of protein synthesis, since cycloheximide fails to inhibit. Greater LT3 
concentrations accelerate fatty acid synthesis in hepatocytes from normal rats 37% in 
4 hr. LT4-injection of normal rats doubles the amount of hepatic citrate lyase and triples 
that of malic enzyme in 7.5 hr, 17° and increases fatty acid synthetase and acetyl-CoA 
carboxylase activities more slowly. 366 
Starvation, 7,s,17°.6~ diabetes, 1°5 or hypophysectomy 324a decrease hepatic fatty acid syn- 
thesis more severely (to < 10% of normal), as well as activities of fatty acid synthetase, 
acetyl-CoA carboxylase, malic enzyme, citrate lyase, and glucose-6-phosphate dehy- 
drogenase. In starved or diabetic rats, the liver contains considerable amounts of 
immunoreactive fatty acid synthetase that is enzymatically inactive. Carbohydrate fed to 
fasted rats 64s increases fatty acid synthetase in two phases. Within 1 hr, additional inactive 
fatty acid synthetase is synthesized. After 3 hr, fatty acid synthetase activity begins to 
increase, in parallel with incorporation of labeled 4'-phosphopantotheine into fatty acid 
synthetase apoenzyme, forming holoenzyme. We do not know what makes existing 
apoenzyme take up its prosthetic group. Refeeding accelerates synthesis of malic enzyme 
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and citrate lyase in 6 hrJ 7° When rats are refed with carbohydrates for 15 days, depressed 
activities of hepatocyte cytosol acetyl-CoA carboxylase, fatty acid synthetase, malic 
enzyme, citrate lyase, and glucose-6-phosphate dehydrogenase coordinately rise to levels 
many times normalJ 7° This coordination prevents the increased flux of metabolites from 
accumulating behind each relatively slowed step. Supplementation of fat-free diet with 
18:2 or 20:4 (but not 16:0 or 18:1) dampens the induction of all these enzymes; as 
discussed under Section II.I, major regulatory properties are also ascribed to dietary 
linoleate through its potent inhibition of liver fatty acid synthetase and the fatty acyl-CoA 
A9-desaturase. 279 Thyroid state controls the hepatic uptake and esterification of 
administered 18:209 6, thereby further regulating lipogenic enzymes. The suppressive effect 
of fat-feeding on the carbohydrate-inductions of acetyl-CoA carboxylase, fatty acid 
synthetase, and malic enzyme diminishes with aging of rats, and is relieved by T3- 
treatment, more in young rats than in old. 163 Thyroid hormones and refeeding fasted 
rats with carbohydrates exert synergistic effects on lipogenic enzyme gene expression (see 
Section II.B.2). 
Effects of one T3 injection on hepatic fatty acid synthetase and acetyl-CoA carboxylase 
have been measured in hypophysectomized 32~ or diabetic ~°5 rats. T3 given to hypophy- 
sectomized rats does not increase fatty acid synthetase activity from 4--12 hr later, but 
Kumar et al. 32~ did not measure short-term effects on fatty acid synthetase amount or 
synthesis. Long-term, T3 activates fatty acid synthetase and acetyl-CoA carboxylase only 
after 24 hr, to reach maximal activity at 3-4 days; injecting T3 twice over 7 days accelerates 
activities of fatty acid synthetase and acetyl-CoA carboxylase 15- to 20-fold, and synthesis 
of fatty acid synthetase ~ 10-fold. A different biphasic pattern is seen after diabetic rats 
are injected with T3.1°5 In 4-12hr, activities of fatty acid synthetase and acetyl-CoA 
carboxylase rise slowly, together with conversion of apoenzyme--,holoenzyme and accu- 
mulation of immnoreactive fatty acid synthetase; however, cycloheximide or actinomycin 
D does not block the increase in activities or the parallel holoenzyme formation. In a 
second stage from 24-72 hr after T3 injection, a more rapid increase in activities and fatty 
acid synthetase antibody titer occurs that is inhibited by blockage of transcription or 
translation and so represents net protein synthesis. Comparable long-term T3 treatment 
of diabetic animals stimulates hepatic fatty acid synthesis from all precursors. 5~ Here, 
insulin does not mediate T3 effects. Insulin given to diabetic rats acts more quickly than 
T3, and increases fatty acid synthetase activity 5-fold in 6 hr, 20-fold in 12 hr (see Kumar 
et al. 324~ for Refs). In contrast, in avian liver explant culture, insulin induces a 5-fold 
increase in fatty acid synthetase; T3 o r  hydrocortisone potentiate the induction, individ- 
ually 2-fold, together 4-fold; without insulin, they are ineffective. ~5°':85 Apparently, these 
cultures require insulin, and T3 or hydrocortisone play supportive roles in induction of 
fatty acid synthetase. 
1. Protein Phosphorylat ion-Dephosphorylat ion 
As noted above, cAMP-dependent and -independent protein kinases inhibit rate- 
limiting enzymes of fatty acid synthesis. In vitro, sequential additions of protein kinases 
and phosphatases interconvert active and inactive forms of an enzyme. 2~4'4~ For example, 
in vitro dephosphorylation activates pigeon liver fatty acid synthetase 15-fold, and 
phosphorylation inactivates to the same degree. ¢7 Usual procedures for fractionation 
indicate that under normal physiologic conditions 90% of a lipogenic liver enzyme, 
/~-hydroxy-p-methylglutaryl-CoA reductase (HMGR, see Section II.H), exists i n  an 
inactive phosphorylated form. ~9 In this case, decapitating conscious rats is shown to result 
in almost complete phosphorylation of enzyme in seconds. Using anesthetized fed rats, 
and cold-clamped liver to eliminate the delay during centrifugal fractionations, HMGR 
is 80% active. Such procedures may well be critical in correlating the receptor-mediated 
thyroid-state effects on other lipogenic enzymes as well. 
Thyroid treatment induces several protein kinases and increases the in vivo phos- 
phorylation of endogenous proteins. In the absence of valid examinations of phos- 
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phorylation states of lipogenic enzymes, evidence for direct connections with thyroid levels 
remains circumstantial--we discern motive, means, and opportunity but have no witness 
to dephosphorylation. In the myocardium, 2 hr after T3-injection, the kinase activity of 
nuclear non-histone proteins increases for each substrate tested (histones, casein, phos- 
vitin). TM Activity doubles after 3 daily T3-injections but even continued treatment for more 
than 7 days does not prevent the return of kinase activities to control levels. T3-treatment 
also activates two isozymes of a myocardial cytosol cAMP-dependent protein kinase I in 
2 hr; detectable rises in [cAMP] and [cGMP] start at 4 hr. ¢ The significance of these early 
kinase activations or inductions for lipogenesis is uncertain, since the heart has little 
lipogenic enzyme apparatus. 
In rat liver, T3-treatment produces stimulations analogous to those in heart, but more 
slowly. When hepatocytes from fetal rats are incubated with T3 for 3 days (but not for 
5 hr) increased activity of nuclear protein kinases and susceptibility of chromosomal 
non-histone proteins to phosphorylation are observedfl 9 Nuclear non-histone proteins 
extracted from livers of rats after 2 daily injections of T3 are increased in phosphorylative 
actions on casein and phosvitin by 60-90%; partially purified fractions of nuclear extracts 
obtained after 8 daily injections are 4 times more active than those from control rats .  324,5°1 
These T3-induced fractions, as compared with controls, have different pI values, are more 
heat-labile, are less sensitive to inhibition by a sulfhydryl reagent, and have greater 
autophosphorylative activity. 324 Thus T3 seems to be evoking gene expression of 'new' 
protein kinases. Since these kinases, like those in heart, disappear even with continued 
T3-treatment, a down-regulation may decrease the number of nuclear receptors TM or LT3 
access to the receptors. 
In livers of hypothyroid rats, phosphorus-content of ribosomal proteins, and activities 
and cAMP-binding of soluble protein-kinases, are below euthyroid levels. ~°° Nuclear 
chromatin non-histone proteins autophosphorylate at a subnormal level, except for one 
large fraction that is much more active than normal?  4 Hypothyroidism decreases both 
nuclear and cytosolic casein kinase activity and T3-injection restores these activities in 
1 5 hr. Protamine kinase in the cytosol is more than normally active, and decreases after 
T3-treatment. 5°t Thus, thyroid state appears to modulate specific protein kinases, and 
hypothyroidism even activates some nuclear kinase(s) while inactivating others. Further 
characterization of thyroid-responsive cytosolic protein kinases in livers of hypothyroid 
ra ts  416'469'47° shows that the cAMP-independent histone kinases are normally active while 
the casein kinases have half-normal activity. T4-treatment restores one fraction of the 
cAMP-dependent casein kinases to normal levels in 2-5 days, 469'47° and these are re- 
sponsible for the phosphorylation of the cytosolic proteins. 416 In addition, T3-adminis- 
tration to hypothyroid rats for 3 days activates a cytosolic cAMP-dependent protamine 
kinase. 416 Lag periods of days must be compared with the few hours it takes for T3 to 
activate hepatic lipogenic enzymes that are well documented to be activated when 
dephosphorylated. Thus, in vivo studies on protein phosphorylation in hypothyroid rats 
fasted-and-refed-glucose and injected with 32P i and T3 before killing, 93 are instructive 
because fasted/refed animals normally dephosphorylate hepatic cytosolic lipogenic 
enzymes. Before the hypothyroid rats receive T3, nuclear proteins incorporate injected 32p 
at 15-35% below normal levels--so hypothyroidism suppresses nuclear protein phos- 
phorylation. T3-injection progressively increases 3:p-incorporation to reach significant 
levels 6 hr later. Cytosol protein phosphorylation increases even more slowly. Again, the 
lag time in the nucleus seems too great to account for the 40 min that it takes T3 to activate 
the nuclear DNA-dependent RNA polymerase II (Ref. 286; but see Ref. 608). This 
is curious because both the hepatic polymerases I and II are activated by either 
cAMP-dependent or -independent protein kinases and inactivated by phosphoprotein 
phosphatases. 3m9 
Phosphoprotein phosphatases are of particular interest when one regards the number 
of enzyme reactions in the pathways of lipid metabolism (and of carbohydrate metabolism, 
for that matter) that are activated both by T3-treatment and by protein de- 
phosphorylation. 2H'm'267'319 No protein phosphatase has as yet been connected with thyroid 
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state. However, some of these phosphatases are indirectly activated through the phos- 
phorylation of phosphatase-inhibitor proteins by either cAMP-dependent or -independent 
protein kinases, 265 and thyroid state regulates activity of protein kinases of either 
persuasion, as well as [cAMP] (see Section Ill.B). 
Covalent enzyme modifications by phosphorylation/dephosphorylation mechan- 
isms 2tl'2m2 may also account for some hormonal and dietary interactions with T3 effects. 
A preliminary note reports that starvation (which was taken as a glucagon signal) decreases 
the degree of phosphorylation of several histones and non-histones in isolated nuclei 
incubated with [~,-32p]ATP, and refeeding carbohydrate (taken as an insulin signal) 
rephosphorylates nuclear non-histones. 3~ In contrast, insulin promotes dephosphorylation 
in hepatic cytoplasm. Dephosphorylation appears to regulate important cytosol enzymes 
in the pathways that convert glucose-6-phosphate to cytoplasmic acetyl-CoA, viz. phos- 
phofructokinase 2, pyruvate kinase (a cAMP-dependent protein kinase inactivates), and 
pyruvate dehydrogenase. Citrate lyase is subject to reversible phosphorylation, but its 
activity remains unaltered. As is discussed elsewhere in this review, conversion of 
acetyl-CoA to lipids also involves enzymes activated by dephosphorylation, 3m9 insulin, or 
thyroid hormone; these include acetyl-CoA carboxylase, glycerol-3-phosphate acyltrans- 
ferase (inactivated by a cAMP-kinase), HMG-CoA reductase, cholesterol-7~-hydroxylase, 
cholesterol ester-hydrolase (activated by a cAMP-kinase), and possibly fatty acyl-CoA 
A9-desaturase. 
2. Gene Expression 
As noted in the preceding section, T3 or T4 increase amounts and synthetic rates of 
several enzymes involved in fatty acid synthesis, in some cases after activating inactive 
enzyme. The rapid progress of studies on the T3-induction of such enzymes, and its 
relationship to the mechanisms whereby dietary carbohydrate induces lipogenic enzyme 
activities in the livers of starved animals, ~ has been updated; 3st'451-454 the details of 
information transfer are beyond the scope of this review. The enzymes most studied are 
fatty acid synthetase, acetyl-CoA carboxylase, citrate lyase, malic enzyme, glucose-6- 
phosphate dehydrogenase, and 6-phosphogluconate dehydrogenase. Additional rapidly 
induced lipogenic enzymes are the mitochondrial glycerol-3-phosphate dehydrogenase 
(see Section II.E) and the fatty acyl-CoA A9-desaturase (see Section II.I). The mechanisms 
of the synergism between carbohydrate-feeding and T3 treatment do not involve a 
carbohydrate-induced increase in nuclear T3-uptake per dosage, or the number and affinity 
of the T3-receptor sites. Further indication that insulin is not necessary for the T3-effect 
lies in observations that fructose-feeding restores the depressed T3-induction of hepatic 
malic enzyme in diabetic rats, since fructose is metabolized in the absence of insulin 
(see Kumar et al. 32~ for Refs). It is therefore postulated that some intracellular product 
of glucose metabolism induces malic enzyme, and that T3 acts as a constant multiplier of 
that signal in the nucleus. The nature of this metabolite is not known, but it appears to 
be of mitochondrial origin, since dichloroacetate promotes its action: dichloroacetate 
activates the pyruvate dehydrogenase by inhibiting the dehydrogenase kinase in the 
dehydrogenase complex. 
When injected in rico, the hormone augments or suppresses 21 out of 250 separated liver 
mRNAs. A T3-induced increase in pituitary growth hormone level effects the changes in 
7 of these 21 mRNAs. Carbohydrate-feeding also changes 8 of these 21, and in the same 
direction as T3. A dose of T3 large enough to convert receptor occupancy from the 
hypothyroid to the hyperthyroid level augments 4 of the mRNAs in carbohydrate-fed 
animals, from 4-fold to 13-fold. 376 Three of them are mostly induced in the range of 
T3-occupancy from euthyroid to hyperthyroid, as is malic enzyme-mRNA, mRNAst 4 
(see below), and activity of the lipogenic enzymes. Only 1 mRNA is induced at 4 hr 
(the earliest time of examination), the other 3 at > 8 hr. Obviously, only a few more 
proteins are involved in these rapid inductions than the half-dozen or so lipogenic enzymes 
studied, but not nearly enough proteins to account for the great diversity of thyroid effects. 
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And the 11 hr of T3 residence in the liver 537 is too short to account for additional 
T3-receptor-mediated, long-term syntheses. 
Several liver mRNAs respond very rapidly to T3. T3 and carbohydrate-feeding each 
start hepatic malic enzyme synthesis in about 2 hr, so neither works by stimulating the 
other. The amount of malic enzyme-mRNA translated correlates with the increase in malic 
enzyme synthesis, so synthesis and/or processing of the mRNA are primary events. These 
times are still longer than the 20-60 min after T3 injection reported for generation of a 
hepatic mRNA dubbed mRNAs,4. A heteronuclear precursor RNA for mRNAsl4 is said 
to appear as early as 10 min after a dose of T3 that saturates liver T3-receptors. 42° The 
proportion of basal, unstimulated [mRNAs14] to total mRNA contents is high in lipogenic 
tissues: 10 times greater in adipose cells than in livers of males, and 3 times more in livers 
of females (7 times if they are lactating) than in males. Hypothyroidism drops the mRNAst4 
content in fat by 80%. 287 T3 raises [mRNAs14] in lipogenic cells, to a varying degree. At 
24 hr, a receptor-saturating dose of T3 increases mRNAsj4 in fat cells twice as much as 
in liver cells. 287 
Non-lipogenic tissues have much less mRNAs,4: brain contains about 6% as much as 
male liver, kidney, heart and spleen < 1%; mRNAst 4 in these tissues does not increase after 
T3 administration. Thus, the presence of T3 receptors in kidney and heart is not sufficient 
for T3 to evoke this mRNA or its product. The translation product of mRNAsl 4, a 
cytoplasmic polypeptide of 17 kDa, does not appear to be a component of enzymes or 
transporters involved in fatty acid metabolism that have registered sequences. From its 
temporal primacy after T3 treatment, from the involvement of the T3-induced carbo- 
hydrate signal with protein phosphorylation, from the early T3-activation of existing 
inactive lipogenic enzymes, and from the known T3-induction of nuclear protein kinases, 93 
one can not resist the speculation that this is a subunit of such a kinase (or a 
phosphoprotein phosphatase). This, despite the fact that so far T3 induces known kinases 
much too slowly, and has no demonstrated effects on phosphoprotein phosphatases. 
Adipocyte nuclear receptors bind 0.4 ng LT3/mg DNA 71 as compared with 0.6 ng/mg 
DNA in liver nuclei. However, there is more disagreement as to the effects of thyroid state 
on enzymes of fatty acid synthesis and NADP ÷ reduction in adipose tissues. In 
hyperthyroid rats, Roncari and Murthy 499 find a 40% decrease in the in vivo synthesis of 
fatty acids, activities of fatty acid synthetase and acetyl-CoA carboxylase, and total fatty 
acid synthetase; corresponding values in liver are + 40% to + 90%. Contrarily, apparently 
equivalent LT4 or LT3 dose/time schedules increase fatty acid synthetase activity by 
50--70% in white fat ~'5'38° and rat neonate brown fat. 2°5 But Diamant et al)  ~5 find 
hyperthyroidism does not increase malic enzyme activity while it augments glucose-6- 
phosphate dehydrogenase and 6-phosphogluconate dehydrogenase activities, whereas 
Mariash et al. 38° see a rise in malic enzyme activity and no changes in these dehydrogenases. 
In adipose tissue from hypothyroid rats, activities of fatty acid synthetase, malic enzyme, 
glucose-6-phosphate dehydrogenase, and 6-phosphogluconate dehydrogenase are reported 
to be depressed 40% to 80% below normal levels) s° In apparently similar adipose tissue, 
acetyl-CoA carboxylase and glucose-6-phosphate dehydrogenase V values are ,-~ 2.5 times 
normal, and the specific activities of fatty acid synthetase and 6-phosphogluconate 
dehydrogenase are 50o  to 80% above normal levels; in the report of Correze eta/., 97 
T3-injection decreases glucose-6-phosphate dehydrogenase activity to near normal levels 
in 2-5 hr. This rapid inactivation is not attributable to any known activation of specific 
proteolysis, and the glucose-6-phosphate dehydrogenase is reported to be not subject to 
phosphorylation by cAMP-dependent protein kinases. 267 Since responses of lipogenic 
enzymes expected from adipocyte LT3-receptor occupancy and subsequent gene expres- 
sion are not observed by all investigators, it would appear that other regulatory 
mechanisms intervene, perhaps including altered states of phosphorylation. 
The situation is somewhat cleared by studies of cultured precursors of adi- 
pocytes, in which effects of several hormones on lipogenic enzymes can be distinguished 
(see Ref. 634a). Thyroid hormones, insulin, growth hormone, or glucocorticoids induce 
adipogenic activities in clonal lines obtained from fibroblast-like cells. As measured by lipid 
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synthesis and glycerol-3-phosphate dehydrogenase activity, T3 and T4 have no effects on 
primary cultures derived from adipose tissues, but insulin and glucocorticoids are required 
for conversion to adipocytes. T3 is essential for adipose differentiation of ob 17 cells ~9 and 
is active in preadipocytes kept in serum-free medium, but has no effect on rat preadipocytes 
under the culture conditions of Wiederer and L6ffler? 3~ Incubation of ob17 cells with 
1.5 nM T3 for 12 days first activates existing fatty acid synthetase, later increases the 
amount of fatty acid synthetase, and subsequently leads to accumulation of inactive 
enzyme that is still immunoreactive. 169 
Triiodothyronine induces lipogenic enzymes interactively with a number of hormones, 
including estrogens and luteinizing hormone (see discussion above, of the high basal 
[mRNAs~4] in females), growth hormone, glucocorticoids, and insulin. Insulin interactions 
are the most extensively studied. In all lines of adipocyte precursor cells, insulin induces 
a coordinate increase of acetyl-CoA carboxylase, fatty acid synthetase, malic enzyme, and 
citrate lyase. Insulin incubation with extracts of adipocyte plasma membrane normally 
promotes a kinase-mediated phosphorylation of Tyr in the insulin fl-subunit receptor; in 
extracts from hypothyroid rats, this autophosphorylation response to insulin increases 2- 
to 3-fold, and T3-treatment of these hypothyroid rats depresses the insulin 
action to normal levels in 24 hr. 99 Such a mechanism would seem to mediate an insulin-T3 
antagonism, while covalent modifications might mediate collaboration. 
One may ask what physiological purpose is served when calorigenic and anabolic 
hormones like T3 and T4 act so immediately on nuclear receptors to express genes for just 
a few lipogenic enzymes that mediate fatty acid and cholesterol (see Section II.H) synthesis, 
NADP + reduction, and perhaps fatty acyl-CoA desaturation (see Section II.I). 
Elongation of palmitoyl-CoA and general fatty acid chain elongation by malonyl-CoA 
in liver microsomes accelerates up to 3-fold in rats pretreated with thyroid hormones for 
21 days, and slows by 30-40% in rats made hypothyroid. 3°°'336 The competing malonyl- 
CoA decarboxylase remains unchanged by LT3-treatment, and decreases slightly in 
hypothyroidism. Fatty acyl chain elongation by acetyl-CoA condensation in mitochondria 
is not affected by thyroid state, 336 despite the thyroid-responsiveness of the carnitine 
palmitoyltransferase in the outer face of the inner membrane (see Section II.J), which is 
thought to intromit acyl-CoA for elongationfl 
Brains of adult animals readily incorporate labeled acetate from the blood and 
synthesize fatty acids that appear in PL, but the slow turnover contrasts with that of other 
tissues. The acetyl-CoA carboxylase and the fatty acid synthetase of brain are similar to 
those of other tissues, except that they have longer biologic half-lives, and do not respond 
to dietary changes. 6~ Hypothyroidism, when induced from birth, depresses fatty acid 
synthetase activity in brain as well as in liver; fatty acid chain elongation in brain 
microsomes and mitochondria is also reducedJ 93a Daily T3 treatment of normal rats 
starting at 1 day of age increases brain microsomal chain elongation by malonyl-CoA 
2.5-fold by day 6, to synthesize those saturated, long-chain fatty acids characteristic of 
myelin lipids. Thyroid treatment of normal adult animals does not affect brain fatty acid 
synthetase activity in doses that stimulate the liver synthetase. ~2° 
C. N A D P H  Generation and Oxidation 
1. Cytoplasm: N A D P  + ~ N A D P H  
Thyroid inductions of hepatic cytosol enzymes that reduce NADP + to NADPH include 
malic enzyme, glucose-6-phosphate dehydrogenase, and 6-phosphogluconate dehy- 
drogenase, which are discussed in Section II.B.2. Fasting/refeeding does not induce the last 
two enzymes in hypophysectomized rats; partial return of adaptation to refeeding occurs 
after 10-14 days of treatment with T3 (25%), hydrocortisone, or growth hormone; 
hydrocortisone + T3 (or growth hormone) restores induction 50%, and all three produce 
a supernormal response. ~°2'6°3 
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2. Mitochondria: N A D P  + + N A D H - - * N A D P H  + N A D  + 
Mitochondrial energy-dependent pyridine nucleotide transhydrogenase is thought to 
play a role in lipid syntheses by mediating the transfer of reducing equivalents from 
mitochondrial NADH to NADPH, whence the citrate shuttle transfers the equivalents to 
the cytoplasm to regenerate NADPH--a  role analogous to other thyroid-dependent cyto- 
plasmic generators of NADPH (see above). The transhydrogenase also provides mito- 
chondrial NADPH required in the oxidation of unsaturated fatty acids, 55 and so 
contributes to /~-oxidation. Among the auxiliary enzymes that metabolize the unusual 
A3-c/s-enoyl-CoA or A2-trans-A4-cis-dienoyl-CoA esters to intermediates accessible to the 
normal /~-oxidation enzymes are a 2-enoyl-CoA reductase and a 2,4-dienoyl-CoA 
4-reductase, both of which use NADPH to reduce double bonds. 
The hypothyroid state increases energy-dependent transhydrogenase activity but not 
energy-independent activity. ~36,137 In intact liver mitochondria, accelerated reduction of 
NADP + during the State 3--. State 4 transition provides an indirect measurement. 232,234 In 
submitochondrial particles where the enzyme is on the outer surface, manipulation of 
substrate concentrations provides measurements of kinetics) 36'~37 There the V of the 
ATP-supported and the succinate-supported activities is doubled in hypothyroid prepara- 
tions, while the K= values remain unchanged. Since the kinetics of the energy-independent 
mode of the enzyme are unchanged, the amount of enzyme would not appear to have 
increased. Because these particles oxidize succinate at normal rates, the coupling 
between energy source and transhydrogenation is thought to be increased in hypo- 
thyroidism. Within 3 days after injecting hypothyroid rats with LT4 or LT3, energy- 
dependent activities decreased to the lower, normal levels. Possible mechanisms that 
involve membrane lipids in the selective thyroid-dependency of the energy-linked 
transhydrogenase are discussed in Section IV.B.9. 
3. Microsomes: N A D P H  ~ N A D P  + 
Hyperthyroidism increases, and hypothyroidism decreases, activities of flavoprotein 
components of hepatic microsomal NADPH-oxidizing systems (NADPH-cytochrome c 
reductase and NADPH diaphorase). 29s'58s A small dose of LT3, given to hypothyroid rats, 
corrects activities within 20hr. 5ss Hypothyroidism concomitantly increases amounts of 
component hemoproteins (cytochrome b5 and P450). Some of these NADPH-dependent 
systems are involved in steroid metabolism (see Section II.H. 1). Flavoprotein components 
of NADH-cytochrome c reductase and NADH diaphorase are said to increase in activity, 
but we noted no change in NADH-cytochrome c reductase activity in our hypothyroid 
rats. 243 
D. Fatty Acid  Activation 
Long-chain fatty acyl-CoA synthetases (A in Fig. 1) in liver exist mostly in endoplasmic 
reticulum and in outer membrane of mitochondria, and much less in peroxisomes. 
Microsomal and mitochondrial enzymes are not identical. By their location and perhaps 
by their specificity, they segregate fatty acyls into a pool for glycerolipid synthesis (and/or 
chain elongation and desaturation) and a pool for oxidation, as has been shown for the 
two different acyl-CoA synthetases of the yeast Candida lipolytica. 445 Injected labeled 18:2 
is conserved from oxidation in vivo, 9x3~4 although isolated heart mitochondria oxidize 18: 2 
faster than 16:0. 57 Preferential esterification of 18:2 with CoA by the microsomal 
synthetase would direct 18:2 into giycerolipids or further desaturation, and away from 
mitochondrial oxidation. Trigiyceride and PL synthesis in hcpatocytes have different 
specificities for fatty acids. 75 Trigiycerides and diacylgiycerides incorporate all fatty acids 
indiscriminately, in a pattern that reflects the composition of the suspending medium. 
Phospholipids, especially PE and PI, incorporate more 20: 4 than do trigiycerides when the 
medium contains 18: 2 and 20: 4. 
Hepatic esterification of free fatty acids by long-chain acyl-CoA synthetase (A in 
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Fig. 1) is reduced in thyrotoxicosis and increased in hypothyroidism, 5s,333,4ml effects opposed 
to the rates of  triglyceride lipolysis. This seems consistent with the absence of  thermogenic 
cycling of  triglyceride/fatty acid re-esterification in adipose tissue from T3-treated mice. 63'~ 
Thyroid treatments do not alter the activity of  the palmitoyl-CoA hydrolase (B, Fig. 1) 
of  rabbit heart, 295 and so hydrolysis does not appear to compete with esterification. 
Through thyroid stimulation of  triglyceride lipolysis (see Section II.F), free fatty acids 
become more available for acyl-CoA synthesis as thyroid level increases. Thyroid state also 
controls CoA availability, but inconsistent effects are reported. Thus, low CoA contents 
of  livers of  thyroidectomized rats (other tissues are less depleted) increase to above normal 
levels with T4-treatment, 591 while others report CoA depletion in livers of  hyperthyroid 
rats, pigeons, and humans (see Ref. 226), and Mfiller e t  ai .  41m find increased CoA in 
pcrfused livers of  either hyper- or hypothyroid rats. In rats made deficient in pantothenic 
acid, injection of  T4 with pantothenate raises liver CoA content much more than does the 
vitamin alone, 6H suggesting thyroid effects on the enzymes and/or the 5,,-P-bonds involved 
in CoA synthesis. Compartmentation of  CoA accounts for some of these discrepant 
reports. Liver mitochondrial CoA content per unit protein is normally 2-3 times cytosol 
CoA content; cytosol CoA decreases by - 4 0 %  below normal in hypothyroidism, and 
increases 35% above normal in hyperthyroidism, while mitochondrial CoA hardly 
changes. 3~ With the hypothyroid liver containing about  20% of cytosol CoA as malonyl- 
CoA, little free CoA must be available. 
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FIG. 1. Fatty acid and cholesterol metabolism: fatty acid fl-oxidation, synthesis of 18:0, 
acctoacctate and 7a-hydroxycholcsterol; effects of thyroid state. *Affected by thyroid state. (A) 
Fatty acyl-CoA synthetase; +CoA. (B) Fatty acyl-CoA hydrolase; -CoA. (C) fl-oxidation. (D) 
Acetyl-CoA carboxylas¢; +CO 2. (E) Fatty acid synthetas¢; -CO 2. (F) Fatty acid elongation; 
+NAD(P)H. (G) Thiolas¢; +acetyi-CoA, -CoA. (H) HMG-CoA synthas¢; +acctyl-CoA, 
-CoA. (1) HMG-CoA lyas¢; +acetyl-CoA. (J) HMG-CoA reductase; +2NADPH, -2NADP +, 
-CoA; subsequent synthesis of cholesterol. (K) AcyI-CoA: cholesterol acyltransferase, + acylCoA; 
cholesterol esteras¢, -FA. (L) Cholesterol 7a-hydroxylase; +NADPH, +02, -NADP +. 
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TABt~ 2. Distribution of the [1-t4C] of Labeled Linoleate 
into Rat Liver Lipids 6 Hours after Injection ~s 
Normals Hypothyroids 
% of ~4C dose in EL 3.5 0.9 
% of YL 14C in PL 63.1 75.5 
% of Y-L m4C in TG 33.7 22.6 
% of YL 14C in 16:0 4.7 27.4 
% of Y-L 14C in 18:0 0 7.9 
% of Y~L 14C in 18:2 70.4 55.9 
% of YL 14C in 20:4 24.9 8.7 
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Whether the low hepatic free [CoA] or [fatty acids], or a low activity of the syn- 
thetase is (are) responsible, the livers of hypothyroid rats 'take up', i.e. esterify and 
transacylate, 76% less of an injected dose of labeled 18:2 than do the livers of euthyroid 
rats (Table 2; Ref. 248). It should be noted that hypothyroidism here sharply decreases 
reactions that would augment 18:2 acyl contents of membrane PL, yet organdie PL 
contain excess 18:2 (see Section II.A). This apparent paradox can be ascribed to a greater 
decrease in reactions that deplete 18:2 acyl contents, such as desaturations. However, the 
livers of perinatal rats contain little 18:2 while plasma [T3] and IT4] are low--in part, 
because esterification and transacylation enzymes have yet to develop, perhaps under 
influences that include thyroid hormones (see Section IV.C). 
E. Glycerolipid Synthesis 
Effects of thyroid state on triglyceride synthesis are tissue-specific: in hyperthyroid rats 
(normals +LT4, 0.5/zg/g/day × 5 days) triglyceride synthesis decreases in subcellular 
fractions from adipose tissue while it increases 2-fold in those from liver and heart:  99 In 
white adipose tissue of mice similarly pretreated with LT3 and injected with [3H]H20 to 
detect a triglyceride/fatty-acid cycle from the incorporation of tritium into glycerol and 
fatty acyls, triglyceride synthesis decreases by about half while fatty acid synthesis is 
unaffected, showing that cycling is halved. 63.64 The activities of the adipose tissue enzymes 
involved (Fig. 2) have not been described in the various thyroid states. 
The four enzymatic steps that convert glycerol-3-phosphate and fatty acyls-CoA to 
triglyceride (B, C, D, and E in Fig. 2) have been studied in liver and heart. The acylation 
of glycerol-3-phosphate (B in Fig. 2) has been postulated to limit the rates of triglyceride 
and phospholipid synthesis in normal animals. 26° However, relative rates, control 
coefficients, membrane-dependency, or correlations between activity and gene expression, 
[enzyme], and enzyme covalent modification of organelle enzymes of either tissue in 
animals in normal and abnormal thyroid states do not appear to have been compared. The 
increased potential for triglyceride synthesis 499 is apparently not expressed in intact 
perfused livers from LT4-pretreated rats, where synthetic rate decreases by 50%, and where 
making rats hypothyroid accelerates triglyceride synthesis. 333'449 In vivo LT3-injection 
similarly decreases synthesis in subsequently prepared hepatocytes. 449 Perfused livers and 
isolated hepatocytes are said to reveal those effects of thyroid state, probably due to 
A[enzyme], that persist in the absence of extrahepatic influence; thus, perfused livers from 
thyrotoxic animals fail to show the increases in fatty acid and cholesterol synthesis that 
appear in in vivo and in vitro studies. 333 On the other hand, hearts of postnatal rats injected 
daily with T3 30 times incorporate palmitate into triglycerides abnormally slowly: 17 
Because addition of glycerol to liver perfusates or to isolated hepatocytes, ~9 which 
increases cell [glycerol-3-phosphate], restores the depressed rate to normal in the hyper- 
thyroid preparations, Olubadewo and Heimberg 44s conclude that decreased availability of 
glycerol-3-phosphate accounts for the observed decrease in triglyceride synthesis in intact 
cells, even though activities of synthesizing enzymes increase. Competition by the 
extremely thyroid-sensitive mitochondrial glycerol-3-phosphate dehydrogenase (see below) 
would decrease the availability of glycerol-3-phosphate for acylations. Competition for 
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FIG. 2. Effects of thyroid state on some steps in the conversion of glycerol-3-phosphate to 
triglycerides and phosphoglycerides. P = phosphate; *affected by thyroid state, others not tested. 
(A) Glycerol-3-phosphatE dehydrogenase; +NAD(H) or FAD(H2). (B) Acyl-CoA:glycerol-3- 
phosphate acyltransferase; +acyI-CoA, -CoA.  (C) l-Acylglycerol-3-phosphate acyltransferase; 
+acyl-CoA, -CoA.  (D) Phosphatidate phosphohydrolase; +H20, -P i .  (E) Diacylglycerol 
acyltransferase; + acyl-CoA, - CoA. (F) CTP-phosphatidate cytidyltransfErase; +CTP, - PP~, 
((3) Includes phosphatidylglycerophosphate synthEtase (+glycerol-3-P, -CMP), phosphatidyl- 
glycerophosphatE phosphohydrolase (+H20, -Pi) ,  and CDP-diglyceride:ph0sphatidylglyceroi 
phosphatidyltransferasE (+ CDP-diacylglycerol, -CMP). (I-I) CDP-choline pathway to PC syn- 
thesis, which includes choline kinase, phosphocholine-cytidyl transfErase, and phosphocholine 
diacylglycerol transferase; +cholinE, +ATP, +CTP, -ADP,  -PPi,  -CMP. (J) Trans- 
mEthylation pathway to PC synthesis, which includes methyltransferase, + S-adenosylmethionine, 
-S-adenosylhomocysteine. Phospholipase A activities (not shown) can produce FFA at steps B 
and C. For more complete diagrams of pathways, see REfs 60, 388. 
fatty acyls-CoA by the thyroid-sensitive mitochondria! CPTi (see Section II.J) would 
similarly decrease availability of fatty acyls. 
Different glycerol-3-phosphate dehydrogenases (A, in Fig. 2) in cytoplasm and in the 
outer surface of the inner mitochondrial membrane act in a shuttle of substrates that carry 
reducing equivalents from cytoplasmic NADH to mitochondrial FADH2. Activity of the 
NAD+-dependent cytoplasmic enzyme is normally 10 times greater in liver than in heart, 
and does not change with thyroid state. 341"~ The FAD-dependent mitochondrial enzyme 
is normally 40% more active in heart than in liver. The liver mitochondrial FAD-enzyme 
responds so robustly to thyroid state that it is used as a verifying marker. Hypothyroidism 
decreases both liver and heart activity by -75%,  and depresses translocation of reducing 
equivalents into liver mitochondria. 629 Thyroid treatment of hypothyroid rats (LT3, 
,-, 3 #g/g 3 days before killing) or normal rats (thyroid-feeding for 10 days) increases liver 
mitochondrial activity 20-fold and heart mitochondrial activity 3-fold. PAGE and 
histochemical identification suggested that the induction does not involve gene expres- 
sion. 6°7 Because treatment with transcription- or translation-blockers inhibits the rise in 
liver mitochondrial activity, Lee and Miller ~5 concluded that the hormone promotes the 
supply of mRNA for synthesis of the enzyme. Through the use of polyclonal antibodies 
to pig brain glycerol-3-phosphate dehydrogenase that react with the rat liver enzyme, 
Taylor and Ragan 6°' show that T3-treatment of rats concomitantly increases the activity 
and amount of liver mitochondrial enzyme, and the amount of liver mRNA that codes 
for the enzyme. 
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In livers of rats treated with LT3 for 4 days, microsomal acyl-CoA: glycerol-3-phosphate 
acyltransferase (B in Fig. 2) activity decreases but mitochondrial activity remains 
unaffected) °4 This leaves the increased biosynthesis of triglycerides observed by Roncari 
and Murthy 499 unaccounted for, if step B has a high control strength. Hypothyroidism 
accelerates liver mitochondrial activity 38%, but not the microsomal enzyme. I know of 
no studies on effects of thyroid on liver enzymes C and D (Fig. 2). Liver microsomal 
diacylglycerol acyltransferase (E, Fig. 2) activity is thyroid-dependent, being + 60% above 
normal in thyrotoxics and - 4 0 %  below normal in hypothyroids. 647 Heart enzymes have 
been studied more completely. In hearts of rabbits injected with LT3 for 6-10 days, both 
mitochondria and microsomes form diacylglycerol-3-phosphate from glycerol-3:phosphate 
and 16:0 fatty acid (steps B, C in Fig. 2, and A in Fig. 1) 4-5 times faster than normally? 9s 
T3-treatment accelerates the acyl-CoA:monoacylglycerol-3-phosphate acyltransferase 
(C, Fig. 2) reaction more than the acyl-CoA:glycerol-3-phosphate acyltransferase (B in 
Fig. 2) reaction. 294'295 Further conversion of the diacylglycerol-3-phosphate to neutral 
glycerides or phosphoglycerides depends on the activities of three sets of reactions that 
compete for phosphatidate: conversion to triglyceridcs via D, E; to PC and PE Via D, H; 
and to cardiolipins via F, G. Phosphatidate phosphohydrolase (D, Fig. 2) activity increases 
in thyrotoxic rabbit heart microsomes and lysosomes, ~'~95 promoting diglyceride syn- 
thesis. Membrane-bound (but not solubilized) phosphohydrolase responds to T3, sug- 
gesting thyroid-mediated changes in membrane-dependency. But T3 does not alter heart 
mitochondrial or microsomal diacylglycerol acyltransferase (E, Fig. 2) activity, ~9s unlike 
its stimulation of liver enzyme. The increased activities of most of the cardiac triglyceride 
synthesizing enzymes in cell-free fractions seem consistent with a reported increase in 
triglyceride content in hyperthyroid guinea pig hearts. 58 However, no myocardial trigly- 
cerides accumulate in hyperthyroid rabbits, 295 and triglyceride content decreases in hearts 
of postnatal rats made hyperthyroid. 617 
Thyroid status relates directly to rates of phospholipid synthesis in organdie mem- 
branes, and more consistently than to rates of triglyceride synthesis. Hyperthyroidism 
increases the incorporation of 32P i injected in vivo into all individual PL of rat liver and 
kidney mitochondria and into PC and PE of heart, while hypothyroidism decreases 
incorporation into most of the PL in the mitochondria of liver and kidney but does not 
affect those of heart. 424'596'598'599 During the first 6 hr after injecting chickens with T3, 32P i 
enters liver PC and PE and then the other PL abnormally rapidly, m Hearts of thyrotoxic 
rats, as compared with those of controls, incorporate more administered fatty acid into 
PC, PE, and CL; 617 with the increased formation of diacylglycerol, this suggests that 
thyroid stimulates pathways to PL synthesis (H, Fig. 2) more than the synthesis of 
triglycerides (E, Fig. 2). 
The major metabolic route to phosphatidylcholine synthesis is from choline--,phos- 
phocholine--.CDP-choline + 1,2-diacylglycerol; these steps are included under H in Fig. 2. 
This pathway is thyroid-regulated, from studies on the incorporation of injected labeled 
choline into the PC of liver organdies. In liver mitochondria of hypothyroid rats, uptake 
decreases to half-normal, in thyrotoxic rats it increases 2- to 3-fold? 93 In livers of 
hypothyroid rats that receive one injection of LT3, uptake increases after 10 hr and 
progresses to 2-fold by 48 hr; choline incorporation into membranes is in the order 
microsomes > mitochondria > nuclei. 596,598'599 Recognized thyroid-sensitive steps are the 
phosphocholine (and -ethanolamine and ceramide) diacylglycerol transferases in liver 
microsomes. LT3-feeding of rats increases phosphocholine diacylglycerol transferase 
activity 40%, but induction of hypothyroidism has no effect. 647 In hypothyroid chicks, 
activities decline to levels that are 10-15% of controls; LT4-treatment of these chicks 
restores all three transferases to normal activity in 36--48 hr)  6s Cycloheximide given 
to the hypothyroid chicks restores all activities even faster, in 24hr, and does not 
alter the LT4 effect. This suggests that blocking synthesis of some protein (a protein 
kinase or phosphatase?) allows full activity of existing transferase enzymes. The 
phosphocholine-cytidyl transferase enzyme is inhibited by cAMP-dependent protein 
kinases) °~ In contrast to these enzymes, activity of a liver microsomal acyI-CoA: 1-acyl- 
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glycerol-3-phosphocholine acyltransferase increases in hypothyroidism and decreases in 
hyperthyroidism. 104 
The minor path for the hepatic synthesis of PC, with a rate-limiting step at the first 
methylation of PE by methyltransferase I and S-adenosylmethionine in plasma membranes 
and microsomes (J, Fig. 2), is augmented in the hearts of hyperthyroid rats (see Ref. 101). 
In vivo incorporation of (methyl-~4C)methionine into PC and lysoPC is maximally 
accelerated 5.5 hr after T3-injection. 3s~ These methyltransferases are activated by cAMP- 
dependent protein kinases, reciprocally with the inhibition of the CDP-choline pathway.~°~ 
Because PC synthesized via transmethylation contains more unsaturated fatty acyl groups 
than PC synthesized via CDP-choline transfer, a differential sensitivity of these paths to 
thyroid levels may produce some of the observed alterations in PC unsaturation, ~48 and 
perhaps modulate receptor responses) °~ 
In CL synthesis, step F and the several steps in G (Fig. 2) are accelerated in rats made 
thyrotoxic with 7 large daily doses of T4 (K. Y. Hostetler, personal communication). 
Hepatic CL synthesis is completely in the mitochondrial inner membrane) °6:1°'253'254,573 The 
required liponucleotides are produced by mitochondrial or microsomal CTP-specific 
transferases from phosphatidate (F, Fig. 2). 482 The T4-treatment increases mitochondrial 
CTP-phosphatidate cytidyltransferase activity 101% and mitochondrial phosphatidyl- 
glycerophosphate synthetase activity 41%. Activity of the mitochondrial phosphatidyl- 
glycerophosphate phosphohydrolase was not measured, but is generally thought not to 
limit CL synthesis. T4 accelerates synthesis of CL by the CDP-diglyceride:phosphatidyl- 
glycerol phosphatidyltransferase by 35%. If thyroid treatment stimulates CL synthesis, 
how then does hypothyroidism increase the CL/PL ratio in rat liver mitochondria? Hypo- 
thyroidism usually augments the concentration of a metabolic intermediate by decreasing 
its degradation more than its synthesis, not by increasing its synthesis. Although 18: 2 acyls 
normally turn over slightly faster in liver CL than in other PL, CL turns over much more 
slowly than other PL, 337 and CL and mitochondrial half-lives arecomparable. CL is 
degraded by phospholipases A and perhaps D, but not C; Ca2÷-ions activate a mito- 
chondrial phospholipase A2 that readily acts on CL in situ, although less than on PC, PS, 
or PE? 53 Brief T4-treatment enhances hepatic phospholipase As activity, 255'~ and a 
reciprocal suppression in hypothyroidism might depress 2-deacylation in CL more than 
in the other PL. Lysosomal hydrolases ultimately degrade CL, but do not appear to have 
been examined for thyroid-dependence. Alternatively, and depending on the substrate 
turnover rates of steps F + G vs. D (Fig. 2), the phosphatidate phosphohydrolase might 
be a metabolic branch-point where lack of thyroid hormone increases phosphatidate~CL 
conversion by decreasing diglyceride synthesis more. 
The mechanisms whereby cardiolipins from heart, liver and kidney (but not brain) are 
normally so enriched in 18:2 acyls are not known. Acyltransferases reacylate dilyso-CL 
with substrate specificities 18: 0-CoA > 18: 1-CoA >> 18 : 2-CoA, 253 yet the labeled 18: 2 acyl 
moieties of CL turn over more rapidly than other CL fatty acyls 337 and still maintain their 
profusion. Hyperthyroidism depletes CL 18:2 acyls (see Section II.A) presumably by 
stimulating the desaturative conversion 18:2-CoA~20:4-CoA (see Section II.I), but then 
it is not clear why hypothyroidism does not increase CL 18:2 acyls since it retards this 
conversion (unless 18:2 content is already maximal). These mechanisms are pertinent to 
thyroid influences on membrane content of CL and CL content of 18:2 acyls, and on 
oxidative phosphorylation, that are discussed in Section IV. 
F. Lipolysis 
LT4-injection into normal rats stimulates hepatic phospholipase A2 activity in 2 days, 
as well as the oxidative conversion of a small fraction of the liberated 20:4 acyls to 
prostaglandins (see Section II.K). No studies on hypothyroid rats are on hand. Since these 
enzymes selectively remove PUFA from sn-2 positions of PL, the simultaneous thyroid 
stimulation of acyltransferases (B, C in Fig. 2) should increase exchange and 
remodeling 338'369"~ of PL fatty acyl groups. 
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Adequate levels oi" thyroid hormone are permissive for epinephrine-induced but not 
basal unstimulated lipolysis of triglycerides in adipose tissue; n4'576 hyperthyroidism triples 
both basal and epinephrine-stimulated lipolysis; one injection of T3 into a euthyroid rat 
has no effect at 3 hr, but 4 injections over 12hr maximize the lipolytic response to 
epinephrine, n2 Thyroid exerts these effects via the responsiveness of lipolysis to [epi- 
nephrine]: hypothyroidism lowers sensitivity to the point that maximal lipolytic rates 
require 3 times more epinephrine than do euthyroid preparations, but the maximae are 
similar; 16 hr after T3-injection of hypothyroid rats, epinephrine-sensitivity improves. ~76 
Thus, hypothyroidism does not appear to reduce the amount or capacity of lipolytic 
apparatus, although the amount of hormone-sensitive lipase does not appear to have been 
measured directly. Since the lipolytic effects of other hormones (e.g. norepinephrine, 
ACTH, TSH, glucagon, vasopressin) also depend on the thyroid state, it seems that thyroid 
regulates through effects on [cAMP], the phosphorylation state of the hormone-sensitive 
lipase (see Section II.F and III.B), and/or the properties of cell membrane receptors 
(see Section III). 
G. Ketogenesis 
Ketogenesis from 18: 1 oxidation (steps A, C, G, H and I in Fig. 1) increases in perfused 
livers 333'4n and in hepatocytes 44s from LT3-pretreated rats. Livers from hypothyroid rats 
either make more ketone bodies but oxidize less 18:1 to CO2, 233 or show no change 
from normal? I~ The HMG-CoA pool destined for ketogenesis is mitochondrial, that 
for cholesterogenesis cytosolic, and the HMG-CoA synthases are compartmented ac- 
cordingly. The mitochondrial HMG-CoA synthase may be 'rate-limiting' for ketogenesis 
(see Ref. 650), but data are not available on its activity and that of the HMG-CoA lyase 
in different thyroid states. 
H. Cholesterol Metabolism 
A variety of interacting physiological stimuli, including thyroid state, regulate choles- 
terol metabolism. 6s'394'42s Thyroid-sensitive sites in cholesterol metabolism include steps in 
intraceUular synthesis, conversions to other sterols, cholesterol processing at cell mem- 
branes, and cholesterol transport. 
1. Intracellular Cholesterol Metabolism 
The rate of cholesterol synthesis from acetate (but not from mevalonate) and the 
turnover of cholesterol relate directly to thyroid levels. 122 The hepatic microsomal 
~-hydroxy-fl-methylglutaryl-coenzyme A reductase (HMGR; J in Fig. 1) is said to be 
'rate-limiting' for acetyl-CoA-*cholesterol. This enzyme is highly regulated, by hormones, 
and by cholesterol and its precursors and metabolites. Cholesterol or its oxidized products 
decrease cholesterol synthesis by suppressing transcription of the HMGR gene; LDL, 
mevalonate, 25-hydroxycholesterol, and phosphorylation of H M G R  accelerate HMGR 
degradation. In thyrotoxic rats, HMGR, acetate thiokinase, and HMG-condensing 
enzyme activities all increase over normal rates; in hypothyroids only H M G R  activity 
decreases, and to ver~, low levels, t9° Experiments on the effects of thyroid treatment under 
different conditions give complementary information on the time course of the activation 
and later induction of HMGR. Perfusion of isolated livers of hypothyroid rats with T3 
activates H M G R  within 30 min, 5-fold at 120 min and 10-fold at 360 min) 9° One injection 
of T3 into hypothyroid rats induces HMGR: activity is unchanged when the earliest time 
of measurement is 12 hr, and begins to rise only at 36 hr, to reach a maximum at 48 hr. 19v 
Thyroid treatment induces H M G R  even more strikingly in hypophysectomized rats, but 
as slowly as in hypothyroid rats? 29 The liver microsomal HMGR activity in untreated 
animals is depressed more than the 50% seen in hypothyroids, to barely detectable levels. 
A dose of LT3 that saturates 90% of liver nuclear T3-receptors increases activity only after 
JPLR 27/3--E 
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36 hr, and maximally at 48-72 hr; HMGR activity in rough microsomes rises to 4 times 
normal, and acetate is converted to cholesterol at 10 times the normal rate. Under these 
circumstances, thyroid hormone induces HMGR only in liver and adrenal, and not in 
kidney, brain, or testis. T3-treatment of normal rats does not activate. Inhibitor studies 
indicate that these relatively slow inductions in hypophys~tomized rats involve new 
mRNA synthesis, m'429 Forty-eight to 72 hr after T3-injection, reductase mRNA appears 
together with a 97 kDa protein that reacts with antisera to pure HMGR, and reductase 
activity accelerates many-fold. 52° An HMGR-immunoreactive, 35 kDa protein is present 
in untreated hypophysectomized rats and is not augmented after T3-treatment. The lag 
period of 36 hr practically eliminates the possibility that T3-occupancy of nuclear receptors 
is directly promoting HMGR gene expression (see Section II.B.2), and indicates that the 
increased activity at 3 hr of liver perfusion is an activation of existing enzyme. It seems 
likely, then, that synthesis of new HMGR is mediated through secondary alterations after 
T3 enters the cell. Zammit and Easom 652 propose that covalent modification of HMGR 
mediates A[HMGR]: phosphorylated enzyme is inactive and is proteolytically degraded 
faster than the active dephosphorylated form. ~7 This would explain the sequence 
activation~persistence but not activation~synthesis. 
Injection of a glucocorticoid blocks the T3-promoted increase in activity TM and the 
appearance of 97 kDa active HMGR, and halves the amount of new reductase mRNA; 52° 
perhaps the absence of ACTH in hypophysectomized rats permits T3-induction to exceed 
that in hypothyroid rats. Feeding mevinolin or cholestyramine to these animals increases 
HMGR activity to levels only 10-40% of those reached after T3-injection. It is concluded 
that T3 is not absolutely required, and may induce HMGR indirectly, perhaps via 
oxysterol metabolites of mevalonate. Thyroid also activates HMGR in concert with insulin 
or fasting/refeeding. In hypophysectomized diabetic rats, the activity that insulin induces 
at 2 hr, and that T3 induces at 54 hr, are each blocked by administration of glucagon or 
glucocorticoids334--perhaps indicating that cAMP-mediated protein-phosphorylation 
blocks both enzyme activation and gene expression. These studies may be pertinent to 
possible thyroid effects through [cAMP] regulation (see Section III.B). 
Most investigators agree that dephosphorylation activates, and phosphorylation deacti- 
vates, the HMGR in situ in microsomes. 29'2~a6s'652 Some find that phosphorylation 
reversibly inactivates purified, electrophoreticaUy homogeneous HMGR, 427'432 others that 
it does not. 42s Ness et al. 42s'43°'43~ suggest that a mevalonate kinase, present in preparations 
of HMGR kinase, accounts for effects attributed to the HMGR kinase, and that the 
allosteric kinetics of NADPH as cofactor for the double reduction of HMGCoA may 
mediate regulatory effects. Thyroid state controls cytoplasmic [NADPH] (see Section II.C). 
The significance of HMGR regulation by such covalent modification has been questioned 
because the enzyme was found to be >90% phosphorylated and inactive under most 
conditions, including those favoring cholesterol synthesis (see Ref. 652). However, with 
appropriate rapid methods (using cold-clamped livers from anesthetized fed rats), 80% of 
HMGR is in dephosphorylated, active form, and insulin-state in vivo acutely regulates 
HMGR phosphorylation. Analogous specific effects of thyroid-state on HMGR phos- 
phorylation await similar examination, even though T3-administration takes days to 
detectably augment protein kinase activities and a general phosphorylation of endogenous 
proteins (see Section II.B.2). Thyroid also regulates the adenylate kinase and thereby 
[cAMP] (see Section III.B. 1), which may in turn modulate protein kinase or phosphatase 
activities. 
The HMGR is membrane-dependent. Arrbenius profiles of its activity inflect, when 
measured in microsomes, 4°1'472'm'56~ and in a partly purified preparation. 427 Alterations of 
endoplasmic reticulum fatty acyl and cholesterol composition, produced by diet, or by 
inducing diabetes (thyroid effects have not been examined), shift the transition tem- 
peratures and alter E, values. 562~ Compared with rats fed saturated fatty acids, the feeding 
of 18:2 fatty acid doubles the 18:2 content of the endoplasmic reticulum membrane, 
decreases HMGR activity at 37°C by 70%, and doubles acyl-CoA:cholesterol acyl- 
transferase activity (Ref. 401; K in Fig. 1). Adding cholesterol to either the saturated fat 
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or the 18:2 diet decreases HMGR activity by 90%. It has been suggested that membrane 
cholesterol rather than fatty acyls modulates HMGR activity, because the increased E, 
above the transition temperature indicates decreased fluidity? °~ The opposing effects on 
acyl-CoA:cholesterol acyltransferase activity are ascribed to its location in the rough 
endoplasmic reticulum, while the HMGR is in the smooth endoplasmic reticulum-- 
although cholesterol accumulation does not seem to have been so localized. Studies 
comparing normal and leukemic lymphocytes 4n also conclude that endoplasmic reticulum 
membrane cholesterol regulates HMGR activity. If the general inhibition of lipogenesis 
by high contents of 18:2 acyls in endoplasmic reticulum 279'4~3 includes inhibition of 
cholesterol synthesis, T3-injection could produce early activation of HMGR through the 
observed rapid depletion of ER 18:2 acyls, in a period when cholesterol/fatty acyl ratios 
stay constant. 236'24s 
Cholesterol 7~-hydroxylase (L in Fig. 1), an NADPH-dependent cytochrome P450 
(perhaps a specific P450) of the endoplasmic reticulum, catalyzes 'the rate-limiting, 
committal step' in hepatic bile acid biosynthesis, and is thus a major disposal path 
for cholesterol. The enzyme is a regulatory site: it has a short half-life (2-4 hr) and a diur- 
nal rhythm, and is rapidly activated by feeding carbohydrate to starved animals. 
Almost all physiological regulators, including thyroid hormones, act on the 7~-hy- 
droxylase in coordination with, and in the same direction as, their actions on the HMGR, 
the acyl-CoA:cholesterol acyltransferase, and the cholesterol ester-hydrolase. Hypo- 
thyroidism decreases activity. 5s2 Thyroid treatment activates in hypophysectomized rats, 
and so acts independently of those hormones evoked by pituitary trophins. However, 
thyroid state also modulates other regulators of the hepatic cholesterol 7~-hydroxylase. 
The cholesterol 70e-hydroxylase is more sensitive to in vivo thyroid levels than is the 
HMGR. 592 In fasted euthyroid rats, refeeding with glucose activates cholesterol synthesis 
within 3 hr, and increases 70~-hydroxylation starting 1 hr laterfl 3 When rats are made 
increasingly hypothyroid with graded doses of propylthiouracil, and then fasted and refed, 
the lowest dose decreases stimulation of 7~-hydroxylase activity, but only the highest dose 
decreases activation of acetyl-CoA conversion to fatty acids and to cholesterol. Con- 
versely, making rats hyperthyroid with graded doses of T4 increases glucose-induced 
7~-hydroxylase activity at the lowest T4-dose, cholesterol synthesis at the highest. 
Further, glucose stimulates 7~-hydroxylation more rapidly in hyperthyroid than in 
hypothyroid preparations, but activates cholesterol synthesis at about the same time in 
both. 
The mechanisms of the early regulations are consistent with an activation by de- 
phosphorylation, except for the adrenal cortex cholesterol esterase which is inactivated 
thereby, and the liver enzyme which does not appear to be affected at all. However, the 
7~-hydroxylase has only been studied through activity changes in microsomal preparations 
incubated with protein kinase + MgATP, or protein phosphatase. ~Ts'33L524 No measure- 
ments of the phosphorylation stoichiometry of the purified enzyme are on hand, so the 
7~-hydroxylase does not as yet meet the criteria of Krebs and Beavo 319 for an enzyme 
regulated by phos/dephos. Nor have the rapid assays used by Zammit and Easom 652 on 
the HMGR been applied to this enzyme. 
The details of the modulation of the cholesterol 7~-hydroxylase differ from those of the 
HMG-CoA reductase in several ways. Insulin administration, perhaps by way of a specific 
phosphoprotein phosphatase, activates the reductase but not the hydroxylase; hydro- 
cortisone activates the hydroxylase but deactivates the reductase. Possibly the different 
mechanisms are involved in what have seemed to be 'biphasic actions' of the administered 
thyroid hormones 226 on cholesterol levels in cells and blood, in which low T3-dosage raises 
cholesterol levels and high T3-dosage lowers them. 
Thyroid hormones also promote steps in the synthesis of bile acids from 7~-hydroxy- 
cholesterol. 332"4~4 In rats, but not in humans, the hormone increases [chenodeoxycholic acid] 
at the expense of [cholic acid], apparently by activating the microsomal (but not the 
mitochondrial) 26-hydroxylase, and deactivating the 12~-hydroxylase. Hypothyroidism 
effects the opposite changes. These modulations are not general to cytochrome P450s, since 
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thyroid treatment increases, and hypothyroidism decreases, total liver P450. Such select- 
ivity also appears in the undisturbed ability of the hypothyroid rat to induce specific 
hepatic P450s after treatment with methylcholanthrene, u3 phenobarbitone and other 
xenobiotics. ~1 
Thyroid state affects steroid kinetics in the whole body. In thyrotoxic humans, sec- 
retory rates of the C-21 steroids cortisol and aldosterone are augmented, as is their 
metabolic clearance which includes a shorter half-life and increased turnover. Is4 Hypo- 
thyroidism exhibits opposite effects. Contrarily, thyrotoxicosis depresses metabolic clear- 
ance and secretory rates of the C-19 and C-18 steroids testosterone and estradiol, while 
hypothyroidism increases them. These phenomena seem to be caused in part by the 
thyroid-dependence of specific, high-affinity, binding proteins in plasma of males and 
females. The [free steroid] levels in plasma are not changed, nor are symptoms of steroid 
excess or deficiency obvious. Thyroid levels do affect cellular metabolism however. 
Thyroid increases aromatase activity. An increase in hepatic reduction of C------C bonds in 
ring A is attributed to an increase in [NADPH] (see Section II.C) rather than to induction 
of the A4-corticosteroid hydrogenase. 645 Thyroid also accelerates 5~-reductions and 
17~-hydroxysteroid dehydrogenations. 184 Sex difference regulates thyroid effects on pro- 
gesterone metabolism in hepatic microsomes. 298 In males, progesterone hydroxylation is 
normally faster, and A4-reduction slower, than in females. T4-treatment decreases 
hydroxylation and increases A4-reduction in males but not in females. 
Intracellularly, the lysosomal acid cholesterol esterase activity in liver and adipose tissue 
(but not in heart) is thyroid-dependent: ~47 hypothyroidism decreases activity, T3-treatment 
for 3 days increases it. 
2. Cholesterol Transport 
Thyroid hormones reduce plasma [cholesterol] at least in part through increased hepatic 
catabolism of cholesterol. 397 The hypocholesterolemic effects of thyroid hormones offer a 
therapeutic opportunity for prevention and even reversal of atherosclerosis. However, the 
strong inotropic and chronotropic cardiac effects of LT4 and LT3 preclude their use where 
most needed, in coronary atherosclerosis. DT4 lowers [cholesterol] and stimulates heart 
action less than LT4 but still formidably. A recently described T3-analogue, a synthetic 
thyromimetic SK&F-94901, lowers plasma [cholesterol] in hypothyroid rats as effectively 
as LT3 by acting on liver cholesterol metabolism but has a strikingly lesser cardiac 
chronotropic effect; its mechanism of action is described in Section II.B. 
Thyroid hormones participate in the regulation of several steps in the pathways 
described by Bilheimer 3s as transporting exogenous or endogenous cholesterol, and those 
of reverse transport. In the endogenous transport, hypothyroidism decreases the expres- 
sion of hepatic plasma membrane LDL-receptors, and the decreased LDL degradation 
contributes to the observed hypercholesterolemia; 53° T3 treatment restores receptor- 
mediated catabolism of LDL. 74 In the reverse pathway, the PC-cholesterol acyltransferase, 
which is thought to esterify cholesterol in plasma, is poorly secreted from hepatocytes of 
hypothyroid rats, further contributing to the increased [cholesterol]. 2°9'493 In the exogenous 
path, it has been proposed that the intestine plays a major role in cholesterol metabolism. 3s7 
Thyroid state-altered rates of absorption, synthesis and excretion are said to be offset by 
compensatory changes in cholesterol transformation, to maintain the cholesterol balance. 
These workers disagree with the usually accepted idea that continuous thyroid treatment 
decreases blood cholesterol concentration by stimulating cholesterol degradation and 
elimination more than cholesterol synthesis. If this were so, they point out, such treatment 
should progressively deplete body cholesterol--but measured body cholesterol content 
stays constant in hyperthyroidism. They show that hyperthyroidism depresses the 
coefficient of intestinal absorption of cholesterol (the amount of dietary cholesterol 
absorbed/ingested), which promotes biosynthesis and results in large increases in fecal 
excretion of cholesterol and products. Conversely, hypothyroidism increases the absorp- 
tion coefficient, decreases fecal excretion, and thereby depresses biosynthesis. No mech- 
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anisms for this homeostasis are specified, but presumably they would involve effector 
actions of cholesterol and metabolites on synthesis and oxidations. 
Thyroid dysfunction is associated with altered compositions and concentrations of all 
major plasma lipoprotein classes. 2°9,3°5 The lipoprotein lipase that heparin releases into 
blood from extra-hepatic capillary endothelium is involved in all three pathways of plasma 
cholesterol metabolism. Its activity decreases in severe hypothyroidism and normalizes 
after hormone treatment. Conflicting results are reported in thyrotoxicosis, but Hansson 
et al. 2°9 find no change in human plasma activity, where plasma [cholesterol] decreases 20% 
through depressed [LDL] and total [HDL]; it is not clear what lipoprotein lipase hydrolysis 
of glycerides and the subsequent concentration of cholesterol into IDL particles contribute 
to plasma [cholesterol]. The role of the hepatic cell membrane lipase in plasma lipoprotein 
metabolism is also not well understood, but heparin releases less than normal lipase 
activity into the blood stream in hypothyroid subjects and more than normal in euthyroids 
treated with T3.  2°9'263 Feeding hypothyroid rats a diet enriched in 18:2 and 20:4 restores 
levels of heparin-released hepatic lipase in a week, suggesting that depression of liver cell 
membrane fluidity or co 6-PUFA content is responsible for defective binding and/or content 
of this enzyme. 263 
I. Fatty Acid  Desaturation 
Oxygen-dependent liver microsomal fatty acyl-CoA desaturases specific for introducing 
a double bond into the A9 or A6 positions (and probably the A5 and A4 as well) share 
an electron-donating transport system that consists of NADH-cytochrome b 5 reductase 
and cytochrome bs. In microsomes from hypothyroid rats, the V a n d / ~  for the reductase, 
measured with cytochrome c as electron acceptor, are at normal levels. 243 Cytochrome b5 
content is 50% above normal in microsomes from hypothyroid rats, 30% below normal 
in those from thyrotoxic animals, and is transiently decreased hours after hypothyroids 
are injected with T3 (Table 3). However, the thyroid dependency of the desaturase system 
resides in the desaturase proteins, as shown by spectrophotometric assays of the rates of 
reoxidation of reduced b5 in the presence of the acyl-CoA substrate. 4s°'4s7'4ss Apparent 
first-order rate constants, k, are calculated from initial rates; k + is the rate constant 
attributable to electron transport through the substrate, and k -  is the cytochrome b5 
autoxidation rate constant observed in the absence of substrate (Table 3). In hypo- 
thyroidism, k-  is at normal levels; T3 injected into hypothyroid rats progressively raises 
k -  over 4 hr; in T3-injected normal (thyrotoxic) rats k -  is high. 
TABLE 3. Fatty Acyl-CoA Desaturase Activities, Cytochrome bs Autoxidation Rates and Contents in Rat Liver 
Microsomes, and Changes after LT3 Injection(s)* 
Hypothyroids + LT3 
(hours after injection) 
Controls Hypothyroids Controls 
(6--8) (6-10) 0.5 (2) 1.0 (6) 2.5 (5) 4.0 (6) + LT3 (8) 
A9-Desaturase: 
kw~ (rain-i) 2.7 3.1 3.7 4.9 5.6 8.9 ̂  10.2 A 
K m (/~M) 2.0 1.6 1.9 0.7 1.2 3.3 5.3 
A6-Desaturase: 
kwx (rain -t  ) 4.5 2.2 c 6.1 4.4 c 6.0 A 3.5 2.8 
Km (IZM) 17.9 3.6 9.0 10.2 9.7 5.1 2.6 
A5-Desaturase: 
V (pmol/min/mg) 12,8 7.0 26.0 
Kra (/zM) 0.15 0.06 0.14 
Autoxidation: 
k - (rain- t) 1.9 1.6 2.2 2.4 a 2.4 e 2.9 e 4.2 a 
Cyt. b s (nmol/mg) 0.13 0.20" 0.20 0.17 0.14 e 0.18 0.09 e 
*See Table 1 for details, and the text for definitions of kinetic parameters. Only means are shown; for 42 values, 
the coefficient of variation is 21.1% + 2.1% SE. For group comparisons: p < ~'0.001; be0.01; ~"0.05; lower case 
symbols denote p values for comparisons of Hypothyroids vs. Controls, upper case symbols for comparisons of 
Hypothyroids + LT3 vs. Hypothyroids and Controls + LT3 vs. Controls. 
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The extrapolated maximal desaturation rate constant, km~ = k + at [S] = oo, and Km for 
the A9-desaturase (stearoyl-CoA, 37°C) in fasted hypothyroid rats is the same as in fasted 
euthyroid rats; k + is 4 times normal in fasted thyrotoxic rats (Table 3). In hypothyroid 
animals a fasting/refeeding-with-carbohyrate cycle does not increase the A9-dcsaturase k +, 
whereas in normal rats it raises k + strikingly. 243'4ss One LT3 injection increases the 
A9-desaturase k + in fasting hypothyroids linearly over 4 hr (Table 3; r = 0.972) and (not 
shown) to 5-fold at 17hr. The T3-induced changes in microsomal PL fatty acyl 
composition 2~ do not appear to mediate the increased k +, as judged from Arrhenius 
profiles. 243 Brain A9-desaturase activity decreases from birth, to reach 10% of that in the 
fetus at maturity; fasting/refecding does not consistently induce the adult enzyme, s" 
The purpose of the thyroid dependency of this enzyme is likely connected with the 
thyroid dependency of the enzymes of de novo fatty acid synthesis, which also are activated 
1-4 hr after LT3 injection in hypothyroid rats, and are subsequently synthesized (see 
Section II.B). In view of the activations of acetyl-CoA carboxylase and the fatty acid 
synthetase by dephosphorylation, it is therefore of some interest that 2 hr incubation of 
Tetrahymena pyriformis with/~-adrenergic agonists increases [cAMP] together with fatty 
acid synthesis and the activities of the microsomal A9- and A 12-desaturases. 6'3 The dietarily 
'induced' A9 enzyme in rat liver microsomes is partly and progressively inhibited by a 
protein kinase + ATP (unpublished data), further suggesting that the A9-desaturase acts 
in concert with the fatty acid synthesizing process. Unlike the cytosolic fatty acid 
synthesizing enzymes, the A9-desaturase has not yet been resolved from other microsomal 
polyl~ptides for study of its phosphorylation state or for immunoassay. 
Three metabolic roles can be distinguished for the A9-desaturase in converting 
18:0-CoA~18:I-CoA. Derived (as well as dietary) 18:l-acyls are normally a major 
membrane component. Oleoyl-CoA becomes a precursor for PUFA in membranes, mainly 
20:3co9 produced by the A6- and A5-desaturases, only when co6-EFA intake is deficient: 
the A9 enzyme is the first step in producing unsaturated fatty acids from endogenous 
sources when necessary. The A9-desaturase is proposed as a major locus where dietary 
linoleate down-regulates hepatic lipogenesisy 9 18:2 also selectively damps the enzymes of 
de novo fatty acid synthesis, m While dietary carbohydrate rapidly induces the enzyme, 
dietary 18:2 inhibits the A9-desaturase even more effectively and rapidly than it inhibits 
the fatty acid synthetase, the A9 enzyme having the much shorter biological half-life of 
3-4 hr. Insulin induces Ag-desaturase activity when incubated for 48 hr with hepatocytes. 2s° 
In diabetic rats, activity stops in microsomes of liver and fat; fasting/refeeding induces the 
enzyme only 24 hr after insulin treatmenU 6s Interestingly, thyroid treatment of diabetic 
rats induces the A9-desaturase and fatty acid synthesis independently of insulin. ~75 
Liver microsomal A6-, A5- and A4-acyl-CoA desaturases, 56'27s,57° and separate micro- 
somal desaturases that act on the corresponding PL-acyls rather than acyl-CoAs as 
substrates, ~6 synthesize PUFA for membrane components (mainly 20:4<o6 and 22:6co3 
in rat organelles) and as precursors of prostanoids. In hypothyroids, the acyl-CoA A6- and 
A5-desaturase km,~ values are about half-normal (p > 0.05 for the A5- V); values for KI 
are normal (p > 0.05 for the low A6-desaturase Kin) (Table 3). Injecting hypothyroid rats 
with LT3 transiently increases the A6-desaturase km~ about 3-fold in 2.5 hr. Thyrotoxicosis 
doubles the A5-desaturase kmax, and leaves the A6-desaturase kmax unaltered. The high 
A6-desaturase activity in the thyroid-sensitive brain of fetal rats persists to 20 clays after 
birth, as the brain becomes less responsive to thyroid, 94 in consistence with the behavior 
of the hepatic enzyme. 
The thyroid-dependence of the hepatic A6- and A5-desaturases seems to account for 
the 18:2 acyl accumulation in organelle membranes of hypothyroid rats, and depletion 
in thyrotoxics. ~4°'14~'236'239'242'262 It accounts as well for decreased ability of the livers 
of hypothyroid rats to convert administered [1-14C]18:2 fatty acid to 20:4 fatty acyls 
(Table 2). Livers of diabetic rats show a similar defect, ~58 but no insulin-independent 
T3-induction of the A6- and A5-desaturases has been described that parallels the induction 
of the A9-desaturase. m The transience of the restoration of A6-desaturase activity after 
hormone injection (Table 3) suggests either enzyme turnover or successive activation and 
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deactivation. Despite the restored A6-desaturation activity, which should improve the 
18:2--,20:4 conversion (unless the AS-desaturase proves to be unrestored by T3), 
T3-administration counter-correctively depresses PUFA contents in mitochondrial and 
microsomal lipids even below the abnormally low levels in untreated hypothyroid rats 
(Ref. 248; Table 1). The most likely concomitant T3-induced mechanism to remove PUFA 
is massive and rapid substitution by newly synthesized saturated and mono-unsaturated 
fatty acyls (see Section II.B.1), like that after fasting/refeeding. 7̀ s Phospholipase A2 action 
(see Section II.F) may remove PUFA. 
1. Anuran Metamorphosis 
Thyroid-induced metamorphosis involves early general increases in hepatic protein 
synthesis, and phospholipid synthesis increases even earlier--presumably to provide 
membranes to support the increased translation of newly expressed mRNA. 5~599 We have 
recently found that thyroid control over PUFA composition is also involved very early 
in amphibian metamorphosis. 
Tadpoles are naturally athyroid. Lipids of tadpoles and frogs have distinctive fatty acyl 
unsaturation profiles. In the livers of Rana pipiens, Xenopus laevis and Rana catesbeiana 
tadpoles the major unsaturated fatty acyls are monoenes and the polyene acyls of the 
dietarily essential fatty acids 18:2to6 and 18:3to3. 23a'24~ Frog livers contain less monoenes 
and more PUFA products of A6- and A5-desaturations of the essential fatty acids. Heart 
lipids from R. pipiens tadpoles or frogs have higher proportions of biodesaturated polyene 
acyls than do their respective liver lipids. Liver lipids of R. catesbeiana tadpoles contain 
67% neutral lipids, frog liver lipids contain 75% polar lipids. Both neutral and polar lipids 
from the tadpoles are higher in monoenes than are the corresponding lipids from frogs. 
We do not know the relative amounts or the fatty acyl compositions of the PL subclasses. 
Tadpole livers metabolize intraperitoneally injected [1-14C]18:2to6 unexpectedly vigoro- 
usly, considering how few derivatives accumulate in their lipids. In 18 hr, 20% of the 
counts are incorporated into liver lipids, of which 40% is in polar lipids. Frogs incorporate 
10% of the carbon counts into liver lipids, of which 90% is in polar lipids. Of the total 
counts in either tadpoles or frogs, 37% is in biosynthesized co6-PUFA derivatives. This 
degree of metabolism may be compared with that in livers of rats 6 hr after receiving 
labeled 18:2 (Table 2); normal rats incorporate 3.5% of injected label and convert 25% 
of it to the 20:4 derivative; hypothyroids incorporate 0.9% of label and convert only 8.7% 
to 20:4. 
Thyroid hormone specifically induces Anuran metamorphosis) 98 During the natural 
development of tadpoles, the proportions of liver lipid mono-unsaturated acyls decrease 
and those of polyene acyls increase at the stages when plasma thyroxine levels rise 5s8 and 
urea synthesis begins, m6 as shown in Fig. 3. The changes in unsaturation pattern follow the 
natural surge of circulating [T4] at least as closely as does the appearance of urea. 
Thyroid-induced metamorphosis is accompanied by similar lipid alterations. Immersing 
tadpoles in 1 #M T3 for 48 hr converts their liver lipid profile to or beyond the polyene 
pattern typical of frogs. Injecting tadpoles once with T3, 0.2 #g/g, produces similar but 
lesser and transient changes over 5 days. Injecting frogs with T3, 1 #g/g, decreases liver 
monoene contents transiently over 2 days and in addition partially depletes to 6-PUFA--as 
it does more rapidly in hypothyroid rat liver organelle membranes (Table 1). When 
tadpoles are injected with T3 at time = 0 and with labeled 18:2 at 18 hr, the following 
changes occur. The ratio of liver PL to total lipids increases to reach 76% by the 8th 
day after T3 injection. The PL incorporate more of the ~4C, the neutral lipids, less. 
The proportion of label in desaturation products of 18:2 in the PL increases linearly 
over the 8 days to become 2.5 times greater than in untreated tadpoles or in frogs. 
Similar T3 treatment changes tadpole liver endoplasmic reticulum from simple vesicular 
membranes to more complex lamellar s t r u c t u r e s .  ~7 
We conclude that, in tadpole livers, fatty acyl unsaturation patterns reflect a high 
content of neutral lipids that are repleted with monoene acyl groups. In frogs, unsaturation 






;o 1's ~0 is Frog 
Tadpole Stage 
Fio. 3. Developmental changes in the overall unsaturation index and in the contributions of 
polyunsaturated and mono-unsaturated fatty aeyls in the total liver lipids of livers of R. catesbeiana 
tadpoles; and comparisons with values in frogs. Untreated tadpoles were observed from Stage 10 
to Stage 24. Values of unsaturation indices calculated from measured fatty acyl compositions are 
shown for the sum of all fatty acyls (Total), for the sum of the polyunsaturated fatty acyls (PUFA) 
and for the sum of the mono-unsaturated fatty acyls (MUFA). The dashed lines indicate values 
for plasma thyroxine concentrations (1"4, in ng/40 ml) taken from Ref. 588 and for hepatic urea 
concentrations (Urea, in #g/0.4 g) taken from Ref. 16. 
comprises both the high polyene content characteristic of  their PL, and a greater 
proportion of  PL in their liver lipids. Both natural and T3-induced metamorphosis involve 
a shift from the tadpole lipid pattern toward the frog pattern. The shift is early enough 
to serve as a biochemical marker for metamorphosis, like urea synthesis. Tadpole livers 
convert 18:2 to co6-PUFA derivatives as well as frog livers do, so thyroid hormone is not 
necessary for the desaturations involved, but perhaps is necessary for the synthesis of  PL 
that retain the PUFA produced. T3 injection also increases desaturations in tadpoles, 
indicating that T3 is sufficient but not necessary to stimulate Anuran hepatic A6- and 
A5-desaturases. 
J. Fatty Acid Oxidation 
Fatty acid oxidation rate is proportional to the thyroid state.' Mechanisms that regulate 
the partition of fatty acids between oxidation and esterification in liver are discussed by 
Zammit? 5° The major site of control of fatty acid oxidation itself is in the mechanisms that 
transport cytoplasmic fatty acyl-CoA, with the acylcarnitine as an intermediate, to the 
fatty acyl-CoA dehydrogenase in the mitochondrial matrix adjacent to the electron- 
transport chain. Cytoplasmic acyl-CoA--+ acylcarnitine conversion is 'rate-limiting' for 
long-chain fatty acid oxidation in isolated mitochondria, '59'392 because the transferase 
system in intact mitochondria is partly latent. Thyroid hormones increase hepatic 
oxidation of  18:1 by accelerating entry of  18: 1-CoA into the mat r ix : "  
Carnitine acyltransferases, as exemplified by the carnitine palmitoyltransferase (CPT), 
are the most important, although the translocase may also regulate. The CPT enzyme(s) 
are highly regulated 36's4 by positive and negative effectors; by covalent modification 
(phosphorylation activates2'°); by substrate and product; 55'4~'-463 and by vicinal phos- 
pholipids in the inner or outer layers of  the mitochondrial inner membrane. *sl'~2'~3,rs°'rs3 
Kinetic measurements are a dubious basis for determining mechanisms of  thyroid control 
over CPT, because the amphipathic substrates and products form micelles readily and may 
act non-specifically as detergents, s9 
The outer enzyme, CPTo, in intact liver mitochondria normally has about 10-20% of  
the total CPT activity found in detergent-lysed mitochondria, depending on the detergent 
(Refs 32, 53; see Table 4); CPT o activity in the intact membrane has been estimated as 0.2% 
of  inner enzyme, CPT i, ac t iv i ty?  CPT i activity is expressed fully by gentle disruption of  
the membranes, but loses appreciable activity when solubilized by more drastic extractions, 
suggesting that its active configuration requires lipid. 
Lipids and thyroid hormones 225 
TABLE 4. The Effects of Thyroid State (Fed Rats) on 16:0 Oxidation 
(nmol/min/mg protein; 37°C) in Isolated Hepatoeytes; and on CPTo and Total 
CPT Activity, and by Difference, cirri (nmol 16:0-Carnitine Formed/min/mg 
protein; 30°C) in Liver Mitoehondria; from Refs 571,572 
System Activity Normal Hypothyroid Hypo + LT3 
Hepatoeytes Oxidation 1.5 0.3 2.6 
Mitoehondria CPTo 3.8 1.7 6.7 
Total CPT 33.8 29.6 31.5 
A -- Cirri 30.0 27.9 24.8 
Whether CPTo and CPT~ are two proteins with different primary structures and lipid 
affinities, or one protein in the different lipid environments of the inner and outer layers 
of the mitochondrial inner membrane, is crucial for determining thyroid control mech- 
anisms. CPTo and CPT~ are said to be the same enzyme by the criteria of their physical 
properties (molecular weights, solubilities, electro-mobilities), and kinetics (e.g. Km values 
of membrane-free enzymes for their several substrates), 53'12s and their immunologic 
identity. 32'5° Evidence presented for liver mitochondrial CPTo and CPTi being differ- 
ent enzymes, or more ambiguously, different 'forms of CPT', includes the following. 
CPTo and CPTi have different susceptibilities to inhibition by malonyl-CoA, thought by 
some to reside in a regulatory subunit; 651 and different Mr values (CPTo = 63 kDa, 
CPTi = 67 kDa). 491 Polyclonal antibodies raised against a mono-disperse, PL-free CPT o 
prepared from beef liver mitochondria uncontaminated with peroxisomes 49°'491 (which 
contain molecularly distinct short- and medium-chain acyltransferases aS) and against a 
purified CPTi, do not cross-react by Western blot or by inhibiting activity? 91 Although 
these experiments are thought to demonstrate that CPTo and CPTi differ in physical 
properties rather than in membrane environment, in earlier work antibodies against a 
purified homogeneous CPTo purified from calf liver mitochondria 313 inhibited CPTo, but 
those from 1 out of 3 rabbits also inhibited CPTi.65'314 Taken together with observations 
that urea or guanidine convert CPTo~CPTi, Kopec and Fritz 314 thought CPTi is a 
'transformed product' of CPTo. Since it appears possible that even immuno-reactivity is 
modified by membrane environment, yet more specific molecular properties such as 
primary structure may be needed to determine when gene expression of CPT~ or CPTo, 
and/or membrane lipid changes, regulate CPT activities. 
Hypothyroidism halves the activity of the CPTo in isolated rat liver mitochondria, 
and reduces 14CO 2 production from 14C-palmitoyl-CoA in isolated hepatocytes by 80% 
(Table 4). T3-treatment restores CPTo activity and 16:0 oxidation even beyond normal 
levels (?thyrotoxic). Total CPT activity, in lysed mitochondria, remains similarly high in 
all three groups; by difference, C P T  i in hypothyroids is at about the control activity, but 
in T3-treated animals is rather lower. The approximate constancy of the total CPT activity 
speaks for there being one enzyme that thyroid treatment converts from inactive CPT~ to 
active CPTo form, thereby increasing the oxidation of 16:0. Given the uncertainties of 
these activity measurements, additional quantitation of thyroid effects on amounts of each 
'form' are needed, as well as more direct determination as to whether or not thyroid 
induces only the CPTo form. 
It is also possible that thyroid state regulates CPTo activity in the intact cell indirectly, 
through [malonyl-CoA] and CPT sensitivity to inhibition by malonyl-CoA. In perfused 
livers, hypothyroidism decreases [malonyl-CoA] and hyperthyroidism does not affect 
[malonyl-CoA], so Miiller e t  al .  4H doubt its regulatory role in thyroid effects. However, 
in freeze-clamped livers, hypothyroidism doubles [malonyl-CoA] while hyperthyroidism 
decreases it slightly, 365 effects consistent with a regulatory role. Malonyl-CoA inhibits the 
increased activity of CPTo that follows T3-treatment (Table 4) less than normally, 55 
accenting the decreased concentration. The diminution of malonyl-CoA inhibition of fatty 
acid oxidation is thought to permit a futile, calorigenic cycle of simultaneously accelerated 
synthesis and oxidation. The CPTo in hypothyroid rats (Table 4) retains normal sensitivity 
to the high [malonyl-CoA], and so is depressed. 
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When liver mitochondria from normal rats are preincubated in KCl-media, malonyl- 
CoA does not inhibit; mitochondria from hypothyroid rats lose sensitivity more slowly and 
those from hyperthyroid rats, faster. Therefore, CPTo is thought to be regulated by 
components of membranes that respond to physiological stimuli. 3j'46m'65m'653 Malonyl-CoA 
acts on membrane-bound CPTo like a classical negative allosteric effector, 36 but does not 
inhibit after the membrane is exposed to phospholipase C (which itself activates CPTo643), 
or after CPTo is solubilized. Malonyl-CoA inhibition of CPTo depends on high membrane 
fluidity: in liver mitochondria (especially from fed rats) kept at 25-37°C (but not at 
<25°C), slow conformation changes make CPTo less sensitive to malonyl-CoA and 
increase CPTo activity. 6~1 
Another mechanism may involve regulation of CPTo through phosphorylation status. 
Thyroid state modifies the effects of starvation. Fasting increases oxidation 25-50% in 
mitochondria from euthyroid rats, 300-400% in hypothyroids, and not at all in thyrotoxics 
(where it is already increased). Starvation normally augments both CPTo and (acyl)carni- 
tine translocase activities, and hepatic fatty acid oxidation; cycloheximide blocks the 
increase in CPTo activity, indicating that starvation induces microsomal synthesis of new 
protein(s). 519 The new protein might be either CPTo or a protein phosphatase or kinase, 
since starvation signals protein phosphorylation, and phosphorylation may activate 
CPT. 2j0 
(Acyl)carnitine translocase mediates a 1 : 1 exchange of carnitine and an acylcarnitine. 
At 37°C, the exchange rate appears to be much greater than the capacity for//-oxidation. 
However, at low tissue [acylcarnitine], the translocase may come to share control over 
oxidation with the CPTo. 55 Urinary excretion of carnitine, and serum carnitine concen- 
tration, are proportional to serum IT4] in hypo- and hyperthyroid subjects ,  375 but there 
are no measurements that show cell carnitine availability limits either the translocase or 
CPT activity. It is not known if thyroid state affects translocase activity, but thyroid 
regulation of mitochondrial inner membrane CL content and composition offers a possible 
mechanism to explain some effects attributed to membrane environment. The purified 
translocase contains bound CL,  149 and reconstitution of the solubilized (acyl)carnitine 
translocase requires cardiolipins: 43 Adriamycin, which binds CL specifically (see Section 
IV.B.5), inhibits both native and reconstituted translocase activity. 4~° Since the purified 
CPT is also activated by CL, Noel and Pande ~.3 propose that CL provides orienting 
binding sites for the translocase and the transferase, and thereby facilitates the flow of 
acylcarnitines from the outer to the inner layers of the membrane. 
The asymmetry of CL distribution, 75-90% being in the inner layer of the inner 
membrane of mitochondria (see Ref. 106), resembles that of the activities of liver CPTo 
and CPT~ (Table 4). If CL does bind CPT firmly in vivo, and if the distinction between 
CPTo and CPT~ reflects only their membrane environment, the paucity of CL in the outer 
face may account for the relatively small fraction of CPT in the outer face. Although effects 
of thyroid state on the sidedness of CL in hepatic mitochondrial inner membranes have 
not been reported, hypothyroidism increases the proportion of liver mitochondrial 
CL/YPL by 72% while maintaining the high 18:2 content of the CL. 2gs The physical 
properties of CL favor the excess CL being in the inner layer (see Section IV); less 
transferase would then exist in the CPTo form (Table 4). Thyrotoxicosis also increases liver 
mitochondrial CL/PL 34%, but the CL is depleted in 18:2 by 63%. 5~m If this abnormal 
CL does not bind CPT fully, the fraction in the CPTo form would increase. 
In liver mitochondria of 1-5 day old pigs, CPTo = C P T i  .37 In liver mitochondria of 
neonatal rats none of the CPT is in latent form, 17 CL/PL is low, and the CL 18:2 content 
is halved, as compared with adults. In adult heart mitochondria, LT3 (0.33 #g/g/day x 2 
days) given to hypothyroid rats does not change the activity of CPTo, although it increases 
liver mitochondrial CPTo (Ref. 55; Table 4). Neither does such short-term thyroid 
hormone treatment of normal rats (LT3, 1 #g/g/day x 3 days) change heart mitochondrial 
18:2 content or CL/PL ratio; 237 we did not examine CL/PL values in heart mitochondria 
of T3-treated hypothyroid rats. The apparent disparity in T3 effects on heart and liver may 
reflect only that heart responses require greater dose-time schedules, as is explicated in 
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Section IV.D. Thyroid feeding for 6 days accelerates palmitate oxidation in perfused hearts 
of dogs; 174 and LT4-injection, ,,,0.25/ag/g/day x 10 days, more than doubles CPT activity 
in guinea pig heart homogenates, ss The latter workers attribute the increase in 
fatty acid oxidation to the high plasma [FFA], and the doubled heart [acylcarnitine] and 
[total carnitine], after thyroid pretreatment. 
In mitochondria of mature brain, the activity of CPTo plus CPTi is about 25% of that 
in liver;//-oxidation is much slower, and neither CPT o o r  C P T  i is rate-limiting. 41 Neither 
thyroid-treatment nor starvation increases activities in these I o w - C L  632 mitochondria. The 
higher CPTo activity in fetal brain decreases 50% after weaning, as what small amounts 
of CL there are in the adult brain begin to appear (see Section IV.D). 
K. Prostanoid Synthesis 
Brief treatment of rats with LT4, 0.2#g/g/day x 2 days, increases prostaglandin 
synthetase activity by 179'/o in kidney and 300% in lung; at the same time, it inhibits renal 
PGF2~ metabolism by 40% in pathways that include conversions by 15-hydroxyprosta- 
glandin dehydrogenase and prostaglandin A13-reductase, and prostaglandin 9-hydroxy- 
dehydrogenase. ~55'~ The prostaglandin synthetase of spleen microsomes, as measured by 
the conversion 20:4--*PGE2, also increases in hyperthyroidism but is unaffected by 
hypothyroidism; however, concentrations of indomethacin or phenylbutazone that inhibit 
PGE2 formation about 50% in preparations from normal and hyperthyroid animals inhibit 
only about 20% in hypothyroids. ~s5 It seems unlikely that T3 stimulates conversion of 
enough hepatic microsomal 20:4 acyl groups to prostaglandins to contribute to the 
observed rapid depletion of 20:4 (see Section II.A). 
L. Sulfolipid Synthesis 
Brain myelination and maturation require adequate thyroid hormone levels. *z Hypo- 
thyroidism in the neonate retards accumulation of brain cholesterol, cerebrosides, and 
sulfatides. T3-treatment at 18 days after birth does not replenish the very low amounts 
of these lipids, although T3 given much earlier does stimulate sulfatide synthesis. 62s The 
defect in sulfatide synthesis is caused by depressed synthesis of 3'-phosphoadenosine-5'- 
phosphosulfate and/or the subsequent NADPH-dependent (and thereby thyroid-depen- 
dent?; see Section II.C) reduction of the sulfate of this donor to SOl-. Thyroid effects have 
been studied in myelin-synthesizing glial cells grown in culture, free of contamination with 
neurones (which complicate interpretations by producing nerve growth factors in response 
to T3). 3~5 Growth in T3-supplemented media for 3-5 days stimulates [35S]sulfate incorpo- 
ration into sulfatides and sulfogalactosyl dialkylglycerols, as well as synthesis of fatty acids 
and cholesterol, and activity of 2',3'-cyclic-nucleotide 3'-phosphodiesterase. These cultures 
progressively lose their sensitivity to T3, rather like neonatal rats lose brain responses to 
developmental thyroid effects (see Section IV.D). 
M. Summary 
The pervasiveness of thyroid-state influence on enzymatic steps in lipid metabolism is 
striking. Especially in the branching pathways of fatty acid and cholesterol metabolism 
(Fig. 1) and conversions of glycerol-3-phosphate to triglycerides and phosphoglycerides 
(Fig. 2), as well as in fatty acid desaturations, almost all steps are thyroid-sensitive. Several 
points can be made: (i) the conversions of carbohydrate to lipids show an analogous 
prevalence of steps sensitive to insulin, and to protein phosphorylation. 2~2 Observed effects 
of thyroid hormones on protein phosphorylations are suggestive, but no such rigorous 
correlation has been made with the enzymes involved in lipid conversions. (ii) Thyroid 
levels do not exert their influence at a single 'rate-controlling' enzyme in a lipid pathway, 
but on  successive enzymes. To regulate the evolution of the lipid product, the hormone 
must act differentially on each step, and several steps may contribute to rate-control. Such 
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analysis of thyroid controls has been done on the steps of mitochondrial oxidative 
phosphorylation (see Section IV). (iii) Thyroid stimulation of gene expression can account 
for only a few of the many sensitive loci in lipid metabolism. In the succeeding sections, 
mechanisms are discussed whereby thyroid-effected changes in lipid metabolism may 
amplify signals of T3-receptor occupancy to modulate membrane-dependent catalysts, 
transporters, and receptors. 
III. CELL MEMBRANE AND ASSOCIATED SYSTEMS 
Plasma membranes contain a number of enzymes, transporters and receptors that are 
thyroid-responsive. Such sensitivity may be mediated by mechanisms of gene expression, 
covalent modifications of the proteins, and lipid-mediated membrane-dependency of the 
proteins, and ion leaks. 
A. Lipid Composition and Physical Properties 
All the thyroid-sensitive active proteins in the plasma membrane are known to change 
activity when membrane lipid composition is manipulated. However, I find no reports on 
fatty acyl and cholesterol compositions of purifed plasma membranes from animals in 
different thyroid states, so causal connections with altered activities remain uncertain. 
Inferences from coincidence and circumstantial evidence should be guarded, especially 
because the plasma membrane differs in several important respects from organelle 
membranes. Lipid composition of purified hepatocyte plasma membranes (and erythrocyte 
membranes) is quite different from that of the thyroid-responsive membranes of the 
endoplasmic reticulum, mitochondria, and nuclei (plasma membranes are usually sedimen- 
ted with nuclei as heavy fractions). The unsaturation index of the YPL of hepatocyte 
plasma membrane ranges from 703°~'5s~ to 130, 423 as compared with about 190 in the 
organelle membranes, and 215 in heart sarcolemma. 2 Twenty percent of the liver plasma 
membrane and erythrocyte membrane PL are sphingomyelins, with their characteristically 
high contents of saturated long chain fatty acyls, and UI ,,,45, which lowers overall 
unsaturation. Molar ratios o f  free cholesterol/PL contents in plasma membranes are 
0.35-0.6, and in mitochondria and rough endoplasmic reticulum, 0.03-0.05. ~32'565'5s1'6~5 
Some investigators take the presence of cholesterol in mitochondria to denote con- 
tamination with heavy fractions, but Rogers et al. 4n find that cholesterol-feeding increases 
mitochondrial cholesterol content in rat liver (but not in other tissues), depresses State 3 
respiration, and desensitizes the ATP-synthetase toward oligomycin inhibition. 
An acute lipogenic stimulus--feeding carbohydrate for a few hours to a starved 
rat--does not deplete hepatocyte plasma membrane 18: 2 acyls and actually increases 20: 4 
acyl contents (in organelle membranes, it extensively replaces both 18:2 and 20:4 with 
newly synthesized MUFA and saturated fatty acyls), but decreases the cholesterol/PL ratio 
by -24%.  58~ More prolonged EFA-deficiency, in Ehrlich cells grown in EFA-deficient 
mice, does severely deplete plasma membrane co-6-PUFA (18:2 by -80%,  20:4 by 
-45%)  and replaces them with biosynthesized co9-PUFA (18:1, 20:3, 22:3), but the 
cholesterol/PL ratio and the proportions of PL classes remain at control levels. 3°s'Ssl 
Thyroid effects on plasma membrane lipid contents need measuring in preparations 
certified to be minimally contaminated with organelle membranes--it seems possible that 
plasma membrane and organelle membrane fatty acyl compositions do not respond 
similarly to thyroid state. 
However, thyroid state or dietary lipids affect plasma membrane general physical 
properties, and enzyme and transporter activities, in a manner consistent with mediation 
through lipid changes. Plasma membrane lipids are known to modify the mechanism of 
a number of receptors. TM Arrhenius plots of the motion parameter of 12-nitroxide stearic 
acid probes in isolated plasma membranes of Ehrlich tumor cells exhibit transitions at 31 °C 
and 19°C when prepared from control-fed mice, and at 31.5°C and 24.5°C when prepared 
from EFA-deficient animals. 3°8 The order parameter at 37°C is greater in the EFA-deficient 
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membranes. These changes are attributed to the decrease in unsaturation at the 
co6-position, where larger kinks in the fatty acyl chains disturb the packing order especially 
toward the center of the bilayer. In contrast, when fatty acyls of the plasma membranes 
of murine T lymphocyte tumor cells in culture are substituted by less or more unsaturated 
fatty acyls, the temperature-dependence of order parameters and rotational correlation 
times of both 5- and 12-nitroxide probes remain normal (although enzyme activities 
change; see below). ~1 It should be noted that the UI of the Ehrlich tumor cells in animals 
on normal diets is 140-170, higher than the UI of liver plasma membranes, and that tumor 
cell lipid metabolism and membrane composition differ from those of normal cells, sIT In 
thyrotoxic rats, liver plasma membrane preparations are abnormally rigid and ordered (as 
estimated from polarization of fluorescent cis- and trans-parinaric acid probes), and lose 
their reactivity to added insulin or glucagon. TM Plasma membranes from hypothyroid rats 
are normally ordered, but T3 added in vitro increases their rigidity. Arrhenius plots of 
fluorescence polarization of these probes in plasma membranes from thyrotoxic rats inflect 
at 25°C, in hypothyroids, near 18°C. Such abnormalities seem consistent with excess 
thyroid levels decreasing fatty acyl unsaturation, and emphasize the need for lipid analysis 
since thyroid-treatment usually increases unsaturation in organelle membranes. 
B. cAMP Synthesis and Hydrolysis 
The concentration of cAMP in contact with its target enzymes mediates thyroid state 
regulation in several cases, notably the hormone-sensitive lipase. Hypothyroidism de- 
creases the rise of [cAMP] in adipocytes after application of lipolytic hormones (cate- 
cholamines, glucagon, ACTH). 97'98'616 The mechanisms include simultaneous impairment of 
synthesis and enhancement of degradation of cAMP, decreased cAMP-dependent protein 
kinase activity, and decreased phosphorylation of the lipase that lowers its activity. 
Hyperthyroidism increases adipocyte [cAMP] rise effected by lipolytic agents, and thereby 
increases lipolysis. Whatever the mechanisms, thyroid control over [cAMP] appears to be 
analogous to that over hepatic [cholesterol] in that the hormone differentially regulates 
their synthesis and (more acutely) their degradation, and both cAMP and cholesterol are 
effectors in a variety of enzyme and transporter processes. 
1. Adenylate Cyclase 
Thyroid hormone regulation of the adenylate cyclase system in plasma membranes is 
important in lipid metabolism because cAMP mediates reversible phosphorylation of 
many enzymes in these metabolic pathways, and because thyroid state regulates the 
adenylate cyclase system at several membrane-dependent components that respond to lipid 
changes. Many regulators, together with the thyroid state, are tissue-specific in controlling 
the multicomponent adenylate cyclase system. Some thyroid effects are primary in the 
sense that they occur during in vitro incubation with plasma membranes. Some are exerted 
secondarily and result in permissive effects of thyroid state on such regulators of lipid 
metabolism as catecholamines, 579 glucagon and insulin. 
Some thyroid effects may be mediated by plasma membrane PL. Adenylate cyclase 
activity and its coupling to hormone receptors require plasma membrane PL. Removal of 
acidic PL (PI, PS) but not neutral PL (PC, PE, Sph) by phospholipase C inactivates the 
cyclase and ablates its activation by epinephrine or glucagon) 49-351,497,5°9 Addition of PS 
(and to a lesser extent PE or Sph, but not PC or CL) reconstitutes the solubilized, inactive 
cat heart cyclase. TM In rat liver plasma membranes, EFA-deficiency depresses glucagon- 
stimulated adenylate cyclase activity, 363 but in titrations with A[dietary linoleate], contents 
of co6-PUFA in phosphatidylcholines correlate inversely with activity; 423 it is not clear to 
what degree fatty acyl dependency of the adenylate cyclase or the glucagon-receptor 
systems is being measured. Repletion of the plasma membrane phospholipids of a 
T-lymphocyte tumor cell or LM cell line with saturated fatty acyls suppresses basal and 
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PGE2-sensitive adenylatc cyclase (and Na+K+-ATPase, see Section III.D) activity, while 
repletion with 18: 1 or 18: 2 fatty acyls enhances activity, both compared with cells grown 
with minimal amounts of 18:2. m'4s~ The constancy of overall membrane lipid fluidity 
parameters during these substitutions suggests a more specific interaction between the PL 
fatty acyls and the enzyme system. In contrast to the thymocyte and fibroblast cultures, 
when plasma membrane fluidity of turkey erythrocytes is progressively increased by 
insertion of c/s-vaccenic acid (18: leo 7), the rate constant for activation of the cyclasc by 
epinephrine increases linearly with membrane fluidity (measured by fluorescence polar- 
ization of a probe), indicating that coupling between the epinephrine receptor and the 
cyclase depends on the lipidsfl °s.494 The maximal activity of the catalytic unit itself, when 
stimulated by several activators, also increases with lipid fluidity. In contrast, adenosine 
activates the cyclase in these erythrocytcs independently of membrane fluidity, probably 
at a site on a G-protein. 
Either hyper- or hypothyroidism in vivo or incubation with hormone in vitro can 
modulate adenylatc cyclase activity in broken-cell preparations. 53s Adcnylate cyclasc 
activity is twice-normal in minces of fat pads from hyperthyroid rats, and half-normal in 
hypothyroids. 322 Epinephrine stimulates lipolysis, when added to adipose tissue of 
hyperthyroid rats, to maximal levels 2-3 times those reached in tissue from euthyroid rats. 
Even high [epinephrine] fails to activate the cyclase in fat cells from hypothyroid rats; 
T4-trcatment restores the response in 48 hr. 
In vivo mechanisms that mediate such thyroid effects in adipose and other tissues include 
changes in: numbers and affinity of fl-adrcncrgic receptors in plasma membranes; coupling 
between receptors and cyclase components; and function and amounts of regulatory and 
catalytic cyclase components. 579 In vivo thyroid effects differ in heart, adipose tissue, lung, 
renal medulla, and nucleated crythrocytes from those in liver. 377 Hypothyroidism de- 
creases, and hyperthyroidism increases, the number of fl-adrencrgic receptors in heart, ~ 
fa t ,  377 turkey crythrocytes, and rat reticulocytes. In hyperthyroid animals, the cardiac 
receptors have abnormally high affinity for fl-adrenergic agonists. Since blood and tissue 
[catecholaminc] arc in the normal range in thyrotoxicosis, the many cardiovascular signs 
seem to arise from hypersensitivity to catecholamines. However, see Rcf. 349 for the 
opposing view that the thyrotoxic hearts of several species arc not hypersensitive to 
norcpincphrinc, based mainly on their mechanical function. 
The rat liver shows effects opposite to those in the tissues just discussed. Perhaps this 
specificity is accounted for by observations that, in normal rats, a-adrcnoceptors mediate 
activation of hepatic glycogen phosphorylase by catecholamines, in other species, 
//-receptors (see Rcf. 485). Hypothyroidism increases total cyclase activity in rat hepatic 
plasma membranes by 30-45%, 2°°'2~ and the number of//-adrenergic receptors by 2- to 
3-fold. 579 Hyperthyroidism decreases the number of liver//-adrenoceptors, cyclase activity, 
and response of cyclase to //-agonists, 579 or does not change cyclase activity and the 
//-receptor response. 2s4 The cyclasc deficiencies in hyperthyroidism arc not associated with 
a decrease in amount of G-protein, but with lesser effectiveness of the G-proteins in 
reconstituting adcnylate cyclase in other membranes, and/or with decreases in function of 
the catalytic cyclase unit (see Rcf. 579 for additional references). 
In vivo effects on the permanent coupling between //-adrenergic receptors and the 
catalytic subunit of adenylate cyclase through the regulatory G-proteins are also tissue- 
specific. Hypothyroidism decreases the amount of G-protein in rat reticulocyte plasma 
membranes together with the number of//-receptors; both defects are tentatively ascribed 
to decreased protein synthesis. 579 Some of the effects of hypothyroidism on the adipocyte 
adenylate cyclase system are apparently mediated by the GTP-dependent regulatory 
proteins. 378 The (measured) amount and the activity of the inhibitory protein G i increases 
while the amount of the stimulatory protein Gs is little changed. Thereby the inhibitory 
regulation by GTP, adenosine (which inhibits in fat cells), and other metabolites is 
enhanced by up to 50 times. At the same time, cyclase activity and response to activators 
are dampened, probably through a change in a / / -  or ~-subunit common to Gi and Gs. 
It is unusual for the hypothyroid state to evoke an increase in the amount of a protein, 
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because hypothyroidism diminishes gene expression; the mRNAs for the subunit pcptides 
will be interesting to sec. 
Thyroid state not only modifies /~-receptor-mediated lipolytic and positive cardiac 
chronotropic and inotropic effects, but also what appear to be ~-receptor-mediated effects 
on these parameters. Thus, norepincphrine (a mixed ~t-fl agonist) elicits no lipolytic 
response in adipocytes from hypothyroid humans although those from normals arc quite 
responsive; addition of an ~t-receptor antagonist normalizes the lipolytic action, and 
hypothyroidism augments an ~-response which inhibits the adenylate cyclase, j91''92'5°2'5°3 
Chronotropic dose-effects of norcpinephrine are subnormal in isolated atria of hearts from 
thyrotoxic rats but normal in those from hypothyroid animals, while dose-effects of 
epinephrine decrease in hypothyroids and remain normal in thyrotoxics. 5s3 As measured 
by inotropic actions, atria from hypothyroids have suprasensitive oc-receptors while their 
fl-receptors are 10-times less sensitive than normals, from measured potency ratios of 
agonists, and the new susceptibility to inhibition by an ~-receptor blocking agent. 3°,327-329 
The sensitivities revert to or beyond control levels after hypothyroid animals receive 7 daily 
T4- or T3-injections, the only dose schedule examined. Alpha-agonists also make aortae 
from hypothyroid rabbits contract more forcibly than normals) 92 Hypothyroidism also 
augments the ~-adrenoceptor-mediated rise in [cAMP] in electrically driven contracting rat 
heart muscle, and reciprocally depresses the fl-receptor-mediated rise; T4-treatment of 
hypothyroid rats restores thc normal pattern in 8 days. 326 As in measurements of total 
cyclase activity and number of adrenergic receptors, liver cells show the opposite pattern: 
in hepatocytes from hypothyroid rats ~-receptor mediation falls and fl-receptor mediation 
increases reciprocally. ~5 
Evidence is presented that the reciprocity of ~ and/3 effects reflects interconversion of 
myocardial c¢- and fl-adrenoceptors through an allosteric change in one common 
precursor adrenoceptor. 327-329 The fl-receptors convert to oc-receptors when the temperature 
of isolated hearts of frogs or rats is lowered to < 17°C. 329 Others 7° confirm that a f l - ~  
transition occurs on cooling isolated frog hearts, but from the effects of irreversible 
antagonists conclude that separate pools of fl- and ~-precursor receptors are recruited at 
the different temperatures. Since these studies on isolated hearts seem to preclude 
adaptations through hormone actions, it seems likely that temperature-sensitive plasma 
membrane fluidity is involved, since either cold or hypothyroidism decreases fluidity in 
organelle membranes, and perhaps also in myocardial plasma membranes. It is claimed 
that the observed effects of thyroid status on adrenergic sensitivities are not reflected in 
the number of fl- and ~-receptors. As measured by the binding of 3H-dihydroalprenolol at 
37°C and 3H-dihydroergocryptine at 25°C to estimate the number of fl- and ~-receptors, 
respectively, crude preparations of heart plasma membranes from hypothyroid rats have 
only 20% as many ~-receptors and 70% as many//-receptors as normals. 87 Thyrotoxicosis 
halves the number of ~-receptors and triples the fl-receptors, while keeping the total 
number about constant. If hypothyroidism converts fl to ~, the total/3 + ~ should remain 
constant, but the unexplained measurements of receptors at different temperatures would 
seem to vitiate such a totalling, from the data of Kunos et al. 326-329 Besides, the shift from 
fl- to ~-receptor-induced rise in [cAMP] requires that the myocardium be contracting. 326 
Thermotropic properties of receptor-coupled adcnylate cyclase activity in washed 
membrane particles of livers from normal rats may pertain to the above studies. Arrhenius 
plots of basal activity and activity stimulated in vitro by F-  or PGE~ are linear, but plots 
of activity stimulated by epinephrine or glucagon are inflected. 32° The plots of hormone- 
activated rates are superimposable and unusual: both transition temperatures, Tt, are at 
32°C, whereas those secn with lipid-sensitive membrane-dependent enzymes are usually 
between 17°C and 22°C; ~9 E, at > T~ is double the E, at < Tt, while the opposite is usually 
seen in membrane-dependent enzymes where decreased fluidity at the low temperatures 
increases the damping effects on activity. Because either saturating or lower [epinephrine] 
and [glucagon] produce identical Arrhenius profiles, Kreiner eta/.  32° think it unlikely that 
temperature changes alter receptor count, but rather that they act on a protein component 
common to the hormone-stimulated system but not to the F--  or the PGEl-stimulated 
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systems. One wonders if these observations are explained by an increased number of 
~-receptors in hearts at the higher temperatures, and one hopes for direct measurements 
of thermotropic effects on adrenoceptors in these liver membranes. 
Glucagon-receptors also respond to changes in thyroid status. Again there are appar- 
ently conflicting findings. In liver cell plasma membranes (frozen and thawed) from 
hypothyroid rats, Sperling et al. 569 report a 50% decrease in the number of glucagon- 
receptors; receptors have normal affinity for glucagon in vitro and bind less glucagon than 
normals at all [glucagon]; increased [glucagon] is necessary to produce a maximal increase 
in [cAMP], and the maximal [cAMP] produced is also half the maximum in euthyroid 
preparations. In intact hepatocytes from hypothyroid and euthyroid rats, Malbon et al. 377 
find that glucagon raises [cAMP] identically. When liver cell plasma membranes are 
prepared from rats treated with small doses of LT4, 0.05/zg/g/day × 14 days, glucagon- 
receptors and [cAMP] responses are all normal. 569 But in fat cells from rats treated about 
10 times more vigorously with LT3, ~0.1/~g/g/day x 8 days, the number of  glucagon- 
receptors and the response of [cAMP] to glucagon are more than twice-normal. 374 It is 
difficult to say whether a lesser degree of hyperthyroidism or a greater responsiveness of 
fat cells contributes to the latter disparity, and whether plasma membrane integrity is 
involved in the former. 
In vitro incubation of rat fat cells, 322 thymocyte plasma membranes, 53s or cat myo- 
cardium membrane preparations, 352 with I nM to 1 #M LT3 stimulates cyclase activity.* 
Maximal increases occur at the/ZM concentrations, and as rapidly as 3-5 min. 352'53s From 
congener efficacies and the effects of transcription blockers, T3 receptors (perhaps in 
plasma membranes) and protein synthesis mediate these increases in adenylate cyclase 
activity, except in cat heart. 352 These in vitro actions eliminate possible mediation by 
receptors for other activators and indicate that thyroid hormones can activate indepen- 
dently. Thyroid hormones in vitro can also regulate the receptors for other hormones that 
are coupled to the adenylate cyclase system. Incubation of rat heart ventricle slices (but 
not isolated membranes) with LT3 quadruples the number of/~-adrenergic receptors at 
1.5-2 hr with no immediate further increase; 15 pM LT3 gives half-maximal stimulation, 
0.1 nM LT3 saturates /~-agonist binding. 3°3 Synthesis of protein is not involved. A 15-hr 
incubation increases the number of/~-receptors another 4 times, which does involve 
synthesis of new protein. Both the early and the later effects apear to be mediated by 
specific LT3 receptors. The rapid augmentation of cell surface ~-adrenoceptors is attribu- 
ted to an in vitro effect of T3 that somehow promotes their insertion from an existing 
cytosolic receptor pool. The increased number of ~-receptors should increase [cAMP], 
if they are efficiently coupled to the adenylate cyclase, and phosphodiesterase activities 
are low. 
2. Cyclic Nucleot ide Phosphodiesterases  
These diesterases are not in the plasma membrane but in the particulate membrane 
fractions that sediment at > 100,000 x g (microsomes), and in the supernatants. They are 
included here because there is evidence that thyroid hormone regulation of low-Kin cAMP 
phosphodiesterase activity complements and even predominates over thyroid regulation 
of adenylate cyclase activity in control of [cAMP]. Studies on thyroid effects on this 
heterogeneous group of enzymes are complicated by the existence of multiple enzyme 
'forms', as shown by diesterase elution patterns during various chromatographic pro- 
cedures, by their solubilities and kinetic properties, and by their specificities for substrate, 
*Not so long ago, in vitro effects of thyroid hormones on oxidative phosphorylation were transferred from a 
'physiologic' to a 'pharmacologic' category because they required micromolar concentrations. ~7 In Ref. 538, the 
i nM ['1"3] needed for significant activation, and the 1 #M needed for maximal activation, of adenylate cyclase are 
recognized to be well in excess of the ~ 10 pM [free T3] available in vivo; Segal et al. s38 note that in 1985 the 
frequent need for 'supraphysiologic' concentrations of hormones to induce an/n vitro effect that parallels their 
in vivo action is well known. They give as an example that most tissues of the rat require 0.1-100/~ M [epinephrine] 
to activate adenylate cyclase, whereas [epinephrine] in rat plasma is ~ 1 riM. 
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effector, and antibodies. 2s Some of the forms may be convertible by solubilization from 
their loci in membranes, and by changes in phosphorylation status: insulin- and cAMP- 
dependent phosphorylation doubles the V of a phosphodiesterase in liver membranes. 
Membrane-binding seems crucial for exhibiting phosphodiesterase thyroid-dependence, 
at least in fat cells. Hypothyroidism increases the activity and the V of membrane- 
bound, but not of soluble or solubilized, low-Kin cAMP phosphodiesterase in rat 
adipocytes 12.96'9s'ls6 and in liver. 2°°'4°7 Five days of T3-treatment of hypothyroids decreases 
fat cell phosphodiesterase V by - 4 0 % .  Adipocyte membranes contain only 10-20% of 
the total phosphodiesterase activity, and the 2- to 3-fold increase in activity, which is seen 
when hypothyroid preparations are disrupted in isotonic (but not hypotonic) buffers, 
occurs in a resolvable component uniquely sensitive to complete inhibition by excess 
cGMP; solubilization decreases the amount of this component. ~86 In 3T3-L1 adipocytes in 
culture, in contrast, both soluble and membrane-bound phosphodiesterase activity in- 
creases in cells in a low-T3 medium, and decreases in cells in a hyperthyroid (,-, 0.1 nM T3) 
medium, as compared with cells in a medium containing serum from a euthyroid c a l f .  t29 
Since epinephrine stimulates lipolysis in fat pads from hypothyroid rats hardly at all (c.f. 
~ 2.5 times in euthyroids), and since theophylline-inhibition of phosphodiesterase restores 
the epinephrine stimulation in hypothyroid preparations, several workers propose that 
thyroid (and insulin) regulation of cAMP-dependent lipolysis in adipocytes is mediated by 
cGMP and the phosphodiesterase. 
Destruction of membrane-dependence in hypotonic media seems to account for several 
reports that thyroid status does not alter low-K~ cAMP phosphodiesterase activity. In the 
liver, Morgan et al. 4°7 s e e  no increase in V of a phosphodiesterase that is solubilized from 
membranes of hypothyroid rats (although hyperthyroidism decreases V); and the phos- 
phodiesterase activity of hypotonic homogenates of hepatocytes T M  and of fat cells 322 from 
T3-injected rats is at control levels. Thymocyte phosphodiesterase activity is nil _ T3 in 
vitro) 3s Fat pads minced in Krebs-Ringer-5% albumin show similar phosphodiesterase 
activities in euthyroid and hyperthyroid rats. 322 Cat heart preparations may be an 
exception; when homogenized in isotonic buffer, their phosphodiesterase activity remains 
unchanged after incubation with 5/~M T3 although adenylate cyclase is activated, 352 and 
Levy et al )  52a find normal phosphodiesterase activity in sedimented membrane particles 
(medium isotonic) prepared from cats treated with T3 for up to 21 days. It should be noted 
that cats are unique among mammals in lacking a hepatic A6-desaturase to convert 
1 8:2-COA to 20:4-CoA, 495a and that there is no information on their cardiac membranes 
in different thyroid states. Thus, in hyperthyroid rat heart membranes prepared in isotonic 
buffer, cAMP phosphodiesterase activity is below normal levels. 61° I find no investigations 
of the membrane-dependence of the cGMP-sensitive form of phosphodiesterase in 
adipocytes, or the possible effects of the known changes in hepatic microsome fatty acyl 
unsaturation in hypothyroidism 24s on phosphodiesterase activity. 
C. Ca2+-A TPases 
Thyroid levels affect the amount of intracellular Ca :+ ions. Thyroid treatment markedly 
increases accumulation of Ca in liver and uterus, less so in skeletal muscle, ~42 and stimulates 
both efflux and influx of Ca 2+ in liver in vitro without increasing binding or protein 
synthesis. 624 Hypothyroidism depletes a slow-turnover pool of intracellular Ca 2+ in isolated 
hepatocytes while leaving a fast-turnover pool unchanged; 48 hr after T3-treatment the 
more inert pool remains unrestored although respiration increases. 5°3 These observations 
reflect the actions of plasma membrane Ca2+-ATPase that partly dephosphorylates 
MgATP 2- (Ca2+/Mg2+-dependent ATPase) to pump Ca from the cell. The concentration 
of free Ca 2+ ions in cytoplasm ([free Ca2+]cyto) is the physiologically important effector. 
Calcium ion pumps located in several membranes normally maintain a low [free Ca2+]cyto 
against a 104 times greater [free Ca 2+] in serum--a higher gradient across the plasma 
membrane than that of any other ion) s3 The Ca2+-ATPase of plasma membranes is 
supplemented by another Ca2+-ATPase in endoplasmic reticulum and by Ca2+-carriers in 
JPLR 27/3--F 
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the mitochondrial inner membrane. The sarcoplasmic reticulum Ca2+-ATPase pumps 
cytoplasmic C a  2+ ions into the reticulum lumen where they are sequestered by binding to 
proteins, and the mitochondrial systems segregate Ca 2+ in the matrix. Thus, [free Cae+]cyto 
depends on three separate membrane systems. In resting non-muscle cells the plasma 
membrane Ca-ATPase and the mitochondrial Ca2+-carriers predominate. Thyroid state 
modulates all these mechanisms; effects on the mitochondrial carriers are discussed in 
Section IV.B.8. In addition, Ca 2+ efltux is stimulated by high extracellular [Na +] via a 
plasma membrane Ca2+-Na + exchange carrier; in this way, changes in rates of the thyroid- 
sensitive plasma membrane Na+K+-ATPase (see Section III.D) and Na+-H+-antiporter 
(see Section III.E.2) can affect Ca 2+ transports. 
Ca 2+ efflux across plasma membranes is best studied in red blood cell ghosts, in the 
absence of organelle membranes, protein synthesis, and nuclear actions. In hypothyroid 
rats, activity of erythrocyte membrane Ca2+-ATPase (at an unspecified temperature) is 
twice that in membranes from euthyroids. 's5 Because acceleration is confined to the 
calmodulin-dependent fraction of total activity and depends on iso-osmotic preparation 
of the membranes, thyroid deficiency is thought to increase the association of activated 
Ca-calmodulin complex with the membrane rather than to induce Ca2+-ATPase (by some 
mechanism unusual to hypothyroidism). These findings, if applicable to other plasma 
membranes, are inconsistent with observed depletion of cell Ca in hypothyroidism) °2 In 
contrast to an inverse relationship between activity and thyroid level, incubation of human 
erythrocyte membranes with 0.1 nM T4 triples activity, and with 0.1 nM T3, almost doubles 
activity measured at 37°C. '°9 Because these preparations do not convert T4 to T3, this is 
a direct effect of T4, and one probably not mediated by known cell membrane 
T3-receptors. Rat erythrocyte Ca2+-ATPase does not respond to these low T3 and 3"4 
concentrations) °9 but incubation with 1 nM T3 or 100 nM T4 affects activity in a manner 
that depends on whether the rats have been fed a diet that contains corn oil or lard--and 
therefore that probably depends on membrane fatty acyl composition? 64 The ratios 
20:4co6/18:2co6 and 18:1c~9/18:2c~6 are 46% and 131% higher, respectively, in mem- 
branes from lard-fed rats than in membranes from corn oil-fed animals. T3, and less so 
T4, inhibits Ca2+-ATPase activity in ghosts from the lard-fed group, but activates 
Ca2+-ATPase in ghosts from the corn oil group. Only T3 and T4 among thyroid analogues 
are active, so these effects might be receptor-mediated. 
Activity of endoplasmic reticulum Ca 2+-ATPase is directly proportional to thyroid state, 
at least when measured at 25°C in the specialized sarcoplasmic reticulum of muscle cells. 
Sarcoplasmic reticulum of heart 3~'5s5 and skeletal muscle '5' of thyrotoxic rats and rabbits 
accumulates Ca 2+ ions and has a Ca2+-ATPase activity twice as fast as preparations from 
euthyroid controls, but stores normal amounts of Ca 2+. In rats, these T4 effects depend 
on protein synthesis, and are associated with increased passive permeability of the 
membranes to Ca 2+ ions, increased sarcoplasmic reticulum phospholipid contents, and 
depleted 18:2 and 20:4 acyl contents that are replaced with 16:0 and 18:0 fatty acyls. 3~ 
In hypothyroid animals, Ca 2+ uptake and Ca2+-ATPase activity measured at 25°C are 
40-70% below normal levels) 46'5s5 Treating hypothyroid rats (newborns from hypothyroid 
mothers) with T3 restores skeletal muscle membrane Ca 2+ uptake slowly, by 50% in 5 days 
and 100% in 10 days, which suggests that synthesis of both protein and phospholipid are 
involved. 's6 Partly contrasting results are reported in thyrotoxic dogs, where cardiac 
sarcoplasmic reticulum accumulates and exchanges Ca 2+ at 37°C faster than control 
preparations, while Ca2+-ATPase activity at that temperature is at normal levels and 
activity of the 'basic' Mg2+-ATPase is depressed. 42' The Mg2+-ATPase is not a sarco- 
plasmic reticulum enzyme but is contributed by contaminating plasma membranes and 
mitochondria. ~¢ Without rigorous comparisons, it is not possible to decide whether the 
thyroid-insensitivity of the Ca2+-ATPase in a report by Naylor et  al. 42' arises from 
differences in species or in temperature of measurement. However, temperature affects 
myocardial contractility differently in normal and abnormal thyroid conditions, and at 
least part of these contractile defects are attributed to altered in s i tu  behavior of 
sarcoplasmic reticulum Ca2+-ATPase, through control of [free Ca2+]cyto. '°'~5''42~ 
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Isometrically contracting heart muscles from hyperthyroid cats, as compared with 
euthyroids, shorten faster, develop tension faster, and remain contracted for a shorter 
time. ~ Muscles from hypothyroid cats show opposite changes. These abnormalities occur 
in isolated muscles kept at temperatures between 21°C and 32°C, but the degr¢~ of 
difference at any one temperature varies with thyroid state--that is, thyroid levels regulate 
the thermotropic properties of contractility parameters. Since such behavior characterizes 
membrane-dependent processes, the molecular mechanisms are relevant here. Thyrotoxic 
hearts hypertrophy and hypothyroid hearts atrophy. Amounts of sarcotubular membrane 
per unit of myofibrillar volume remain constant while mitochondrial membranes increase 
in thyrotoxic rats. ~° Actomyosin proliferates in thyrotoxic hearts and changes qual- 
itatively, the proportion of the Vt isomyosin rising to 90%, as compared with 12% Vt and 
88% V3 in euthyroids.t3s In hypothyroids, only V3 heavy-chain myosin mRNA is expressed; 
V~ mRNA appears 4 hr after such rats receive T3, and becomes 90% of total myosin 
mRNA at 72hr. Thyrotoxic rabbit hearts at 21°C contract with decreased efficiency, 
measured as heat production per J'(tension-time), which is equivalent to the ratio 'energy 
(ATP) utilized during cross-bridge cycling' per unit of work done.t° Most of the defect is 
ascribed to an increase in Vl, which cycles with a faster rate-limiting step and has higher 
myosin-ATPase activity than V3. The remainder is attributed to the enhanced rates of 
depression of [free Ca2+]cyto and Ca 2+ release by sarcoplasmic reticulum membranes 
during depolarization. In view of observations that absence of Vt isomyosin accounts for 
60% of the abnormal contractility in pressure-overload hypertrophy, t° presumably the 
major depletion of V~ contributes comparably to the defects in hypothyroidism. 
No studies of thermotropic properties of V 3 or Vl isomyosins seem to be available. 
However, the sarcoplasmic reticulum Ca2+-ATPase depends on lipids. Delipidated 
Ca2+-ATPase is reactivated by either phospholipids or hydrocarbon anionic detergents, TM 
but requires phospholipids to transport Ca2+) s6 Cholesterol enrichment in liposomes also 
increases Ca2+-ATPase activity. 373 The degree of fatty acyl unsaturation plays no im- 
portant role in reactivation at room temperature, 3s6 although it does alter Tt and Ea values 
in the inflected Arrhenius plots of activity. 225'635 Experiments are still needed to decide if 
changes in sarcoplasmic reticulum lipids actually mediate part of the thyroid effects on 
Ca2+-ATPase activity. 
D. Na +K+-ATPase 
The Na+K+-ATPase protein complex is integral to cell membranes of vertebrates 
(except dog erythrocytes), where it maintains low [Na +] and high [K +] inside the cell 
([Na+]i and [K+]i). Na+K+-ATPase is highly regulated. Highest activities are found in 
renal tubules and neural tissues, cells meant to exchange ions. Activity and regulation are, 
not unexpectedly, lipid-dependent, and in thyroid-sensitive tissues, thyroid-dependent. A 
major calorigenic role is proposed for this enzyme-transporter system, so its general 
relationship to lipids is relevant. 
Several lines of evidence clarify Na + K+-ATPase membrane-dependency. Delipidation of  
plasma membranes with phospholipase A inactivates Na+K+-ATPase, but phospholipase 
C is relatively ineffective, 78"595 which indicates that PL fatty acyls play a role in 
Na+K+-ATPase activity. Low concentrations of non-specific lipid-solubilizing detergents 
such as dodecyl sulfate and deoxycholate actually increase Na+K+-ATPase activity, 
whereas higher concentrations decrease activity. The activation may expose enzyme active 
sites otherwise covered by lipids, since the more lipid-soluble a cardiac glycoside is, the 
better it binds to rat brain Na+K+-ATPase. 4 Heart sarcolemma Na+K+-ATPase seems to 
lack this lipid barrier, and binds the glycoside ouabain with extremely low affinity and 
dissociates from bound ouabain very rapidly; the enzyme is in lipids with a UI about twice 
that in other plasma membranes, which may contribute to its unusual behavior. Recon- 
stitutions of delipidated Na+K+-ATPase in liposomes of acidic PL (PS or PG are those 
naturally present in plasma membranes) are most effective in restoring normal levels of 
activity, sensitivity to inhibition by ouabain, and biphasic Arrhenius plots of activity. 79 
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Although PS seems so specific as to indicate it is essential for activity in brain or rabbit 
kidney enzyme, 7s'3°7'595 1:1 PC + PE and dioleoylphosphatidylglycerol are also effective 
with renal enzyme. 3°7 A 1981 review 535 concludes that activity requires no one PL polar 
head-group, and that the PL fatty acyls non-specifically provide a degree of lipid fluidity 
essential for Na+K+-ATPase activity, but the following evidence indicates that fatty acyls 
play a more specific role. 
Fatty acyl composition of cell membrane phospholipids, when altered by diet, affects 
Na+K+-ATPase specific activity, the amount of Na+K+-ATPase, and Na+K+-ATPase 
membrane-dependency as shown by Arrhenius profiles and cooperativity of effectors. 
Chronic dietary deficiency of o~6-fatty acids partly replaces plasma membrane o~6-PUFA 
with c09-PUFA, and increases Na+K+-ATPase activity and amounts--surprisingly, 
considering the paucity of o~6-PUFA in normal plasma membrane phospholipids and in 
the PS of plasma membranes. 632 The number of Na+K+-ATPase molecules increases in 
liver and kidney particulate fractions. 355'356 Activity increases in plasma membranes of 
hepatocytes, 58~ brain synaptosomes, 596 heart sarcolemma, 2 and in Ehrlich ascites tumor 
cells grown in mice so fed. 565 Plasma membranes of cultured murine T-lymphocyte tumor 
EL4 cells incorporate saturated or unsaturated (18 : 1 or 18:2) fatty acids from their growth 
media to the extent of 20-50% of total PL fatty acyls. 48~ Neither saturated or unsaturated 
fatty acids affect ouabain-sensitive Na+K+-ATPase specific activity at 37°C but the 
unsaturates decrease ouabain-binding or fluidity calculated from ESR of substituted 
18:0-derivative probes. The 'molecular activity' ([ouabain-sensitive Na+K+-ATPase] 
[bound ouabain] -~) is about 8 times higher in UFA-media, which is thought to represent 
the exposure of more existing Na+K+-ATPase ouabain-binding sites through direct 
molecular interactions between Na+K+-ATPase and unsaturated fatty acyl moieties. In 
Arrhenius plots of Ehrlich cell plasma membrane Na+K+-ATPase activity, the transition 
temperature is ~ 14°C in EFA-deficiency (c.f. 22°C in controls); at temperatures > 14°C, 
Na+K+-ATPase activity is greater than control activity while Ea is unchanged; at 
temperatures < 14°C, Ea is twice the control value, 565 indicating that the Na+K+-ATPase 
is in a less fluid lipid environment. The fatty acyl chain order parameters of plasma 
membranes from a hamster ovary cell line can be manipulated to change Na+K+-ATPase 
activity 10-fold without altering the number of ATPase molecules, 556 further indication that 
fluidity and activity are related. In heart sarcolemma from EFA-deficient rats, 
Na+K+-ATPase activity is greater than control levels at all temperatures below the 
transition temperature but the transition temperature is unchanged? Arrhenius profiles 
show that membrane lipids of rat brain interact progressively differently with 
Na+K+-ATPase during the postnatal phase of brain development, 425 a period when brain 
cell respiration loses thyroid-dependence. 
The PL fatty acyl composition of rat erythrocyte membranes resembles that of 
hepatocyte plasma membranes. The effects of EFA-deficiency on the Na+K+-ATPase of 
erythrocyte membranes have been examined through alterations in responses to 
Na+K+-ATPase effectors as measured by n, the Hill coefficient, as an index of degree of 
cooperativity (see Section IV.A). 147 Since the specific activity of Na+K+-ATPase as 
measured in vitro depends strongly on the history and current state of the enzyme's 
exposure to effectors, 4 these studies seem pertinent to considerations of thyroid regulation 
of Na+K+-ATPase. In red cells from rats fed the usual corn oil-supplemented diet, n = 2.9 
for Na+-activation of the ATPase; Na+-activation would need to be a high power 
term of [Na +] for amplification 527-m of the relatively small A[Na+]i that regulates 
Na+K+-ATPase activity. Red cells from rats fed a fat-free diet show decreased n values 
for Na+K÷-ATPase activation by Na + or K + and for Na+K÷-ATPase inhibition by F-.  
As the dietarily manipulated ratio of erythrocyte lipid unsaturated/saturated fatty acyls 
is increased, n decreases. Cholesterol supplementation of the corn oil-containing diet 
increases n for F--inhibition to 3.6. Thus, decreased membrane fluidity seems to increase 
the degree of cooperativity of this inhibitor, through the value of cell [Na÷] n. 
Evidence that activity and amount of Na÷K÷-ATPase mediates thyroid-induced 
calorigenesis includes observed correlations between rates and ouabain-sensitivity of 
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oxygen consumption, Na+K+-ATPase specific activity, Na+K+-ATPase amount, cell 
['Na +] and [K+], tissue thyroid-sensitivity, and time-courses after administration of 
T3. t25,2~9'269'27°'s~ For example, ouabain inhibits 30--40% of the respiration of liver or kidney 
slices from euthyroid rats, .5'269'633 as well as the relatively depressed respiration in slices 
from hypothyroid rats; 269 ouabain inhibits the stimulated respiration after T3-pretreatment 
(3 doses over 6 days) to about the levels in rats not treated with T3; and Na+K+-ATPase 
activity in homogenates is roughly proportional to slice respiration rates. 269 Assumptions 
involved in concluding that Na+K+-ATPase mediates normal and pathological thyroid 
regulation of respiration include: (i) ouabain specifically binds and completely inhibits 
Na+K+-ATPase; (ii) ouabain-blockage of the Na+-pump affects no respiration-linked 
system other than Na+K+-ATPase; and (iii) mitochondrial respiratory control 
mechanisms respond 'normally' to A[ADP] after the Na+-pump is inhibited by ouabain. 
These assumptions were critically reviewed in 1976225a and have been further challenged 
since. 
(i) Ouabain-specificity: although ouabain did not directly inhibit respiration of isolated 
mitochondria from kidney, ~ it inhibited respiration of brain mitochondria by up to 
420/0. 634 Less direct effects were seen in heart mitochondria prepared from guinea pigs 
pretreated with toxic doses of ouabain, where ADP did not fully accelerate respiration, ~ 
perhaps because of interfering cation recompartmentation, as discussed by Gerrais et a l . t~  
These findings throw some doubt on the conclusion that ouabain-inhibition reveals a 40% 
Na+K+-ATPase contribution to thyroid respiratory stimulation. Moreover, tissue slices 
introduce artifacts into measurements of Na+K+-ATPase activity and amounts, 42 and 
quantitative correlation between Na+K+-ATPase activity and amount is not valid when 
respiration and ouabain-binding are measured in different ionic media? Some of the 
problems inherent in the use of slices are avoided in intact cell preparations, but there the 
Na+K+-ATPase contribution to thyroid calorigenesis is minimal or negligible: < 15% in 
striated muscles, 42,9' and 5% in perfused liver 27,~ and in isolated fat cells. '43 Further, in 
broken-cell preparations of rat heart and skeletal muscle, 2°,~s rabbit renal tubules, ~a and 
tissues of genetically obese ob/ob mice, 646 in vivo T3-pretreatment fails to induce 
Na+K+-ATPase. In the rabbits, T3-receptors are shown to be present and renal glycerol- 
3-phosphate dehydrogenase and hepatic Na+K+-ATPase are concomitantly accelerated. 543 
The ob/ob mice lack a thyroid-responsive ouabain-sensitive Na + K +-ATPase although they 
have other thyroid-responsive systems, and York et al. ~ discuss the possible contribution 
of the lack of Na+K+-ATPase-mediated energy consumption to accumulation of trigly- 
cerides that characterizes these animals. Hypothyroidism decreases ouabain-binding in the 
muscle membrane preparations; T3-treatment of either hypothyroid or euthyroid 
rats (0.5/~g/g on days 1, 3, and 5, killed on day 6) raises the ouabain-titer by 
markedly increasing the affinity of the Na+K+-ATPase for ouabain2°.~S--which is 
more consistent with T3-alteration of membrane lipids than with synthesis of 
Na+K+-ATPase. 
(ii) Ouabain-blockage of the Na +-pump decreases cytosol [K +] and [ADP], and increases 
[Na +] and [Pi]. It is the decrease in [ADP] that is postulated to account for the 
ouabain-inhibition of respiration. Additions of K + sufficient to prevent most of the 
decrease in [K +] in ouabain-bathed slices did not affect ouabain-insensitive respira- 
tion. 269'27° However, through effects on proton entry into mitochondria, the mitochondrial 
inner membrane Na+/H + antiport would slow respiration when cytosol [Na +] increases, 
and the Pi/OH- antiport (which is equivalent to a Pi/H + symport) would stimulate 
respiration when [Pi] increases. 
(iii) Mitochondrial respiratory control: the premise that cytosol [ADP] always controls 
mitochondrial respiration in hypothyroid and hyperthyroid cells is overtaken by recent 
advances in understanding of control sensitivities in oxidative phosphorylation and the 
effects thereon of thyroid state changes (see Section IV.B.1). Briefly, [ADP] controls the 
increase in respiration during the State 4--*State 3 transition only at intermediate rates of 
respiration, and not at all in State 3; the adenine nucleotide translocase contributes 29% 
of the control over State 3 respiration in mitochondria from normal rats, and only 19% 
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in thyrotoxic rats. Why State 4 increases in thyrotoxicosis is discussed at length in Section 
IV.A. Furthermore, effects of altered Na+K+-ATPase activity on respiration must be 
measured in whole cells to preserve the existing cytosol [ADP]. But substrate efficacies in 
increasing cell respiration greatly modify mitochondrial State 4--,State 3 transitions: 
glucose, which is conventionally used with whole-cell preparations, provides relatively little 
(24%) oxidative support for the Na+K+-ATPase, while glucose plus fatty acids provides 
the most support (68%). 213 All this makes uncertain which control-contributing step (see 
Section IV.A) might link Na+K+-ATPase activity to respiration. 
Ouabain-binding, immunoassay, and incorporation of [35S]methionine or [y-32p]ATP 
into electrophoretically resolved ~t- and fl-subunits ~°3'357-359 have been used to show that 
T3-treatment of hypothyroid or euthyroid rats increases the number of Na+K+-ATPase 
molecules per mg protein in cells or membrane preparations. In vivo T3-treatment of 
hypothyroid rats also increases the amount of a mRNA for the ~t-subunit of 
Na+K+-ATPase (mRNA~) after 40-72 hr (not detectable at 5 hr but detectable at 24 hr in 
kidney and heart126.2u.39°,a91--this does not seem consistent with findings that T3 fails to 
increase the V=~ of Na+K+-ATPase? °'us Comparable lengths of time are required in a 
variety o f  cultured cells for 10-100 nM T3 or 100 n i  1"4 to increase Na+K+-ATPase 
activity, mRNA~, or transmembrane resting potential, or to decrease cell [Na+]. 21's0'271,306 
Na+K+-ATPase in different tissues may be genetically heterogeneous) 44'145'39~'532'59° Thus, 
although immunoassay and ouabain-binding show similar numbers of Na+K+-ATPase 
molecules in erythrocytes and myotubes, they show a 25-fold discrepancy in fibroblasts and 
some other cells, and ouabain and antibody do not compete for binding. ~'t45 Only one 
or very few genes code for Na+K+-ATPase but mRNA~ levels vary in different tissues, 
suggesting control at transcriptional or post-transcriptional processes) 33 Although trans- 
lation-blockers prevent the induction (increased ouabain-binding) of the Na+K+-ATPase 
in HeLa cells grown in low [K +] medium, a transcription-blocker permits ouabain-binding 
to increase but decreases K+-influx activity. 47 The ,t- and fl-subunits are initially inserted 
into endoplasmic reticulum membranes, ~26'2u the fl at the start of its synthesis, the ,t as late 
as 40%-syntbesized, depending on unspecified properties of the membrane) 66 Normally, 
about half the newly synthesized Na+K+-ATPase later appears in the plasma membrane 
while the rest accumulates intracellularly. 594 Thyroid hormones coordinately induce both 
0t and fl subunits. 35s'a59 Brain contains distinct ~t and ,t + forms; 53a'59° in developing brain, 
thyroid treatment hastens the appearance of both ,t (also found in kidney) and ~ + (the 
axolemmal form), while hypothyroidism blunts these increases. 39j'Sa2 
The slowness of these thyroid inductions, which begin at 24-48 hr after T3 adminis- 
tration, is worth noting. The much earlier inductions of enzymes of lipogenesis and fatty 
acyl desaturation (see Section III.B. 1) are not, from evidence available, directly connected 
with changes in the membrane-dependency of Na+K+-ATPase activity, although sur- 
rounding membrane lipids do affect activity (see above). Arrhenius plots of activity in 
myocardial microsomes from control or T3-treated rats each inflect at 24°C and have 
similar calculated values of Ea, while Na+K+-ATPase activity is about 35% higher in the 
hyperthyroid preparations at temperatures from 13°C to 40°C. 473 Further, in crude 
homogenates of liver or kidney, the Ea of Na+K+-ATPase activity and of 
Na+K+-ATPase-dependent respiratory rates (S = glucose) between 31°C and 40°C are 
unchanged in hyperthyroidism although Na+K+-ATPase and respiration are acceler- 
ated. ~a Thus, one may conclude either that hyperthyroidism does not change the local lipid 
environment of the Na + K +-ATPase in the plasma membrane (Ref. 473; see Section III.A), 
or that any change that hyperthyroidism does effect in plasma membrane lipids does not 
alter Na+K+-ATPase thermotropic responses--perhaps in analogy with the failure of 
documented lipid changes in the mitochondrial inner membrane to alter those of the 
normally lipid dependent pyridine nucleotide transhydrogenase (see Section IV.B.9). What, 
then, might be the relationship between the T3-induced expression of genes, first and very 
early on those for a few lipogenic enzymes, and, later, those for the subunits of cell 
membrane Na+K+-ATPase? 
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E. Plasma Membrane Permeability 
Evidence now accumulates that T3-treatment first increases plasma membrane passive 
permeability to Na + and K +, and that increased cytosol [Na +] or decreased [H +] then 
mediates Na÷K+-ATPase induction. High demands for Na+-transport generally induce 
Na+K+-ATPase, and are striking in renal tubules, especially those of the remaining 
kidney after uninephrectomyfl 9 The leakiness of cell membranes to Na + and K + correlates 
with the number of Na+K+-ATPase molecules in the membrane, and inhibition of 
Na+K+-ATPase leads to synthesis of more Na+K+-ATPase (see Ref. 225a). Dystrophic 
hamsters have sarcolemmae in heart and skeletal muscle that leak K + and have very high 
Na+K÷-ATPase activity. In HeLa cells grown in low [K +] medium to induce the 
Na+K÷-ATPase, [Na+]i increases to a maximum at 8 hr and then starts to fall as ouabain- 
binding rises. 47 An experimental doubling of passive Na+-influx into neuroblastoma cells 
more promptly increases Na+K+-pump activity that keeps [Na+]i constant. 4°3 
Although thyroid hormones increase the activity of Na+K+-ATPase measured in 
isolated plasma membrane preparations, in intact cells the passive permeability of the 
plasma membrane to Na+-influx and K+-etflux, rather than the Na+K+-ATPase capacity, 
limits any sustained increase in active pumping of Na + and K + .  13'14'154'202-204'403 Thyroid 
hormones (0.2-1 #M T3 or T4) (see footnote on page 232) applied in vitro increase, within 
the first hour, passive Na+-transport in the isolated bladder of the toad, t87 and passive K ÷ 
permeability in frog skeletal muscle, m Thyroid pretreatment in vivo stimulates perme- 
ability first. In diaphragm, and in heart and liver slices, passive permeability was initially 
rated a secondary target because thyroid treatment seemed to stimulate Na÷K+-ATPase 
activity without changing cell [Na ÷] or [K+]Y ° However, T3-administration consisting 
of 3 doses of 0.5 #g/g given to normal rats over 6 days increases net passive flux of K ÷ 
and Na ÷ in perfused isolated livers TM and in liver slices, 2°3 and in isolated skeletal 
muscle. 14'2°2 Very small doses (0.01 #g/g/day x 14-16 days) given to hypothyroid rats 
increase K+-efflux but leave Na+K÷-ATPase activity unchanged in liver slices ~ and 
renal proximal tubules, 73 whereas 0.5 #g/g/day for 3-7 days first augments K+-efflux, then 
stimulates Na÷K÷-ATPase activity. Thus, increased passive mono-cation fluxes, rather 
than T3-occupancy of nuclear receptors, more immediately mediate thyroid activation of 
Na+K+-ATPase. 2°:-~ Thyroid effects on passive Na+-influx in intact tissues tend to be 
obscured by the difficulty of differentiating [Na+]i from extracellular [Na+]. The use of 
thyroid-sensitive cultured hepatocytes ts8 appears to circumvent this problem. Exposure to 
10 nM T3, renewed daily for 3 days, increases both passive Na+-influx and K+-efflux. 272 
The time course of such T3 actions is not yet available, but changes appear in days rather 
than in minutes. 
Na ÷ and K + can move passively across cell membranes by unmediated diffusion across 
the membrane lipids or by protein-mediated mechanisms. Non-mediated passive diffusion 
of Na ÷ and K ÷ across the phospholipids of the plasma membrane are discussed by Else 
and Hulbert TM as regulating calorigenesis in resting cells and being under the control of 
thyroid hormone levels. Membrane fatty acyl composition regulates cation leakage: Na ÷ 
and K + diffuse across artificial PL membranes prepared from lipids of normal rats 
(E,--- 15-17 kcal/mol), and more readily across membranes from EFA-deficient animals 
(Ea--4 kcal/mol). 4°s'~5 Mediated transport has been studied more extensively. 
1. Na +, K÷.Cotransporters 
The Na÷-K÷-CI - cotransporter in the cultured hepatocytes is eliminated as a mediator 
in T3-stimulation of passive K+-influx because T3-treatment does not change its inhibition 
by furosemidefl 2 The glucose-Na + symporter in epithelial cells of small intestine and renal 
proximal tubules simulates a Na+-leak, and glucose is the conventional energy source for 
whole-cell preparations. The intestinal hexose-Na + symporter promptly activates the 
Na÷K÷-ATPase to maintain [Na+]i homeostasis. ~61 However, neither hypo- nor hyper- 
thyroidism changes Na+-dependent glucose uptake by renal tubule preparations. ~ 
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T3-incubation accelerates the insulin-dependent 2-deoxy-D-glucose transporter in cultured 
chick, embryo heart ce l l s  539 but the expected concomitant entry of K + would presumably 
decrease Na+K+-ATPase activity. Since blockage of synthesis of DNA, RNA, or proteins 
fails to affect T3-stimulation of deoxyglucose uptake in these cells: 41 and the in vitro 
effectiveness of thyroid hormone analogues ranks almost similar to their efficacy in other 
in vivo assays, T3-receptors in the cell membrane are thought to mediate this glucose 
transport. Rat liver plasma membranes contain such specific, high-affinity sites 479 but 
analogous sites do not appear to be connected with glucose-Na + entry into renal proximal 
tubules. T3-incubation with rat thymocytes first raises [cAMP] transiently, then increases 
2-deoxyglucose uptake, and both effects require extracellular Ca2+. ~ Epinephrine acts 
similarly but more rapidly, although no Ca 2+ is required. Since alprenolol blocks the 
T3-effects as well as the epinephrine-effects, T3 seems to be acting here via/~-adrenergic 
receptors. 
2. Na +-H + Antiporter 
The plasma membrane Na+-H ÷ antiporter is thyroid-responsive. This antiporter has 
been recently recognized to be ubiquitous in plasma membranes of nucleated mammalian 
cells, where it exchanges Na ÷ for H ÷ one-for-one, electroneutrally, to contribute to 
cytoplasm pH (pHi) homeostasis (reviewed in Ref. 311). Cytoplasm [H ÷] is increased by 
mitochondrial and other oxidations. Na+-H ÷ antiporter senses pHi, perhaps through a site 
on its cytoplasmic face that binds H ÷ and thereupon activates exchange) 93 In effect, this 
transporter has a steep v vs. pHi profile. Proton-efflux is driven in many cells by the 
pre-existing energy of the concentration gradient of [Na+]-outside > [Na+]i, which has, in 
turn, been generated by the Na÷K+-ATPase at the expense of ATP hydrolysis. The 
Na+-H + antiporter in brush border plasma membranes of epithelial cells of renal proximal 
tubules depends on thyroid status. 5~8 The antiporter couples Na+-influx down the 
[Na+]-gradient (lumen~cell) with secretion o f H  + against the [I-I+]-gradient (cell~lumen). 
The basolateral plasma membrane of these renal cells contains a (thyroid-sensitive) 
Na+K+-ATPase that pumps Na + out of the cytoplasm into the blood stream while 
returning K + from blood to cytoplasm. Initial rates of Na÷-H + antiporter activity in brush 
border membrane preparations from hypothyroid rats are half those in euthyroid controls; 
and V is twice normal in membranes from hypothyroid rats made hyperthyroid by thyroid 
treatment for 3 weeks. At least 24 hr is required for these effects of thyroid state change 
to appear. Na+-H + antiporter activity correlates highly with log[T4] in serum, under these 
conditions. Normally, increase in cytosol [H +] is a positive cooperative activator of 
Na÷-H + antiporter, with a Hill coefficient, n = 1.43; this is a relatively low n to amplify 
the signal from observed ApHi values of 0.1-0.6, that correspond to a A[H ÷] of 1.26--4, 
during metabolic and developmental transitions in a variety of cells. Thyroid treatment 
affects neither n nor [H+]05. From these findings, Sacktor and Kinsella sts suggest that 
thyroid hormone either increases the number of Na+-H + antiporter per unit membrane 
or increases the exchange activity of existing Na+-H + antiporter. It is not yet clear what 
the relative rates and thyroid sensitivities are of the Na+-H + antiporter that puts Na + into 
the cytosol and the Na+K+-ATPase that pumps Na + out. Differential thyroid effects on 
cytosol [Na +] may resemble the classical balancing of hepatic [cholesterol] through thyroid 
regulation of both synthesis and further metabolism. 
Amiloride (a specific Na+-H + antiporter inhibitor) blocks > 80% of the entry of Na + 
into either control or T3-incubated (for 72 hr) cultured liver cells, indicating that most of 
the Na + enters via the Na+-H + antiporter with or without added T3. 272 However, T3 
stimulates the remaining <20% of Na+-entry (Table IV in Ref. 272), by +86% with an 
active Na+-H + antiporter and by + 56% with inactive Na+-H + antiporter. It is not clear 
if T3 up-regulates this minor Na+-leakage path early enough and sufficiently to account 
for the later stimulation of Na+K+-ATPase specific activity or synthesis, or if this leakage 
is mediated or unmediated. 
In considering how thyroid hormones may effect gene expression through alterations in 
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membrane permeability to cations, it is of interest that hypothyroidism produces striking 
renal atrophy, and hyperthyroidism, hypertrophy. Thyroid state is only one of several 
regulators of the Na+-H + antiporter: among other activators are second messengers, 
growth-promoting factors, mitogens, phorbol diesters, insulin, glucocorticoids, PGE2. 
Several of these agents, as well as normal fertilization of sea urchin eggs, exert a common 
effect in raising pHi, which is thought to mediate activation of DNA synthesis. 72 
Reports that T3-treatment leaves the membrane-dependency of the Na+K+-ATPase 
unchanged 473 suggest that, if the hormone induces changes in plasma membrane lipids, they 
might affect the cation-leakage (via the Na+-H + antiporter and possibly across the PL as 
well) that initiates activation of the Na+K+-ATPase. The steps in a sequence of mech- 
anisms, A[T3, T4]~ Alipid composition ~increased C + permeability ~ A[C + ]i--*activation of  
gene expression--,translation of  the C+-pump protein, would merit measurements of the 
control strengths, Ci (see Section IV.B). The step(s) A[C+]i--*gene expression is of great 
interest for the mechanisms of a number of instances where thyroid hormone first 
promotes activation of existing enzyme (e.g. by covalent modification; see Section II.B. 1), 
then synthesis of that enzyme. 235'236 Evidence discussed above indicates that C + = H+: the 
cell membrane system that exchanges Na + and H + is thyroid-responsive, and thyroid 
treatment decreases [H+]i, which in turn may stimulate transcription and synthesis of 
Na+K+-ATPase. Thyroid regulation of cell H +-circuits is discussed in the next section, on 
oxidative phosphorylation. 
IV. MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION 
Thyroid-state dependent changes in membrane lipid composition are likely to alter 
function in the inner membrane of mitochondria, which functions so completely through 
its properties as a barrier and as a matrix for deeply embedded transporter and enzyme 
proteins. Changes in inner membrane lipid composition brought about by a variety of 
means correlate with defects in oxidative phosphorylation. 92'24°'37°'393'489 Three examples can 
be given: (i) ethanol-feeding is of particular interest, in view of current observations that 
propylthiouracil, given in dosage used to convert human hyperthyroid subjects to 
euthyroid status, protects their livers against the lethal toxic effects of chronic excessive 
ethanol intake? ~ Ethanol feeding produces the following changes in rats. It brings about 
a 'hyperthyroid' metabolic pattern in liver, 27a but the mitochondrial dysfunction comprises 
decreases in both State 4 and State 3 respiration. It raises 18:2 and depresses 20:4 acyl 
proportions in liver mitochondrial YPL, PC, and PE, 157'395 but specifically lowers CL/PL 
ratios by 33% in a report by Miceli and Ferrell, a95 and depletes 18:2 content in CL by 
25%. 626 It alters thermotropic properties of State 4 respiration, 5°S's°7 and decreases activities 
of the microsomal fatty acyl-CoA A5- and A6-desaturases? 26 However, for an opposing 
view, see Ref. 182. In contrast, hypothyroidism raises CL/PL and the CL contains 
normally high amounts of 18:2 acyls; 2¢ one wonders if this is connected with the 
therapeutic effects of induced hypothyroidism. (ii) Adaptation to a cold environment is 
accompanied by changes in mitochondrial fatty acyl composi t ion,  37°,468,47s,4sg,575 and fails in 
hypothyroid rats. ~5 (iii) The most straight-forward demonstration of the degree to which 
mitochondrial o~ 6-PUFA distributions must be altered to affect coupling and the proton 
leak should come from experiments that involve dietarily induced 18:2co6-deficiency and 
refeeding. Contradictory reports, and the importance of estimating the roles of these fatty 
acyls in thyroid mechanisms, make it advisable to examine effects of EFA-deficiency on 
oxidative phosphorylation here (see Section IV.E). 
The degree of respiratory stimulation after thyroid treatment in vivo, and of respiratory 
depression in hypothyroidism, has been correlated with the amount of nuclear 
T3-receptors in different tissues. 453'455 As shown in Table 5, spleen, testis, and brain from 
euthyroid rats have relatively few T3-receptors, as compared with liver, or on an absolute 
basis. Slices from those tissues (in which one cannot define respiration as being in State 
4 or State 3) respire at about the rates of the thyroid-responsive tissues like liver, kidney, 
and heart, but T3-treatment does not stimulate their respiration, nor does hypothyroidism 
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TABLE 5. T3-Rcceptors, Respiration of Slices, and Mitochondrial Cardiolipins (CL) in Various Tissues 
Respiration (#1 O2/mg wet weight/hr) Mitochondrial C L  d 
T3-receptors 
T issue  (normalized a) Eu b A% Eu + T4 H c A% H + T3 %CL/PL % 18 : 2/CL 
Liver 1.0 1.29 + 62.4 1.01 + 63.8 14.8 59.4 
Kidney 1.47 3.62 + 37.8 3.11 9.0 60.5 
Heart 0.45 0.76 + 24.2 0.47 + 200 20.0 74.8 
Sk. muscle 0.57 +28.6 0.45 +47.7 12.5 23.3 
Spleen 0.18 1.45 + 10.8 1.43 + 1.6 7.3 48.6 
Testis 0.01 0.61 - 3.6 0.63 - 5.7 0.15 13.2 
Brain 0.24 1.01 + 4.3 0.93 + 2.4 1.6 I 0.3 
ang T3 bound/mg DNA, normalized to liver. 453 b(Ref. 183). C(Refs 24, 25, 312). d(Refs 253, 632). 
depress it. Both receptor count and respiratory response to altered thyroid levels correlate 
as well with the relative amounts of tissue cardiolipins (CL/PL ratio) and with the 18 : 2 
acyl content of  the CL. Thus, testis and brain PL include very little CL, and their CLs 
contain relatively little 18:2, as compared with the 10-20% CL/PL ratios in liver, kidney, 
and heart, and the 60-75% 18:2 contents in those CLs (Table 5). Spleen is intermediate, 
with a 7.3% CL/PL ratio and 50% 18:2 in the CL. In contrast, heart PL combine the 
highest CL proportion with the highest percentage of 18: 2 in the CL, and heart respiration 
responds to T3 treatment of hypothyroid rats most robustly despite a relatively low 
T3-receptor content. These data seem consistent with the 18:2 acyls of CL mediating 
effects of T3-receptor occupancy on tissue respiration. Respiratory responses to thyroid 
levels may depend on (mitochondrial) amount and 18: 2 contents of CL, which may in turn 
depend on T3-receptor count, by way of T3-regulation of lipogenic enzymes. 
Table 6 compares effects of  thyroid levels on State 4 and State 3 respiration in rat 
heart mitochondria, with mitochondrial 18:2 content and CL/PL ratios. Hypothyroidism 
depresses respiration in either State, depending on the temperature of  measurement. At 
25°C, hyperthyroidism accelerates either respiratory State, depending on the thyroid 
dose x time treatment schedule. 474 In heart mitochondria, hypothyroidism leaves CL/PL 
ratios unchanged while 18:2 in CL decreases 22%; 237 in liver mitochondria, hypothy- 
roidism increases the ratio CL/PL by 72% but leaves the 18:2 content in CL unchanged. 24s 
In liver mitochondria of thyrotoxic rats (normals injected with T3, 0.3/zg/g/day x 3 days), 
CL/PL increases by 34% and CL 18:2 content decreases by 63%. 5~' In our studies 
on thyrotoxics, T3 (1/~g/g/day x 3 days) decreases liver mitochondrial 18:2 in PL by 
26% (Table 1); in heart mitochondria, that dose does not alter CL/PL or 18:2 per- 
centage in CL or PL. 237 Thus, heart and liver mitochondrial CL compositions respond to 
thyroid levels differently; heart and liver mitochondrial functions differ, as is discussed in 
Section IV.D. 
Membrane PL regulate a number of oxidative enzymes and related anion-carriers. 335'523 
Evidence from delipidation and reconstitution experiments also assigns a special role to 
cardiolipins in mediating thyroid effects on oxidative phosphorylation component pro- 
teins, as will be detailed. Cardiolipins are necessary for full reconstitution of several steps 
in oxidative phosphorylation but they are not sufficient without other PL. Cardiolipins 
bind some membrane proteins strongly and activate, or inhibit and make activity 'latent'. 
Distinctive properties of cardiolipins include the following. They contain 18:2 as about 
55% (liver mitochondria) to 80% (heart mitochondria) of total fatty acyls, as compared 
to less than 15% in PCs and less than 10% in PEs. ~°6:53'632 Cardiolipins are almost all in 
mitochondria, where they comprise 10% to 20% of the Y.PL. The inner face of the inner 
membrane contains about 90% of the CLs of mitochondria, 65% of the PEs and 50% of 
the PCs) °6 Hence, in heart mitochondria, the CL should be 40% of the inner face PL, and 
account for 85% of the inner face 18:2 acyls; in liver mitochondria, CL should be 20% 
of inner face PL and contain 60% of the 18:2. Cardiolipins have high activities in 
translocating cations across an organic phase separating two aqueous phases. 612 Their 
extended hydrophilic group with its four long-chain hydrophobic moieties creates regions 
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the inner surface of liposomes formed from mixtures of PL, 41° and why CL digestion but 
not PE or PC digestion correlates with the disruption of inner membrane structure) s 
Most workers agree that thyrotoxicosis accelerates, and hypothyroidism slows, mito- 
chondrial State 4 respiration measured in vitro and its expression in vivo, the BMR. Three 
daily T4-injections given to normal rats accelerate liver mitochondrial State 4 respiration 
at 30°C 30-50%, and decrease State 3 respiration slightly, with glutamate, oe-ketoglutarate, 
or fl-hydroxybutyrate as substrate. 245'2~s Observations on State 3 respiration conflict: some 
find that thyroid state has no effect, 245'246 and others that it alters State 3 in the same 
direction as State 4, 6m'62'551'552 depending on the substrate; 229 several report uncoupling of 
phosphorylation after high-dosage thyroid treatment in vivo, 245.246'3s4"3s5 and others find 
normal P/O ratios after lower doses. ~°'~ Recent non-invasive in situ measurements show 
decreased mitochondrial P/O ratios in hearts of rats made hyperthyroid with small doses 
of T4. 3°4 
Despite the fact that thyroid treatment promotes gene expression and late synthesis of 
mitochondrial cytochromes, 51'292'5°°'53m'597'~ liver mitochondria from our normal and hypo- 
thyroid rats, and rats treated for short periods with hormone, show no major changes in 
either the relative amounts of proteins as measured by SDS-PAGE; s~'s3 in the amounts of 
cytochromes measured spectroscopically; 5~'6~'62 or in protein/lipid ratios. 24s Taken together 
with the multiplicity of thyroid-dependent membrane enzymes and transporters, and the 
small number of genes expressed after T3-treatment, these observations indicate to me the 
existence of one basic causal phenomenon, to others, multiple action loci. 412'577 That 
phenomenon is temperature-sensitive. 
Effects of altered lipid compositions on membrane proteins have been estimated through 
measurements of physical properties, and through effects of temperature and cooperativity 
of effectors on protein-mediated or lipid-mediated rate processes. Kinetic measurements 
have the advantage of measuring specific biological function. Since membrane lipids sense 
temperature changes, Arrhenius plots demonstrate how membrane enzymes and trans- 
porters respond to their lipid environment. 393'4s9 Arrhenius profiles of State 4 respiratory 
rates in mitochondria from rat heart are normally linear from 10°C to 37°C whereas those 
of State 3 inflect at ~ 25°C 2~ as do State 3 plots with liver mitochondria. 3°2'347 Studies on 
State 4 respiration of liver mitochondria, especially in simple media, are difficult to 
find. However, it appears that State 3 respiration in this temperature range proceeds 
under at least two sets of mechanisms in either liver or heart mitochondria. Thyroid 
hormone deficiency in rats alters the inflected Arrhenius plot profiles obtained from liver 
or heart mitochondrial State 3 respiration, s~-s3'237'262'55° respiration-supported ATP-syn- 
thetase, sl's2 adenine nucleotide translocations, 23~ and calcium ion transport (J. Peabody 
and F. L. Hoch, unpublished data). Hypothyroidism usually lowers activities and makes 
the Arrhenius profiles more linear at temperatures between 10°C and 37°C. In some cases 
the hypothyroid and euthyroid plots intersect, making the temperature of measurement 
crucial for demonstrating hormone effect. Thus, observations that LT4-feeding does not 
change some mitochondrial systems measured at 37°C have been taken to indicate that 
concomitant thyroid responses at <37°C are artifacts, lms'l~9 
Cooperativity of lipids and effectors on kinetics of membrane-dependent systems is also 
thyroid-dependent. Changes in the Hill coefficients of activations or inhibitions of allosteric 
membrane-bound enzymes denote a regulation of the enzyme through changes in 
membrane lipid unsaturation, effected by feeding rats EFA-deficient diets. 147 The Hill 
number is said to detect changes in Ea of ,,,0.75 kcal/mol as compared to ,-~3 kcal/mol 
needed to shift the corresponding break in the Arrhenius profile. Wallach 62a points out 
that, in a lattice mosaic model of biomembranes, protein-lipid subunits show positive 
cooperative interactions, and gel-,liquid-crystal phase transitions can be effected either by 
raising temperature or by changing the ionic composition of the aqueous environment at 
constant temperature. The latter is the important phenomenon in membranes of homeo- 
thermic animal cells. The fact that a temperature change induces a lipid phase transition 
that alters function of a membrane enzyme or transporter, implies that ionic or effector 
changes would alter function similarly. An abnormal Arrhenius profile of a transporter 
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caused by redistribution of membrane fatty acyls implies that the transporter will also 
respond abnormally in vivo to effectors. In poikilotherms, Arrhenius plots may directly 
reflect adaptations through altered membrane lipids. 
If some thyroid effects are mediated through interactions of membrane lipids and 
proteins, altered interactions should be measurable in situ in biomembranes by spec- 
troscopic methods. Here, apparently incompatible findings need conciliation for inter- 
preting thyroid mechanisms. By 2H-NMR, all the PL form a homogeneous phase: no lipid 
shell persists long enough to allow a stoichiometric complex. 77'562 Intrinsic membrane 
proteins enveloped by the hydrophilic parts of amphiphilic lipids appear to respond only 
to the average properties of the PL, presumably at the level of amino acid side chain 
molecular rotation and translation, although Smith and Oldfield s62 do not rule out specific 
interactions that are beyond current detection limits. Such methods do not appear to have 
been applied to possible thyroid influences on protein-lipid interactions as yet. On the 
other hand, membrane PL do affect membrane proteins, and all PL do not affect proteins 
similarly. In model membranes, PLs are not 'specifically' required for activity since 
detergents also activate, which is valuable information for understanding molecular 
mechanisms. However, membrane proteins do not see detergents in the mitochondrion, 
they see the natural amphiphiles PC, PE, CL, PS, PI, and perhaps some lyso-PLs. Evidence 
exists that proteins respond to changes in the proportions and fatty acyl compositions of 
these PLs--a biological selectivity if not a chemical specificity. And some thyroid- 
responsive proteins are difficult to delipidate, they retain stoichiometric amounts of CL, 
and CL effectively reconstitutes function after they are vigorously delipidated (see below). 
A. State 4 Respiration in Liver Mitochondria 
Recent insights into proton circuits, 364'39s-4°°'436'437 control mechanisms of oxidative 
phosphorylation, and their dependence upon membrane lipids explain some apparent 
discrepancies in studies on thyroid regulation. State 4 and State 3 respiration are differently 
controlled: State 4 depends on the barrier properties of membrane phospholipids. State 
3 depends on several transporter proteins that participate in rate regulation, according to 
experiments (see Section B below) based on theoretical formulations of Refs 220, 221,289, 
290 and 527-529. The regulatory contributions of these transporters are tissue specific and 
strongly affected by the rate of respiration, the extra- or intramitochondrial location of 
the ADP-generating process, and the nature of their lipid matrix in the membrane. Thus, 
the respiratory control ratio, State 3/State 4, is hybrid, and State 4 respiratory rate is a 
more valid index of intactness of the inner membrane. 436 
Shears and Bronk m'552 show that LT4-treatment of normal rats, 8 #g/g body weight 
injected sc 24 hr before killing, accelerates State 4 respiration and increases Ap across the 
liver mitochondrial membrane, mainly by increasing A~(+  13 mV) rather than ApH 
(+  3 mV) (Expt. 1, Table 7). The State 3 rate increases by 36%; because the accompanying 
Ap (113 mV; not shown) remains unchanged, the hormone was thought to accelerate State 
3 and State 4 by different mechanisms, m'552 In hypothyroid rats killed 24hr after 
TABLE 7. Rat Liver Mitochondrial State 4 and State 3 Respiration (ng atom O/min/mg); 
A~, ApH, Ap (mV); Effects of LT4-injection, and the Presence of 'Decoupling' Agents 
State 4 
State 3 
Resp. A~, ApH Ap Resp. (Ref.) 
1. Controls (succinate 25 °) 20 181 14 195 104 (551,552) 
+LT4 (8 #g/g, 24h) 30 194 17 211 141 
2. Controls (glutamate 30 ° ) 14 158 51 209 (584) 
+ Bilirubin (24 #M) 41 164 65 229 
3. Controls (succinate 37 °) 80 155 32 190 176 (506) 
+ 16:0 (10 nmol/mg) 175 160 20 180 175 
Controls (succinate 25 °) 40 190 120 
+ 18:1 (20 nmol/mg) 180 190 180 
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T3-injection, A~b increases + 7 m V .  6Is However, no reports of which I am aware compare 
Ap in liver mitochondria from euthyroid and hypothyroid rats, or from hypothyroids 
subjected to lesser dose × time treatments; and extrapolation from effects of thyroid on 
euthyroid rats is risky. Further, interpreting these data in terms of delocalized chem- 
iosmosis poses a dilemma: if T4-injection acts as a protonophore, State 4 would accelerate 
but Ap would fall; if T4 decreases the leak, Ap will be maintained or increase but then State 
4 should decrease. 
Shears 55m proposes that thyroid injection of normal rats might increase proton current 
non-ohmically under State 4 conditions by two effects: an increase in Ap (presumably from 
electron-transport stimulation) enough to break down the proton resistivity of the 
thyroid-state-altered membrane lipids. The necessity for such postulates under State 3 
conditions is disputed by Brand and Murphy? ~ A non-ohmic, exponential relation- 
ship between Jx+ and Ap in rat liver mitochondria does become important at values 
of Ap ~-200mV 323,435,456 and pertains particularly to State 4 respiration, where Ap 
is around 200mV: State 4 would thus be highly sensitive to changes in Ap. This 
exponential relationship is seen not only in intact mitochondria but also in protein-free 
liposomes made from mitochondrial l ip ids  323 and in bilayer membranes consisting of pure 
phospholipids.201.439, 5°4 
The great disparity between induced changes in electron transport and A/2H+ is dismissed 
by Rottenberg and Hashimoto ~ in their own experiments and those of Nicholls 435 and 
Pietrobon and Caplan 47s as artifactual because it occurs at 25°C but not at 37°C. However, 
this thermosensitivity suggests that the fatty acyl chains of the membrane PL are involved. 
Saturated fatty acyl chains pack closely in membranes; unsaturated acyls kink and do not 
pack as closely, which permits water intercalation. Water molecules within the hydro- 
phobic domain appear to conduct protons across pure PL membranes. 52'2°~ Unsaturation 
at the co6-position disturbs packing order mostly at the center of the bilayer. 56,3°s Thus 
oJ6-unsaturated fatty acyls may play a special role in proton conductance. The observed 
redistribution of mitochondrial inner membrane co6-PUFA contents (see Section II.A) 
may mediate at least some thyroid effects on proton flux in State 4 respiration. 
Although proton current in State 4 is dissipated through the permeation of H + through 
membrane PL, mediated cation/H + antiport and anion/H + symport also transport protons 
under usual conditions of assay. 39~-~° Recommended and standard procedures 76,~35 measure 
State 4 in the presence of Pi and Mg 2+ ions that are necessary only for subsequent assay 
of State 3 but also contribute to carrier-mediated proton transport in State 4. State 4 
respiration may well provide energy for such ion-pumping in vivo. However, adding 
mitochondria last to reaction mixtures designed for measurement of proton leaks through 
the PL of the membrane significantly depresses State 4 respiration because no unnecessary 
ions (e.g. K +, Na +, Mg 2+, Pi) are present and inhibitors are added to block ion 
transporters and the ATP-synthetase. "'67'323'438 Measurements under such conditions would 
help to decide whether changes in membrane phospholipid fatty acyl groups and/or 
proton-cotransport proteins mediate thyroid-state regulation of the proton leak and State 
4 respiration. In particular, while a substrate cartier must support State 4 respiration, in 
effect, the carriers for tricarboxylates, glutamate, pyruvate, and dicarboxylates (see Ref. 
51) introduce H + into the matrix; the (acyl)carnitine + carrier seems free from this 
objection. Besides, fatty acids are a more physiological substrate for mitochondrial 
oxidations; the succinate carrier is not required because succinate is generated and oxidized 
intramitochondrially.~°7 
An alternative interpretation of the effects of thryoid state involves the existence of 
localized intramembrane proton circuits. 637 In a mosaic chemiosmosis scheme, an intra- 
membrane route coexists in parallel with the external proton circuit to regulate competition 
between energy-dependent processes .  459'631 Decouplers are thought to introduce the intra- 
membrane protons to transmembrane leakage routes. T4-injection (Expt. 1, Table 7) acts 
much like a decoupler does in vitro. Among the decouplers are free fatty acids 5°6 
and bilirubin 584 (see Expts 2 and 3, Table 7). Chronic ethanol-feeding (which changes 
mitochondrial fatty acyl composition) also decouples. 5°7 Decouplers accelerate State 4 
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respiration but do not decrease Ap in concentrations that uncouple; they produce loose 
coupling, 342 as does thyroid treatment. 22~'24~ They uncouple most in systems that require 
a high Ap (reverse electron flow), less in those with an intermediate energy demand 
(ATP-synthetase), and minimally in those with low energy load (pyridine nucleotide 
transhydrogenase). 5°5'~ Decouplers act in at least stoichiometric quantities; the amount of 
free fatty acids required for maximal uncoupling far exceeds the content of proton pumps 
(1 nmol/mg protein), and the amount of bilirubin needed is even greater. Protonophores 
act in catalytic quantity. 438 Normal rat liver mitochondria contain little T4 or T3, about 
0.4pmol/mg protein; in hypothyroidism, hormone content decreases by 80%; after 
hormone injection, in hypothyroids, the mitochondrial hormone increases 100-fold in 
2min, and in euthyroids 550-fold by 3 hr. 116'22s These data speak strongly against the 
normal amount of hormone molecules acting directly as decouplers, although hormone 
accumulation after thyroid injection in euthyroid rats does approach stoichiometric values. 
On the other hand, thyroid treatment redistributes the phospholipid fatty acyl composition 
in bulk, and the fatty acyl chains seem eligible as decouplers. 
Proton leakage under State 4 conditions has been quantitated in terms of the amount 
of added FCCP that is equivalent to the leak at [FCCP]=0)  94 In normal liver 
mitochondria in a reaction mixture containing succinate/malate and the traditional 
irrelevant ionic ingredients (K +, Mg 2+, Pi, and even 1 mM ATP) at 25°C, the extrapolated 
value is about 12 pmol FCCP per mg protein (State 4, Table 8). Liver mitochondria from 
hypothyroid rats leak protons under these State 4 conditions abnormally slowly; one 
injection of LT3, 0.4/~g/g body weight, partly restores the leak in 24 hr (more completely 
when measured by State 4 respiration). Verhoeven e t  al.  61s recognize that their uncoupler 
titrations do not reveal the process responsible for proton leakage that is affected by the 
hormone, other than that the presence of oligomycin eliminates participation by the 
ATPase. The rate of State 4 respiration itself is more informative on mechanism. 
From separate experiments, State 4 respiration is, in general, inversely proportional to 
the percentage of 18:2co6 fatty acyls in membrane phospholipids, s~-83 but does not 
correlate with contents of 20:4co6 or 22:6co 3 or the overall UI (membrane fluidity). To 
determine if a rigorous correlation exists, concomitant measurements of State 4 respiration 
under appropriate conditions, and fatty acyl compositions, are still needed, especially as 
functions of dose x time after thyroid treatment of euthyroid and hypothyroid animals. 
Such a correlation casts 18:2 as a 'proton-plug' that decreases transmembrane proton 
leakage; and/or as a 'coupler' that conducts intramembrane protons from the redox pump 
directly to the ATP-syntbetase but away from the leak that connects intramembrane 
protons with the bulk phases; or as a positive effector for the redox pump that increases 
Ap, particularly at the cytochrome bc~ segment (Table 8). These considerations imply that 
thyroid state regulates both the incorporation of 18:2 into liver PL (Table 2) and the 
desaturations of 18:2 to 20:4 (see Section II.I) to adjust the inner membrane content of 
18:2 fatty acyls, and thereby maintains efficient proton transport for oxidative phos- 
phorylation. Desaturation of linoleoyl acyl groups would then supply 20: 4 for prostanoid 
TABLE 8. Liver Mitochondria: The Effects of Thyroid State on the Proton Leak 
During State 4 Respiration, on the Distribution of Control Strengths (Ci) during 
State 3 Respiration, and on Respiration Rates (Succinate/Malate, 25-26°C); From 
Refs 194, 618 
Step Normal Hypo H + T 
State 4 
State 3 
Proton leak (pmol FCCP/mg) 11.8 4.5 5.8 
(ng ion H+/min/mg) * 318 198 276 
Respiration (ng atom 0/min/mg) 305 227 338 
ADP/ATP carder (C~) 0.29 0.18 0.27 
Dicarboxylate carrier (Ci) 0.33 0.21 0.34 
Cytochrome bc I (C)  0.03 0.21 0.14 
Cytochrome oxidase (Ci) 0.17 0.14 0.18 
Proton leak (Ci) 0.04 
Z(C~) 0.86 0.74 0.93 
*Calculated from State 4 respiration (not shown), and H+/O = 6. 
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synthesis rather than for a role in oxidative phosphorylation, and would decrease 18:2 acyl 
content and thereby accelerate proton leakage. 
One injection of LT4 into hypothyroid rats progressively increases State 4 respiration 
at 25°C in liver mitochondria from animals killed 2-180min later, 22s'229 a period when 
PUFA contents decrease and saturated fatty acyls increase (Table 1). We in effect 
estimated proton leakage by titrating liver mitochondria with dinitrophenol (glutamate; 
in the presence of K + and P~; 25°C) and measuring the 'sensitivity' of the increase in 
respiration by the calculated Hill coefficient, n. 147,527-529 In mitochondria from hypothyroid 
rats, n is depressed below normal values; injection of LT4, 5 ~g/g body weight, increases 
n, within minutes in hypothyroid rats and in 6 hr in normal rats (Table 9). Thus, the 
DNP-sensitivity of the proton leak relates directly to thyroid state and to State 4 
respiration. DNP is partly ionized at pH 7.4 and so titrates respiration non-linearly because 
the first molecules added remain in the aqueous phase; at pH 6.5, DNP titrates respiration 
linearly, like FCCP at pH 7.4194 (which dissolves completely in the membrane lipids even 
at low [FCCP]). 222'43s Hill numbers thus reflect the relative partition of DNP into the 
membrane lipids, which is apparently less in hypothyroid mitochondria than in normals, 
and increases rapidly after LT4-treatment. The altered fatty acyl composition of mito- 
chondria in hypothyroid animals would thus seem to be involved in the observed changes 
in DNP partition and effectiveness. DNP injected into euthyroid rats increases mito- 
chondrial calorigenesis in 30 min, as measured by the BMR. DNP-induced calorigenesis 
decreases markedly in severely hypothyroid rats, and a sub-calorigenic dose of LT4 
restores it within 6 hr.  227 These in vivo effects may reflect the effectiveness of DNP on 
mitochondrial proton leakage. 
I do not known why the addition of albumin reverses the increased proton leak that 
occurs 30 min after T4-injection. 22s'247 Albumin has been used to 'improve' mitochondrial 
respiratory control in normal mitochondria ~ by decreasing the proton leak. If altered 
fatty acyl composition mediates the T4-induced leak increase, albumin should have no 
effect--albeit no one has reported what albumin does to mitochondrial fatty acyls. It seems 
more likely that the affinity of albumin for cations, fatty acids, and thyroid hormones is 
involved. Although albumin partly removes hormone from mitochondria of euthyroid and 
hormone-treated hypothyroid rats, there are reasons against thinking that T3 or T4 acts 
directly as a protonophore, i.e. in catalytic amounts. Measurements in the absence of 
unneeded permeant ions might provide answers. 
B. State 3 Respiration in Liver Mitochondria 
Calculations of control stength, Ci, from titrations of respiration with inhibitors specific 
for component steps, show that State 3 respiration (succinate/malate; 25°C) in liver 
mitochondria from normal rats is regulated almost completely (Y.Ci = 0.82) by three 
protein-mediated transports: the dicarboxylate and the ADP/ATP carriers together 
account for a Ci = 0.62, and the electron carriers at the cytochrome aa3 segment for a 
Ci = 0.17 (Table 8). The bc~ site and the proton leak regulate minimally. 49'167'~94 At less than 
TABLE 9. Hill Coefficients (n) of the Dinitrophenol-Titrations of 
Respiration, and State 4 Respiration (ng atom O/min/mg Protein; 
S = Glutamate, 25°C), in the Liver Mitochondria of Normal and 
Hypothyroid Rats; the Effects of One ip Injection of LT4, 5/~g/g; 
Recalculated from Refs 229, 230 
Normal rats Hypothyroid rats 
Time after T4 State 4 Time after T4 State 4 
(hr) n Resp. (rain) n Resp. 
0 1.22 9.5 0 0.79 6.7 
3 1.22 9.2 2 0.98* 8.1" 
6 1.50" 9.8 30 1.06* 7.9* 
24 1.59' 12.2" 180 1.06" 7.9* 
48 2.10" 10.1 
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maximal respiratory stimulation by external ADP, the ATP/ADP carrier Ci increases up 
to about 0.5 and that for the dicarboxylate carrier decreases to 0.2, 49'~67 but the effects of 
thyroid state have been reported only for maximal State 3 respiration. In State 3 the Pi 
carrier Ci and the ATP synthetase 49 Ci = 0. A much different C~ distribution regulates State 
3 in other than adult rat liver mitochondria (see Sections IV.C and D). 
Hypothyroidism decreases the rate of State 3 respiration while markedly increasing the 
C~ of the cytochrome bc~ segment at the expense of the control strengths of the adenine 
nucleotide translocase and the succinate carrier: electron transport through bc~ is slowed 
relative to the capacities of the two carriers that normally regulate most (Table 8). The 
YC~ = 0.74; among the steps not measured are the succinate dehydrogenase, the P~ 
transporter, the various cation transporters, and the proton leak. The proton leak does 
not seem a good candidate for gaining in control over State 3, since it is markedly 
depressed in hypothyroidism. 
LT3-injection restores the State 3 rate and the C~ values toward control levels, although 
the bc~ segment still contributes more than normally. Conspicuously unresponsive to 
thyroid state is the minor C~ of the cytochrome oxidase step. The dose of T3 used does 
not uncouple, and does not increase proton leakage to become a significant regulator of 
State 3 respiration. We still do not know what doses of thyroid hormone large enough 
to uncouple do to mitochondrial lipid composition, but dietary deficiency of 18:2 fatty 
acid, especially when accompanied by feeding of saturated or co 3-unsaturated fatty acids, 
severely depletes mitochondrial 18:2 fatty acyls, and uncouples, albeit inconsistently 
(see Section IV.E). 
The energy-dependent fluorescence yield of 1-anilino-8-naphthalene under State 3 
conditions (succinate, 30°C) decreases in liver mitochondria from hypophysectomized rats 
and is restored after LT4-treatment. 372 Since this probe presumably reports on the 
polar-nonpolar interface region of the inner membrane, these data indicate that thyroid 
affects State 3 through membrane phospholipids. Thyroid-responsive liver mitochondrial 
proteins that regulate State 3 respiration involve cardiolipins: the transporters of (1) 
ADP/ATP, (2) substrates, and electrons at (3) the cytochrome bc~ segment. (4) The 
cytochrome aa3 step also regulates and is CL-dependent, but not thyroid-responsive. Other 
proteins that may not regulate respiration in liver mitochondria (although some regulate 
in mitochondria of neonatal liver and heart; see Section IV.C and D), but also involve CL 
include (5) the P~ carrier, (6) substrate dehydrogenases, (7) the ATP synthetase, (8) the Ca 2+ 
transporter, and (9) the pyridine nucleotide transhydrogenase. 
1. ADP/A TP Carrier 
The observed slowing in adenine nucleotide translocation in mitochondria from livers 
of hypothyroid rats ~a is claimed to depress ATP synthesis 578 because the translocator is 
'rate-limiting') °s Indeed, the ADP/ATP carrier contributes to respiratory regulation in 
euthyroid rat hepatocytes suspended in ionic buffer, Ca 2+ ions, bovine serum albumin, and 
lactate + pyruvate, at 37°C.122a Eighty percent of the respiration is mitochondrial, and 70% 
of that represents State 3 respiration, for which the Ci = 0.26 (c.f. 0.29 in isolated 
mitochondria, Table 8). Hyperthyroidism is thought to accelerate the ADP/ATP carrier 
in vivo, from studies on perfused rat livers where cytoplasm ATP/ADP ratios are twice 
normal even though ATP is more rapidly used for enhanced urea and glucose synthesis, 
and Na+-pumping. ~2 These claims are contradicted by the observed decrease of the Ci in 
hypothyroids and the restoration of the Ci after T3-treatment (Table 8; see also Ref. 51). 
Claims that the ADP/ATP carrier of adult beef heart mitochondria is the LT3-receptor 
that regulates respiration 578 are countered by additional facts: heart mitochondrial 
respiration is not regulated under any experimental conditions by this carrier, H7 and no 
information is available that thyroid state affects the heart translocase; the moles of thyroid 
hormone bound 57s and found H6 in liver mitochondria are at least 3 orders of magnitude 
less than the ,-, 1 nmol of carrier per mg protein; 45 the putative similarity between amino 
acid compositions (not sequences), and perhaps LT3-binding, of the carrier and the 
JPLR 2 7 / ~  
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receptor may be no more than is to be expected from two lipophilic membrane proteins; 
and by other considerations. 51'~°'6~9 
The abnormal thermotropic properties of the ADP/ATP carrier in liver mitochondria 
from hypothyroid rats 2~ suggest that altered fatty acyl composition might also change 
carrier regulation by other effectors. However, in normal mitochondria the Ca = 0.29 at 
25°C (Table 8) and 0.31 at 37°C; 251 in hypothyroid mitochondria, Ci = 0.18 at 25°C, 0.17 
at 37°C. Brief LT3-pretreatment of hypothyroid rats leaves the Ci at 37°C unchanged but 
restores the State 3 rate. 25~ Temperature in this range does not appear to affect the relative 
sensitivity of the carrier, but more rigorous experiments are still needed. 
CL binding is involved in activity, given that the CL on the ADP/ATP carrier is the 
negatively charged target for cationic activators, as Kr/imer et al) ~s propose. The 
ADP/ATP translocase loses 50% of its activity when liver mitochondria are depleted of 
only 1% of their total PL by a pancreatic phospholipase A with substrate specificity 
CL > PE > PC, while Crotalus adamanteus venom phospholipase A, with substrate 
specificity PC = PE>>CL, must remove 8 times more PL to inhibit 50%. 5¢ Although 
incorporation of the delipidated beef heart translocase protein in CL, PC or PE vesicles 
activates equally, 3~7 CL binds to the isolated carrier with the unusually high molar 
stoichiometry of 6: 1 (c.f. 2-3: 1 in the cytochrome oxidase complex), and with great affinity 
that produces strong CL immobilization, inferred from 31p NMR. In contrast, PC and PE 
are not immobilized on the protein and are easily removed; these findings indicate a specific 
CL-protein interaction. 34 The increased mitochondrial CL/PL ratio in the hypothyroid 
liver may account for the abnormal thermotropic properties of the translocase, and the 
maintenance of high activity (decrease in Ci) relative to the other carriers that regulate 
State 3 respiration. 
2. Substrate Carriers 
Among mitochondrial substrate carriers, the 18: l-carnitine translocase has been shown 
to be completely CL-dependent (see Section II.J). Cardiolipins are unique in being the only 
membrane PL that keeps the monocarboxylate, 4~s dicarboxylate, 296 tricarboxylate, 5s° 
~-ketoglutarate, 419 and aspartate/glutamate ~6 carriers active during purification and 
reactivates them after isolation. Only the dicarboxylate carrier has been examined and 
shown to be thyroid-sensitive (Table 8). 
3. Cytochrome bcl Segment 
Surface spectrophotometry of intact perfused rat liver 2~6 and studies on isolated 
mitochondria ~ are taken to show that cytochrome b is normally a control point in electron 
transport, although the very low Ci for the bc~ segment (Table 8) says it is not. In 
hypothyroid rats, when the liver is perfused with fructose to decrease electron flow to the 
State 4 level by depleting P~ and deaminating adenine nucleotides, respiratory inhibition 
and the degree of cytochrome b oxidation are greater than normal, 216 which does agree 
with the significant Ci. In hyperthyroid rat liver, the inhibition of respiration and oxidation 
of cytochrome b that is seen in normals does not occur. Hassinen et aL 2t6 conclude that 
thyroxine loosens the coupling between phosphorylation and electron transport; con- 
versely, hypothyroidism increases coupling in situ. In isolated rat liver mitochondria, 
hyperthyroidism increases the degree of reduction of cytochromes b, c and c~ during 
State 3 respiration (succinate, 37°C), while in State 4 cytochrome b is more oxidized 
and cytochromes c and c~ are more reduced. 62"252 Mitochondrial ubiquinone content 
increases 75%, and ubiquinone becomes more reduced; over this long treatment 
period, LT4 also increases concentrations of b, c and aa3. The hormone is thought to 
regulate State 3 respiration mainly through the bc~ complex, and State 4 by increasing 
proton permeability, 2s2 as had been shown by control strength analyses. 6~s 
The cytochrome bc, segment is lipid dependent. The extremely hydrophobic apo- 
cytochrome b is encoded by mitochondrial DNA and synthesized in the mitochondrion, 559 
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so the nascent protein assumes mature conformation at least near, if not in contact with, 
mitochondrial CL. Arrhenius profiles of the rate of electron transfer through bc~ are 
inflected, suggesting either a conformation change in a membrane component or merely 
a change in the 'rate,limiting' step. 536 Various PL reactivate phospholipid-depleted 
ubiquinol: cytochrome c reductase, which contains 80% of the mitochondrial cytochrome 
b, but only in the presence of CL: CL binds, PL activate; 59'~62 NADH: cytochrome c 
reductase prepared from beef heart mitochondria is also CL-dependent, as judged from 
its inhibition by adriamycin derivatives. 179-~8~ The 90%-delipidated, inactive succinate: 
cytochrome c reductase is reactivated by adding first ubiquinone, then asolectin. ~9 The 
residual lipids are 65% CL, 20% PC and 10% PE, so the 'non-specificity' of the asolectin 
(which itself contains 10% of total lipid P as CL 4~8) activation involves significant amounts 
of CL. 
4. Cytochrome Oxidase 
Cytochrome oxidase of bovine heart mitochondria copurifies with CL. Of the 50 
lipid-binding sites on the 200 kDa complex, 2-3 molecules of tightly bound CL are 
specifically required for catalytic activity of an active four-subunit fragment. Other 
membrane PL have a different, non-specific, activating and dispersive role, that is 
duplicated by detergents such as lysoPC and Tween-20.16°'~6~'496 Based on these findings, 
cardiolipins are described as a prosthetic group of cytochrome oxidase involved in the 
cyclic transport of monovalent cations, although H + ions are omitted from the list. t6° 
However, endogenous CL can be lowered to 0.3-0.4 moles/mol complex by replacement 
with dimyristoyl-PC while full oxidative activity is retained. 4s4 EPR spectroscopy of bound 
spin-labeled CL shows that CL binds to cytochrome oxidase > 5 times more strongly than 
this PC, but none of the binding sites on the enzyme complex are highly specific for CL. 
This lack of specificity may explain why cytochrome oxidase contribution to regulation 
of State 3 respiration in liver mitochondria is impervious to abnormal thyroid states. 
5. Pi Transporter 
Pa transporter protein purified from pig or cow heart mitochondria loses activity when 
CL is removed; only CL protects activity during solubilization. 43 CL reactivates the soluble 
protein, egg yolk PL activates but less. Protein-PC vesicles are inactive unless CL is added, 
then adriamycin inhibits. 4°9'4~° Adriamycin, an antineoplastic anthracycline amino- 
glycoside, forms stable intercalation complexes, probably with phosphodiester bridges of 
DNA and RNA (whereby it inhibits DNA replication and RNA transcription) and with 
the oriented phosphoester groups on the membrane-surface CL (whereby it disrupts 
mitochondrial structure, promotes lipid peroxidation, and inhibits oxidative phos- 
phorylation)J8 °'4t5 In addition, adriamycin inhibits some lipogenic enzymes (isocitrate 
(NADP) dehydrogenase, 6-phosphogluconate dehydrogenase, and malic enzyme) by 
interaction with -SH groups. 142 Adriamycin is thought to inhibit the Pi-transporter by 
making CL inaccessible. 15 These observations suggest absolute CL-dependency. However, 
the Pi carrier does not regulate heart mitochondrial State 3 respiration, and there is no 
information on thyroid effects in heart or liver mitochondria. In yeast mitochondria 
respiring in State 3, the Pa carrier Ca = 0.4-0.6, the cytochrome aa3 Ca = 0.5-0.6; 389 the 
CL/PL ratio is 0.15, but no 18: 2 acyls are present. 2~5 Oddly enough, 40 #M LT4 accelerates 
yeast respiration (glucose; 37°C). 434 
6. Substrate Dehydrogenases 
These can apparently contribute little to the overall control of State 3 respiration in liver 
mitochondria of euthyroid rats (~< 0.14) or hormone-treated hypothyroid rats (~< 0.07), but 
they might contribute some of the 0.26 of unmeasured Ca in mitochondria from 
hypothyroids (Table 8). The soluble dehydrogenases that act on isocitrate, glutamate or 
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malate, as well as the intrinsic membrane-bound succinate or glycerol-3-phosphate 
dehydrogenases, increase in thyrotoxicosis and decrease in hypothyroidism. 29t The 
membrane-bound p-hydroxybutyrate dehydrogenase is an exception, in that thyro- 
toxicosis decreases its activity while hypothyroidism affects it but little. Brand and 
Murphy 5] believe that thyroid treatment increases de novo synthesis or alters lipid 
environment, or both, to increase substrate dehydrogenase activities, and that the increases 
in subsequent electron-transporters are less important in accelerating electron flux. 
Specific PL-binding and specific PL-reactivation of a membrane-dependent enzyme are 
clearly distinguished in studies on the soluble apoenzyme of the D-/~-hydroxybutyrate 
dehydrogenase (NAD ÷) prepared from rat liver or bovine heart mitochondria. The 
apoenzyme specifically requires PC for activity, even when in aqueous solution. 59"t52,165'2ss'~ 
However, although CL (or PE) itself does not reactivate, in the presence of CL 2-5 mol 
of pure PC per mol of enzyme half-reactivates, as compared with 60 mol PC/mol enzyme 
in the absence of CL. Although the apoenzyme interacts with every pure PL tested, it 
interacts most strongly with films containing CL. Berrez et al. 33 propose that CL molecules 
on the inner face govern the binding to the inner membrane. The ~-hydroxybutyrate 
dehydrogenase is normally 'crypticized' and mostly inactive in intact mitochondria, and 
full expression of its activity in vitro requires membrane lysis. The similar latency of the 
mitochondrial inner face carnitine palmitoyltransferase CP%, and the dependency of that 
enzyme on CL (see Section II.J), suggest a common regulatory role for CL. Thyroid- 
induced depression of the/~-hydroxybutyrate dehydrogenase has also been attributed to 
the concomitant decrease in [NAD+], to which this enzyme is sensitive. TM 
Activity and amount of membrane-bound glycerol-3-phosphate dehydrogenase are 
remarkably thyroid-dependent (see Section II.E), but little information is on hand as to 
its lipid-dependency. Succinate dehydrogenase is about 30% latent in situ, and is regulated 
by the availability of the lipid-soluble ubiquinone and by membrane fluidity. 22 
Phospholipid-depleted NADH:ubiquinone reductase, which contains the NADH 
dehydrogenase (FMN, FeS), requires CL specifically, PL non-specifically. The NADH 
dehydrogenase of intact mitochondria is progressively solubilized in correlation with the 
course of CL hydrolysis by phospholipase A, but not with PC or PE hydrolysis, implicating 
CL in its binding into the inner membrane. ~8 
7. ATP-syn the tase  
ATP-synthetase is thyroid- and CL-dependent. In inner membrane vesicles from liver 
mitochondria of hypothyroid rats, the rate of the reaction ADP + Pi--*ATP is depressed 
at 30°C as a reflection of the linearization of the normally inflected Arrhenius profile. 81-83'242 
At 30°C, respiratory rate and flavin and cytochrome contents are all normal but the ATP- 
synthetase, acting independently of the ADP/ATP carrier, shows a decreased V and K~ 
for ADP; titration of phosphorylation rate with oligomycin reveals a diminished apparent 
number of phosphorylating sites, enough to account for most of the phosphorylation 
defect. In normal inner membranes, the progressive decrease in ATPase activity during 
incubation with ascorbate or cysteine, which peroxidize PL and fatty acyls, correlates 
uniquely with the disappearance of 18:2 from CL. 362'525 Reconstitution of the ATPase of 
heart mitochondria (where its Ci is significant) requires lipids for the complete, oligomycin- 
sensitive, amphipathic Fj F0 assembly. CL, in some reports, 102.589 is the most effective of the 
naturally available PL, although lyso-PC is more effective. A highly purified, active 
ATPase that retains oligomycin-sensitivity contains 2 mol of CL per mol, and lesser 
amounts of PC and PE. t23 The cardiac ATP synthetase is thyroid dependent in situ and 
in vivo (see Section IV.D). 
8. Ca2+-transporter 
The Ca2+-transporter, partially purified from cow heart submitochondrial particles, takes 
up very little Ca 2+ when reconstituted in liposomes made of 1 : 1 PC + PE, but increases 
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uptake linearly with [CL] added during reconstitutions, to about 12-fold at [CL] ffi 
10 mol%) 2° Liver mitochondria of hypothyroid rats pump Ca 2+ ions (30°C) into the 
matrix at rates 40% less than normals when the energy source is added ATP, but at near 
normal rates ( - 7 % )  even when supported by slowed substrate oxidation. 242'433 Arrhenius 
profiles of such ATP-driven (but not substrate-driven) transport are abnormal (J. Peabody 
and F. L. Hoch, unpublished data). Again these data indicate that lipid-sensitive utilization 
of proton flux decreases when protons emanate from the H+-ATPase and is normal (or 
even increased) when protons originate from substrate oxidation. When liver mitoehondria 
from hypothyroid rats are incubated for 1 min with T3 at 37°C, respiration in State 4 
and State 3 remains unchanged, but in the presence of Ca 2+ ions, increases in [T3] 
accelerate State 3 linearly. 223 At 1/~M [T3], the V for Ca2+-uptake and the rate constant 
for Ca2+-efflux are increased maximally, suggesting that the hormone acts directly on the 
inner membrane to increase Ca 2÷ ion mobility. Thyroid-state control over Ca 2+ re- 
moval from cytoplasm is more extensively studied in myocardial sarcoplasmic reticulum 
(see Section Ill.C). 
9. Pyridine Nucleotide Transhydrogenase 
As discussed in Section II.C.2, hypothyroidism doubles the V of the ~ TH reaction but 
not the TH reaction in liver mitochondrial inner membrane vesicles, and T3-treatment 
restores normal low values of V. In intact liver mitochondria, the normal steady state of 
substrate-induced delay in reduction of intrinsic pyridine nucleotides during the State 
3~State 4 transition, caused by the rate-controlling ~ T H  reaction, is much accelerated 
in hypothyroid mitochondria. 232'234 Oligomycin similarly accelerates reduction in mito- 
chondria for normal rats, TM by blocking proton egress through the ATP-synthetase and 
thereby stimulating TH activity even in non-phosphorylating submitochondrial par- 
ticles. 343 Thus, the increased proportion of inner membrane 18:2 acyls in hypothyroidism 
may conduct protons to the ~ TH and away from the ATP-synthetase. 
In addition to this unusual increase in rate, the TH differs from the transporters in liver 
mitochondria in lipid dependence and in sensitivity to a decoupler. Energy mode of the 
TH reactions determines lipid dependence. 5t2-5~6 The energy-independent reaction is much 
less inhibited by Crotalus terrificus phospholipase A2 (which is specific for PC and PE but 
hydrolyses little CU s) than is the ~ T H  reaction in submitochondrial particles 33°,367 and 
membrane particles of Escherichia coli WS1.557 Liposomes formed from any of several PL 
reconstitute purified transhydrogenase from beef heart submitochondrial panicles to 
highest TH activity; low [CL] reconstitutes most effectively, but high [CL] inhibits. 5~4 
PC is specific for the ~ TH mode, and small amounts of CL inhibit. Arrhenius profiles 
for ~ T H  activity, measured in everted vesicles prepared from liver mitochondria 
of hypothyroid rats before or after T-treatment, maintain normal values for Ea and Tt 
(transition temperature). 136:37 Since one protein catalyzes both TH and ~ T H  reac- 
tions, these observations suggest that the lipids exert their effects via the proton leak and 
Ap (as they do to regulate State 4 respiration) rather than by binding to the TH protein 
(as they may bind to the transporters that regulate State 3 respiration). 
As noted, the 'decoupler' action of palmitate at 25°C does not inhibit energy-dependent 
TH activities in rat liver submitochondrial particles while it inhibits succinate-supported 
reverse electron-flow and increases State 4 respiration and ATPase activity. 5°6 If, as 
Rottenberg and Hashimoto 5°5'5°6 propose, the ATPase membrane-associated F0-complex 
serves as a 'proton capacitor' that is intermediate between oxidation and phosphorylation, 
and that is discharged by free fatty acids, then the lack of effect of palmitate on ~ TH 
activities indicates that a different proton pathway couples ~ T H  to oxidation and the 
ATPase. If, as is discussed above, proton coupling between oxidation and phosphorylation 
involves 18:2 fatty acyls and CL, then the proton coupling to the ~ T H  does not appear 
to involve 18:2 and CL the same way, or at all. 
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10. Repetitive Additions of  ADP 
Recent measurements of respiration of liver mitochondria from hypothyroid rats show 
rates of State 4 and State 3 (succinate, 26°C) that are at control levels, but both decrease 
progressively as ADP is added repetitively, while rates are maintained in controls, m 
Hypothyroid mitochondria consume less O z during State 4--,3--,4 transitions. Treatment 
of hypothyroid rats with small doses of T4, 0.02/zg/g/day x 21 days, reverses these 
abnormalities. Objections to these data include the presentation of only derivative traces, 
d[O2]/dt, rather than absolute rates, so that 02 used during proton leakage is measured 
indiscriminately with 02 used during phosphorylation; and the absence of added Mg 2+ ions 
to support maximal State 3 respiration. 5s2 Since Ap is abnormally high in State 4 in 
mitochondria of thyrotoxics (Table 7; Ap data are needed in mitochondria from hypo- 
thyroid rats), the absence of differences in State 4 rates in the data of Ezawa et al. 139 seems 
important. To simulate conditions in vivo, they added pulses of ADP successively. Cycling 
of ADP additions is recommended to 'improve' rates of State 3 respiration in normal 
rat liver mitochondria, a7~ but it beclouds physiological control mechanisms. Success- 
ive additions of ADP increase respiration in State 4 (i.e. increase proton leakage) and 
State 3 (i.e. redistribute Ca contributions) progressively but do not change respiratory 
control ratios much. Data similarly disparate with respiration before and after single 
additions of ADP come from ADP-cycling with liver mitochondria from EFA-deficient 
rats (see Section IV.E). The mechanisms do not appear to have been studied. However, 
the ADP/ATP carrier is electrogenic and moves protons across the inner membrane, not 
as part of the mechanism, but electrophoretically. 339 Thus, if this carrier is involved in the 
respiratory effects of ADP-cycling, it may be by way of its introducing additional proton 
circuits. Further, multiple additions of neutralized ADP solutions introduce Na + or K + 
ions, to contribute to proton movements. 
C. Liver Mitochondria of Fetal and Neonatal Rats 
Plasma IT4] and [T3] of newborn rats rise 7- to 8-fold and linearly from day 2 to day 
21, 86,622 as shown in Table 10. Accompanying changes in liver mitochondrial function and 
lipid composition should be informative on physiological and developmental effects of the 
hormone, as opposed to effects of hormone injections. Reports on mitochondrial 
respiration during the fetal and postnatal periods conflict. Some investigators find that 
fetal mitochondria, as compared with those from adult rats, respire (succinate, 30°C) more 
slowly in State 3 but not in State 4.11'19'206'417 This respiratory defect is ascribed to the low 
contents of adenine nucleotides, which are thought to be due to low ADP/ATP carrier 
activityfl 7 Since this carrier exchanges ADP or ATP one-for-one, some other explanation 
seems necessary. The proton leak in mitochondria of newborns is said to be equivalent 
to 7 pmol of FCCP per mg protein, and in adults, to 21.5 pmol/mg, but the titration curves 
TAnLE 10. Neonatal Liver Mitochondria: Plasma [T4] and IT3]; Mitochondrial Respiration (Succinate, 
25-30°C) and Carbamoyl-P Synthetase Content; Liver Phospholipid Composition; and Developmental 
Changes 
Days after birth 
I-2 4-5 9-10 15-21 (Refs) 
Plasma [T4]: (~g/dl) 0.6 1.1 2.5 3.0 (86, 622) 
Plasma IT3]: (ng/dl) 10 20 42 79 (86, 622) 
Respiration: 
State 4 (ng atom O/min/mg) 53 30 26 25 (402, 480) 
State 3 (ng atom O/rain/rag) 159 150 143 150 (402, 480) 
Carbamoyl-P synthetase: 
(% ~ polypeptides) 12 16 20 20 (402) 
Liver PL: 18:2/PL (%) 5.8 5.5 10.6 (546) 
18:2/CL (%) 43 47 45 78 (402, 640) 
CL/PL (%) 6.0 8.8 9.9 12.2 (402) 
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are not linear for the newborns, and the respiratory rates at [FCCP] -- 0 (i.e. State 4) are 
similar to those in adults) 9 Comparison of methods for isolating mitochondria shows that 
the presence of bovine serum albumin greatly improves the poor recovery of fetal (but not 
adult) mitochondria over that in conventional media containing sucrose-EDTA, ~° which 
suggests that conventional methods selectively damage fetal mitochondria. With albumin 
or mannitol in the isolating media, mitochondria prepared by these methods from livers 
of 1-day old rats leak protons (State 4, succinate, 25-30°C) 70-100% faster than do 
mitochondria from adult rats and are permeable to low molecular-weight solutes, while 
State 3 rates are at adult levels 4°2'4s° (Table 10). State 4 respiration halves between day 2 
and 9, while State 3 respiration stays constant. In spite of this leakiness, such fetal 
mitochondria phosphorylate ADP efficiently ~° and the ADP/O ratio stays at 2.0 after 
birth. 4°2 Thus, the proton leak correlates inversely with the increasing plasma IT3] and 
[T4]--tbe opposite of the direct correlation seen when adult thyroid state is altered. In 
newborns, the ATP synthetase (Ci =0.6), the Pi carrier (Ci~<0.13), the dicarboxylate 
carrier (Ca = 0.12) and the ADP/ATP carrier (Ca = 0.15) regulate State 3; .9 the first two do 
not regulate in adult liver mitochondria. 
Liver phospholipids of 1-day rats contain 5.8% 18:2, which doubles between days 5 and 
15:46 The 18:2 deficit in neonates reflects in part the amount and composition of 
mitochondria: the 18:2 content of CL is 26% lower in fetal livers than in maternal livers ~ 
and rises 31% between days 5 and 15; ~6 the low ratio of CL/gPL in the newborn liver 
further contributes to the low 18: 2 contents in liver lipids, and increases linearly from day 
1 to 154°2 (see Ref. 106). However, because mitochondrial CL/mg protein does not change, 
it appears that more mitochondria are made during early developmentY 6 Thus, the 
amounts of 18:2 acyls and of CL correlate inversely with the proton leak, as is seen in 
adults. Relative amounts of the mitochondrial 165 kDa carbamoyl-phosphate synthetase 
increase 67% from days 1-10; 9°'~2 this enzyme is induced during the postnatal rise in 
plasma thyroid hormones much as it is during spontaneous Anuran metamorphosis, ~6'5s7 
and so serves as a marker for gene expression induced by spontaneously rising thyroid 
hormone levels. Other enzymes are also induced in this period: activities of fl-hydroxy- 
butyrate, succinate, glutamate, malate, and NADH dehydogenases increase 4- to 20-fold 
in homogenates, less in mitochondria (further showing mitochondrial replication). ~;76'627 
Mitochondrial glycerol-3-phosphate dehydrogenase activity does not increase, ~ indicating 
that thyroid hormones are not omnipotent in inducing hepatic enzymes during postnatal 
development. 
Thyroid levels do not affect liver PL contents of 18:2 acyls and CL/PL ratios in 
newborns like they do in adults. The effect of thyroid in newborns may be more on the 
incorporation of 18:2 into liver PL and especially CL (Table 2) than on the depletion of 
18:2 acyls by further desaturation as it is in adults. Fetal storage of maternal 18:2 is 
limited, and CL 18:2 is low. 64° EFA-deficiency may produce the rapid mitochondrial 
proton leak (see Section IV.E) and subsequent suckling may supply 18:2 while 
18:2-incorporating enzymes develop under thyroid and insulin ~ss influences. Interestingly, 
the 18: 2 content of PC and PE fractions of fetal livers are at adult levels, but their contents 
of 16:1 and 18:1 are 2.5 to 4 times above contents in the dam? 75 The greater contribution 
of mono-unsaturates to overall unsaturation resembles that seen in tadpole livers as 
compared with frog livers, and decreases as rapidly after injecting the tadpole with LT3 
as the induction of the enzymes synthesizing urea (Ref. 238; see Section II.I). 
D. Heart and Brain Mitochondria 
Thyrotoxicosis has been said to make heart mitochondria inefficient more readily than 
liver mitochondria, ~9 but evidence to the contrary is in Table 6. The decreased economy 
of isometric contraction observed in rabbits treated with LT4, 0.2 #g/g/day x 14 days, is 
not related to decreased mitochondrial resynthesis of ATP. 9''° Calorimetry shows that the 
ratio [recovery heat liberated during diastole]/[initial heat liberated during contraction and 
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relaxation] decreases, and this is mostly accounted for by an abnormal accumulation of 
the VI myosin isoprotein, which develops isometric force less efficiently for structural 
reasons. On the other hand, saturation transfer 31P-NMR studies demonstrate that 
perfused hearts of euthyroid rats injected with LT4, 0.35 #g/g/day x 10--14 days, respire 
more rapidly but do not increase ATP synthesis flux: 3°4 the ATP synthetase is thyroid- 
dependent in situ and in vivo. These findings confirm that excess thyroid hormone 
uncouples when measured by 'non-invasive' methods, as had been suggested in hyper- 
thyroid muscle, liver and kidney by decreased 32P-uptake into ATP in vivo TM (see Ref. 226). 
In contrast, 3~P-NMR measurements on hearts of hypothyroid rats show a slowed ATP 
synthesis that is accounted for by decreased respiratory rate, not uncoupling. ~*Ta 
Isolated heart mitochondria require a greater LT3 or LT4 dose-time treatment than do 
liver mitochondria to achieve comparable increases in State 4 respiration 474 and to deplete 
18:2 (Table 6). Heart mitochondria from our thyrotoxic rats, prepared by treating normal 
animals rather briefly with LT3, 1 #g/g/day for 3 days, are not uncoupled or loose-coupled, 
contain normal amounts of 18:2 and CL in EL, but lose State 3 respiration on standing 
at 4°C for a reason not revealed by the lipid analyses d o n e .  237 Such increased 'fragility' 
might be connected with the mitochondrial swelling that occurs in hypotonic sucrose 
solutions together with activation of endogenous phospholipase and hydrolysis of CL and 
PC;  297 o r  with effects like those in glucagon-treated rats, where liver mitochondria tend to 
lose PC, PE, and CL during preparation? 55 It takes 44-60 daily hormone injections to 
produce heart mitochondria that are uncoupled in vitro and half-depleted of their 18:2 
acyls (Table 6). 
In hypothyroid rats, heart mitochondrial State 4 respiration (glutamate) is at normal 
levels at 32°C) 5° Injecting hypothyroid rats once with LT3, 0.25/zg/g, increases State 4 rate 
by 80% in 1 day and maintains an elevated rate for at least 3 days. State 3 respiration 
responds to altered temperatures abnormally: rates are below normal only when measured 
at temperatures between 20°C and 34°C, reflecting the fact that Arrhenius profiles 
of hypothyroid preparations are normal below about 18°C, but show an 
abnormally high Ea above that temperature. The mitochondrial YL and PL contents are 
normal, as are the proportions of PC, PE, PS, and CL (c.f. the 72% increase in CL/PL 
in liver mitochondria). The 18:2 content in hypothyroid PL is 35.5% (normals, 26.8%), 
due to rises in 18:2 content of PC and PE, but not in CL. 
Heart and liver mitochondria have different lipid compositions, carrier protein contents, 
and regulatory mechanisms, n7'~6 which may account for the differences in thyroid effects. 
Although the heart has less apparatus for lipid syntheses, heart mitochondria contain twice 
as much CL per ~PL as liver mitochondria, and the CL contains about 50% more 18:2. 
Fasting/refeeding depletes the 18:2 acyls in heart mitochondria much less than in liver 
mitochondria 7'8 (Table 5). Heart mitochondria contain twice as much ATP synthetase and 
4 times as much ADP/ATP carrier. Their State 3 respiration (pyruvate/malate, 25°C) is 
regulated by the ATP synthetase ( C  i = 0.46) and the NADH dehydrogenase (Ci = 0.37), 
and not at all by the ADP/ATP carrier"7--all in contrast to the roles of these component 
steps in liver mitochondria (Table 8). 
If mitochondrial 18:2 acyls and/or CL mediate some thyroid actions, as they may in 
liver mitochondria and less in heart mitochondria, then brain mitochondria offer another 
system to test the generality. Mature brain mitochondrial function is completely insensitive 
to thyroid status.564 Brain mitochondrial CL/PL ratios are 2-5 %, and CL 18:2 acyl content 
is only 10%; PC contains no 18:2, PE contains 1% 18:2. 635 Fasting/refeeding fails to 
increase the activities of lipogenic enzymes in brain (see Section II). Essential fatty acid 
(EFA) deficiency depletes tissue 18: 2 in the order liver > heart > brain, and depletes brain 
20:4 little, if at all. Thus, the insensitivity of brain mitochondria to thyroid status is in 
contrast to the low sensitivity of heart mitochondria, which contain lots of CL with lots 
of 18:2 in it, both of which are hard to deplete. However, mitochondria in immature brain 
are quite thyroid-responsive, 564 but contain no CL: as in neonatal liver mitochondria, the 
thyroid-induced development of an adult complement of enzymes and transporters seems 
to predominate over thyroid effects mediated by membrane lipids. 
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E. Essential Fatty Acid Deficiency 
Essential fatty acid metabolism and the thyroid state of animals are related: the BMR 
increases within 1-2 weeks (the earliest sign) in animals on a fat-free diet, and feeding small 
amounts of methyl linoleate corrects it within days; 3~°'63° the hypermetabolism is not 
accompanied by thyroid hypersecretion; 4°8 dietary linoleic acid protects against experi- 
mental thyrotoxicity; TM and Klein and Johnson 31° noted that fat deficiency and hyper- 
thyroidism each uncouple oxidative phosphorylation in a mechanism that might involve 
mitochondrial unsaturated fatty acids. 
Linoleic acid, 18:2~o6, is the essential fatty acid in vertebrates because they lack a 
A12-desaturase; its 20:4w6 derivative is absent from most lab chow diets for rats. 
Considerable evidence contradicts the view 2°7 that co6-PUFA are essential as precursors 
of prostanoids but not for the function of any membrane. Daily EFA requirements are 
orders of magnitude greater than production of prostaglandins; prostaglandin synthetase 
inhibitors do not induce EFA-deficiency; administration of PG does not relieve all the 
symptoms of EFA-deficiency; 249'25° those symptoms are not usually associated with actions 
of PG; 394'495 columbinic acid cures EFA-deficiency but is not a PG precursor and even 
inhibits the primary enzyme for PG synthesis. Columbinic acyls replace 20:4 acyls in 
tissues, and restore the decreased rate of ATP synthesis in heart mitochondria 256'25s but 
State 4 respiration rates are not mentioned. 
Problems with the measurements of mitochondrial function in EFA-deficiency include 
the following. Different essential fatty acids have different functionsfl 5 Individual tissues 
and their individual PL fatty acyls respond differently to EFA-deficiency and replace- 
ment. 4~2 Different temperatures of measurement may produce conflicting results, since 
membrane PUFA distribution affects Arrhenius profiles. 4s9 Respiratory control ratios are 
sometimes presented without mention of the rate of State 4 respiration whereby to estimate 
the proton leak. Respiratory rates or control ratios presented after ADP-cycling "393'5°s are 
similar in controls and EFA-deficient animals; see Section IV.B.10 for objections to this 
procedure. 
Protein-free vesicles formed from natural purified PCs are as impermeable to trapped 
Na +4°5 and K +465 as are erythrocyte membranes, since Ea for diffusion is 15-17 kcal/g ion 
in all. Phosphatidylcholines purified from livers, kidneys and hearts of rats fed a fat-free 
diet for months are severely depleted of 18:2 ( - 8 2 % )  and 20:4 ( - 9 0 % )  acyls, and form 
vesicles that leak Na +, the Ea being 4.5 kcal/g ion--about the value for free ion diffusion 
in water. Proton diffusion in such membranes, as well as Ap and proton leakage rates in 
mitochondria of EFA-deficient rats, have not, to my knowledge, been measured as yet. 
Several dietary regimens to induce EFA-deficiency deplete mitochondrial 18:2 
(especially in CL) and 20:4 acyls (Table 11). Feeding completely saturated fatty acids 
accentuates 18:2co6 fatty acid deficiency. Feeding diets rich in saturated fatty acids 
decreases the ratio of co 6/oJ 3 PUFA in PL of mitochondria from rat liver, heart, or kidney, 
but leaves the ratio of saturated/unsaturated fatty acyls unchanged, suggesting a 'homeo- 
static' mechanism to Gibson et a1.172 Such homeostasis, like the increased co 9-unsaturation, 
may provide membrane fluidity for some nonspecific systems and prevent lethal outcome 
of EFA-deficiency. But only sufficient co6-PUFA prevent appearance of abnormal 
mitochondrial oxidative phosphorylation and membrane properties. 
When State 4 respiration is reported, EFA-deficiency almost always accelerates State 4. 
State 3 respiration and respiratory control ratios almost always decrease. Phosphorylative 
efficiency usually decreases only slightly, indicating that EFA-deficiency produces loose 
coupling a42 or decoupling. 5°6 Alfin-Slater and Aftergood 6 concluded that defective oxidative 
phosphorylation is an early lesion in EFA-deficiency. One group 2s3'574'636 reports no 
abnormalities in mitochondrial oxidative phosphorylation, but shows only respiratory 
control ratios and no absolute values for State 4 or State 3 respiratory rates. Mitochondrial 
co6-PUFA contents in these experiments are greatly decreased, and in correlation the lipid 
domains are tighter packed and allow less motional freedom of spin labels and a slower 
frequency of volume oscillations during energy-dependent ion transport. 636 Some research- 
JPLR 27/3~H 
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TABLE 11. Essential Fatty Acid Deficiency: Changes in Oxidative Phosphorylat ion and Mitochondrial  % 18:2 
Content  after Feeding Diets Deficient in 18:2 for 4-14 Weeks; Controls  Received Diets High in 18:2 
A% vs. Control 
Dietary 
fatty Tissue Substrate State State % 18: 2 
acid prep. T ° 4 3 R C R  P/O Frae. (Ref.) 
1. 0 LMito. , ,KGlutarate  30 ° 
2. 0 LMito. Succinate 30 ° + 5 7  
3. 0 LMito.  aKGlu ta ra te  30 ° +71 
4. 0 LMito.  Succinate 25 ° 
5. 0 LMito.  Succinate 25 ° 
6. Sat LMito. Succinate 25 ° 
7. Sat LMito. , ,KGlutarate  300 +77  
8. Sat HMito.  Glutamate  37 ° +42  
18: ICarnitine 37 ° +33  
9. Tal lowt LMito. Succinate 26 ° - 3 5  
10. Lard HMito.* Pyruvate 37 ° + 9  
11. +22 :1  HMito.  Glutamate  37 ° + 4 9  
12. +22 :1  HMito.* Succinate 37 ° +57  
Pyruvate 37°C + 119 
13. +22:1:~ LMito. Glutamate  25 ° + 17 
HMito.  - 30 
14. 0 Rat  B M R  +25  
15. 0 Rat  B M R  + 9  
16. 0 Rat  B M R  +61 
17. 0 LSlice Succinate 370 + 17 
Diaphragm Succinate 37 ° + 31 
18. 0 LSlice Succinate 37 ° + 6 
Caprylate 37 ° + 7 0  
19. 0 LHomog.  Citrate 37 ° + 5 6  
20. 0 LMito. CytoOxidase 25 ° +38  
21. Sat LMito.  SuccinateDeH 25 ° + 140 
f lOHButyrateDeH 25 ° + 150 
MalateDeH 25 ° +292  
0 - 3 2  (310) 
(353) 
(56O) 
- 16 + 2  (274) 
- 14 - 9  - 7 8  CL (40) 
- 17 - 8  - 8 5  CL (636) 
(560) 
- 4  - 3 2  - 5  - 4 3  CL (259) 
- 9  - 3 1  0 
- 2 0  +23  + 1 4  - 8 0  5ZL (3) 
+ 8  - I - 3  - 4 7  YL (508) 
- 2 6  - 5 1  - lO - 2 3  CL (259) 
- 29  - 35 CL (88) 
+ 8  
- 6 0  
--2 











LMito = liver mitochondria;  HMito  -- heart  mitochondria;  R C R  -- respiratory control ratio; CL = cardiolipins; 
YL = total lipids. *ADP-cycled. "t'Contains 3.4% 18:2. :~Fed 3 days. 
ers find biochemical and structural abnormalities in mitochondria from EFA-deficient rats 
and conclude that they are artifacts resulting from damage during isolation, caused by 
mitochondrial fragility 2s2'353'56~'636 presumably arising from the abnormal fatty acyls and PL 
in the membranes. A similar argument of artifact was raised against thyroid e f f ec t s .  379 
Indirect estimations indicate altered oxidative phosphorylation and mitochondrial 
function in vivo and in situ in EFA-deficiency. The increased BMR so indicates, assuming 
that resting cells respire in State 4, 226~23~'55~ Respiration in intact cells of liver slices from 
EFA-deficient rats is said to be at control rates, ~ but when endogenous respiration is 
subtracted the corrected values are + 17% to 70% faster than controls H3 (Table 1 1). In 
liver homogenates prepared from EFA-deficient rats, the 'un-isolated' mitochondria oxidize 
citrate 56% faster than in homogenates from controls. ~ On the other hand, some but not 
all animal cell lines in culture require no essential fatty acids but subsist on endogenous 
formation of mono-enoic acids? 67 No studies on the respiration or function of mito- 
chondria in such cell lines are available to decide if the State 4 respiratory rate and proton 
leak are 'normal'. 
EFA-deficiency also increases activities of the mitochondrial dehydrogenases specific for 
succinate, fl-hydroxybutyrate, isocitrate, or malate. 2~7'21s The fact that disruption of normal 
mitochondrial membranes by hypo-osmotic lysis, sonication, or phospholipase A raises 
these activities to the levels in EFA-deficiency shows that altered membrane-dependency, 
not synthesis of more dehydrogenases, is responsible. Such altered dependency also 
appears in erythrocyte and tissue membranes of EFA-deficient animals, in the loss of 
normal cooperativity of ionic effectors (Na +, K +, Mg 2+, F-)  of several ATPases? 47 
Mitochondrial structure is reported to be normal in electron microscopic studies of liver 
slices from EFA-deficient rats but abnormal in the isolated mitochondria, ss~ supporting the 
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argument for artifact. However, other electron microscope studies on tissue slices find 
major structural alterations in such mitochondria in situ. ss3"5~4"6~'639 
The importance, if not the essentiality, of  18:2 and its derivative fatty acyls in 
mitochondrial membrane function receives support from the available data on EFA- 
deficient animals. Crucial experimentation, such as determination of Ci values in State 3 
and proton leakage in State 4 are, to my knowledge, still not reported. 
V. P E R S P E C T I V E  
Evidence is presented here, some of it circumstantial or incomplete, that thyroid 
hormone occupancy of specific receptors sets off a train of amplifying and diversifying 
mechanisms. A suggested sequence starts with the expression and modification of a few 
lipogenic enzymes; proceeds through changes in membrane phospholipid fatty acyl and 
cholesterol contents; with subsequent modulation of enzyme, transporter, and receptor 
systems, as well as unmediated membrane permeability to mono-cations; that in turn 
regulate concentrations of multipotent intracellular effectors. These systems include: cell 
membrane adenylate cyclase and intracellular cyclic nucleotide phosphodiesterases, and 
cell and organelle membrane Ca2+-pumps, that regulate [cAMP] and thereby protein 
kinases and phosphoprotein phosphatases; cell membrane Na +, K+-ATPase and 
Na+-H+-antiporter, that regulate intracellular [H +] and thereby gene expression and 
protein synthesis; phospholipases A and prostaglandin synthetases; mitochondrial inner 
membrane permeability and transporters that regulate [ATP] and [cations]. The reduction 
of the diversity of thyroid hormone effects to such amplifying systems is a continuing 
effort. 
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